niacinamide and pyrroles

niacinamide has been researched along with pyrroles in 750 studies

Research

Studies (750)

TimeframeStudies, this research(%)All Research%
pre-199016 (2.13)18.7374
1990's74 (9.87)18.2507
2000's203 (27.07)29.6817
2010's454 (60.53)24.3611
2020's3 (0.40)2.80

Authors

AuthorsStudies
Holzmann, S; Kukovetz, WR; Pöch, G1
Berdeaux, A; Drieu la Rochelle, C; Giudicelli, JF; Richard, V1
Kreye, VA; Lenz, T; Pfründer, D; Theiss, U1
Kamata, K; Kasuya, Y; Miyata, N; Otomo, S; Tsuchida, K; Yamaura, H1
Fang, D; Wu, Y1
Braida, C; Holzmann, S; Kukovetz, WR; Pöch, G1
Cook, D; Stockbridge, N; Vollrath, B; Weir, B; Zhang, H1
Akima, M; Imagawa, J; Nabata, H; Taira, N1
Ichihara, K; Nagasaka, M; Okumura, K1
Kau, ST; Li, JH; Zografos, P1
Kamijo, T; Kido, H; Miwa, A; Nakamura, F; Sugimoto, T; Tomaru, T; Uchida, Y1
Quast, U2
McPherson, GA; Stork, AP1
Andersson, KE1
Hamilton, TC; Longman, SD1
Grover, GJ; Parham, CS; Sleph, PG1
Berdeaux, A; Giudicelli, JF; Richer, C1
Higuera, TR; Kadowitz, PJ; Kvamme, P; Minkes, RK; Nossaman, BD1
Kreye, VA; Lenz, T; Theiss, U1
Satoh, K; Taira, N; Yamada, H1
Ksoll, E; Mackert, JR; Parsons, AA; Schilling, L; Wahl, M1
Arakawa, C; Kasuya, Y; Masuda, Y; Miyajima, M; Shigenobu, K; Tanaka, S; Yamashita, T1
Goto, S; Kitagaki, K; Koda, A; Nagai, H; Suda, H1
Kurachi, Y; Machulda, MM; Shen, WK; Tung, RT1
Cavero, I; Mondot, S; Pratz, J1
Stockbridge, N; Weir, B; Zhang, H1
Colatsky, T; Follmer, C; Parsons, R; Spinelli, W1
Satoh, K; Taira, N; Yamada, H; Yoneyama, F1
Taira, N; Teshigawara, T; Yanagisawa, T1
Satoh, E; Taira, N; Yanagisawa, T1
Satoh, K; Taira, N; Yoneyama, F1
Weir, SW; Weston, AH2
Coldwell, MC; Howlett, DR1
Clapham, JC; Hamilton, TC; Longman, SD; Wilson, C1
Hironaka, T; Kim, S; Koh, E; Morimoto, S; Morita, R; Nabata, T; Ogihara, T; Onishi, T; Takamoto, S1
Eltze, M1
Garrino, MG; Henquin, JC; Plant, TD2
Kamata, K; Kasuya, Y; Miyata, N1
Coldwell, MC; Cooper, SM; Hamilton, TC; Howlett, DR; Wilson, C1
Hashimoto, H; Taira, N; Yanagisawa, T1
Clapham, JC; Wilson, C1
Kitamura, K; Kuriyama, H; Nakao, K; Okabe, K; Weston, AH1
Neurath, G1
Mattocks, AR; White, IN1
Satoh, H2
Kinoshita, M; Nakae, I; Quan, L; Sugimoto, Y; Tsutamoto, T1
Attolini, L; Bruguerolle, B; Gantenbein, M1
Fukushima, H; Jinno, Y; Kaneta, S; Miwa, A; Ogawa, N1
Satake, N; Shibata, S; Zhou, Q1
Bender, AS; White, HS; Woodbury, DM1
Masuda, Y; Tanaka, S; Yamashita, T1
Atwal, KS1
Cook, D; Zhang, H1
Christensen, H; Drottning, P; Storstein, L1
Akamatsu, S; Dohi, S; Iida, H; Ishiyama, T; Ohta, S; Shimonaka, H1
Fabiani, ME; Story, DF1
Hellwig, B1
Hashimoto, K; Kinoshita, M; Nakae, I; Quan, L; Sugimoto, Y; Tsutamoto, T1
Fukata, Y; Fukushima, H; Harada, K; Kasai, H; Ogawa, N1
Fukata, Y; Fukushima, H; Jinno, Y; Kaneta, S; Ogawa, N; Okada, Y; Yokoyama, T1
Cavero, I; Premmereur, J1
Abe, S; Kanaide, H; Nakamura, M; Nishimura, J1
Andersson, KE; Hedlund, H; Hedlund, P; Holmquist, F1
Jun, JY; Kim, KW; Kim, SJ1
Kamouchi, M; Kitamura, K1
Mori, T; Satoh, K; Taira, N; Yamada, H1
Fukata, Y; Fukushima, H; Jinno, Y; Kaneta, S; Miwa, A; Ogawa, N1
Satoh, K1
Nakaya, H1
Fukushima, H; Jinno, Y; Kaneta, S; Kasai, H; Miwa, A; Motoki, K; Ogawa, N; Okada, Y1
Allard, B; Lazdunski, M1
Okamoto, K; Sakuta, H; Watanabe, Y1
Bertaina, V; Heurteaux, C; Lazdunski, M; Widmann, C1
Okamoto, K; Sakuta, H1
Chiang, CH; Lin, CH1
Hara, Y; Kimura, S; Kobayashi, S; Masuda, Y; Nakaya, H; Saito, T; Takizawa, T1
Mizoguchi, K; Tanaka, M; Tanaka, T; Yokoo, H; Yoshida, M1
Chujo, M; Hori, M; Inoue, M; Kamada, T; Kitakaze, M; Komamura, K; Minamino, T; Mori, H; Node, K; Shinozaki, Y1
Hara, Y; Masuda, Y; Nakaya, H; Saito, T; Takizawa, T1
Angus, JA; Fujiwara, T1
Brading, AF; Teramoto, N1
Aya, G; de La Coussaye, JE; Delye, B; Eledjam, JJ; Juan, JM; Péray, P; Robert, E; Sassine, A1
Aisaka, K; Hirata, Y1
Grover, GJ1
Kinoshita, M; Liu, Q; Matsumoto, T; Nakae, I; Omura, T; Takahashi, M; Takaoka, A1
FINGER, H; FRETZDORFF, AM; SCHNEIDER, F; SEYNSCHE, K; WEITZEL, G1
Desai, AA; Stadler, WM1
Branca, MA1
Motzer, RJ; Rini, BI; Sosman, JA1
Armand, JP; Escudier, B; Faivre, S; Raymond, E; Robert, C1
Cooney, MM; Remick, SC; Vogelzang, NJ2
Schiller, JH; Wakelee, HA1
Chaganti, RS; Motzer, RJ; Patel, PH1
Kanetake, H; Koga, S1
Rini, BI4
Ardizzoni, A; Franciosi, V; Tiseo, M1
Hampton, T1
Eto, M; Naito, S1
Bukowski, RM; Rini, BI; Shaheen, PE1
Mancuso, A; Sternberg, CN1
Biedrzycki, BA1
King, CR1
Stadler, W1
Curtiss, FR1
Haseke, N; Heinemann, G; Schöppler, G; Stadler, T; Staehler, M; Stief, CG1
Gascón, P; Mellado, B1
Blanke, C1
Wetherbee, SL1
Bukowski, RM; Motzer, RJ1
Culine, S; Pouessel, D3
Chadalavada, RS; Chaganti, RS; Motzer, RJ; Patel, PH1
Brugarolas, J1
Dreicer, R1
Creel, P; George, D; Speca, J; Yenser, S1
Herbst, RS1
Hussar, DA1
Colantuoni, G; Comunale, D; De Vita, A; Del Gaizo, F; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A1
Figlin, RA1
Michaelson, MD1
Miroglu, C; Silay, MS1
von Mehren, M1
Kruck, S; Kuczyk, M; Merseburger, AS1
Linehan, WM; Novakovic, KR; Pinto, PA; Vira, MA1
Ardizzoni, A; Tiseo, M1
Force, T; Krause, DS; Van Etten, RA1
Angele, MK; Bruns, CJ; Eichhorn, ME; Jauch, KW; Kleespies, A1
De Mulder, PH; Mulder, SF; van Spronsen, DJ1
Senan, S; Smit, EF1
Kamba, T; McDonald, DM1
Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P1
Di Lorenzo, G1
Baz, RC; Bukowski, RM; Choueiri, TK; Elson, P; Garcia, JA; Golshayan, AR; Khasawneh, M; Rini, BI; Usman, S; Wood, L1
Flaherty, KT; Stein, MN1
Atkins, MB1
Rini, BI; Unnithan, J1
Cabebe, E; Wakelee, H1
Albers, P; Bergmann, L; Geschwend, JE; Jäger, E; Jakse, G; Marschner, N; Miller, K1
Goldspiel, BR; Grandinetti, CA1
Bodrogi, I1
Kibble, A; Shumoogam, J1
George, D; Medioni, J; Motzer, R; Oudard, S1
Armand, JP; Mir, O; Ropert, S1
Billemont, B; Izzedine, H; Méric, JB; Rixe, O; Sultan-Amar, V; Taillade, L1
Robert, C1
Duyster, J; Grundler, R; Kancha, RK; Peschel, C1
Fiedler, W; Grünwald, V; Heinzer, H1
Alba, E; Medina, MA; Quesada, AR1
Bjelogrlic, SK; Radulovic, S1
Thomas, X1
Faivre, S; Le Tourneau, C; Raymond, E1
Brozmanova, K; Mardiak, J; Mego, M; Obertova, J; Reckova, M; Sycova-Mila, Z1
Bukowski, RM; Dreicer, R; Elson, P; Garcia, JA; Mekhail, T; Rini, BI; Tamaskar, I; Wood, L1
Culine, S; Patard, JJ; Pouessel, D; Verhoest, G1
Zhu, AX1
Bhojani, N; Hutterer, G; Jeldres, C; Karakiewicz, PI; Oudard, S; Patard, JJ; Patenaude, F; Perrotte, P; Suardi, N1
Bukowski, RM; Choueiri, TK; Elson, P; Escudier, B; Negrier, S; Oudard, S; Plantade, A; Ravaud, A; Rini, BI; Zhou, M1
Bonomi, L; Imarisio, I; Paglino, C; Porta, C1
Hiles, JJ; Kolesar, JM1
Bui, B; Italiano, A1
Cohen, AF; Dubois, EA; Osanto, S; van Bronswijk, H1
Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Yoshida, J1
Demetri, GD; George, S; Humphreys, BD; Maki, RG; Morgan, JA; Patel, TV; Quigley, M1
Ehninger, G; Illmer, T1
Giordano, S; Petrelli, A1
Brauer, KM; Brossart, P; Hilf, N; Hipp, MM; Radsak, MP; Singh-Jasuja, H; Walter, S; Weinschenk, T; Werth, D1
Autier, J; Mateus, C; Robert, C; Spatz, A; Wechsler, J1
Chevreau, C; Delord, JP; Deslandres, M; Sibaud, V1
Burgin, S; Heidary, N; Naik, H1
Bellersen, L1
de Mulder, PH; Gietema, JA; Groenewegen, G; Haanen, JB; Jansen, RL; Kruit, WH; Mulders, PF; Osanto, S; Richel, DJ; Sleijfer, S; van den Eertwegh, AJ; Voest, EE1
Apice, G; Bruni, GS; Caponigro, F; Iaffaioli, RV; Milano, A1
Athar, U; Gentile, TC1
Avakian, R; Belldegrun, AS; Kabbinavar, FF; LaRochelle, JC; Pantuck, AJ; Patard, JJ; Riggs, SB; Shuch, B1
Lee, CB; Socinski, MA1
Baker, SD; Dahl, GV; Hu, S; Inaba, H; Minkin, P; Niu, H; Orwick, S; Rubnitz, J; Shimada, A1
Buhl, R; Fischer, B1
Jonasch, E; Margulis, V; Matin, SF; Swanson, DA; Tamboli, P; Tannir, N; Wood, CG1
Gettinger, S1
Gerami, P; Guitart, J; Lacouture, ME; Reilly, LM1
Del Conte, G; Guibal, A; Rüegg, C; Sessa, C1
Kuczyk, MA; Merseburger, AS1
Figlin, R; Moldawer, NP1
Bierer, S; Bolenz, C; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C1
Strumberg, D1
Gakis, G; Kramer, MW; Kruck, S; Kuczyk, MA; Merseburger, AS; Stenzl, A1
Bukowski, RM; Choueiri, TK; Cotta, C; Dreicer, R; Elson, P; Garcia, J; Khasawneh, MK; Mekhail, T; Rini, BI; Unnithan, J; Wood, L1
Bhalla, IP; Bukowski, RM; Choueiri, TK; Elson, P; Ganapathi, R; Golshayan, AR; Jaeger, E; Rini, BI; Sein, N; Sercia, L; Simko, J; Small, EJ; Vaziri, SA; Waldman, FM; Weinberg, V; Wood, L; Zhou, M1
Dykens, JA; Hirakawa, B; Hynes, J; Jamieson, J; Jessen, BA; Marroquin, LD; Nadanaciva, S; Patyna, S; Will, Y1
Rini, BI; Vakkalanka, BK1
Rübben, H1
Culine, S; Patard, JJ; Pouessel, D2
Chun, FK; Eichelberg, C; Heinzer, H; Heuer, R; Hinrichs, K; Huland, H; Zacharias, M1
O'Dowd, A1
Bierer, S; Hertle, L; Nitschmann, S1
Bensalah, K; Cornu, JN; Oudard, S; Patard, JJ; Rouprêt, M1
Alexandrescu, DT; Dasanu, CA; Farzanmehr, H; McClure, R1
Bierer, S; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C1
Billemont, B; Boudou-Rouquette, P; Goldwasser, F; Loriot, Y; Ropert, S1
Tuma, RS1
Moch, H1
Alexandrescu, DT; Anderson, RT; Atkins, MB; Dutcher, JP; Garbe, C; Guitart, J; Hauschild, A; Kong, HH; Lacouture, ME; Puzanov, I; Robert, C; Wood, L; Wu, S1
Fujioka, T; Obara, W1
Kakehi, Y1
Aguilar-Ponce, JL; Buzaid, AC; de la Garza, J; Fernandes, Gdos S; Kann, AG; Maluf, FC1
Bukowski, RM; Vakkalanka, BK1
Haseke, N; Karl, A; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K1
Chowdhury, S; Gore, ME; Larkin, JM1
Ferrière, JM; Grenier, N; Kilkoski, F; Ravaud, A; Sire, M; Wallerand, H1
Figlin, RA; Hutson, TE; Kuhn, JG; Motzer, RJ1
Lenihan, DJ1
Bojic, A; Bojic, M; Hejna, M; Ruhsam, M; Schmidinger, H; Schmidinger, M; Schukro, C; Vogl, UM; Zielinski, CC1
Daher, IN; Yeh, ET1
Bamias, A1
Bex, A; Cosentino, M; Ficarra, V; Flörcken, A; Grünwald, V; Johannsen, M; Kloeters, C; Miller, K; Rief, M; Rogalla, P; Roigas, J1
Kroog, GS; Motzer, RJ1
Greten, TF; Korangy, F; Malek, NP; Manns, MP1
Azizi, M; Bobrie, G; Bouché, O; Deray, G; des Guetz, G; Halimi, JM; Lecomte, T; Levy, B; Mourad, JJ; Nochy, D; Oudard, S; Rieu, P; Sahali, D1
Iwata, C; Kano, MR; Kataoka, K; Komuta, Y; Miyazono, K; Morishita, Y; Oka, M; Ouchi, Y; Shirai, YT1
Dham, A; Dudek, AZ; Lindgren, BR; Szczylik, C; Zolnierek, J1
Aydin, H; Bukowski, RM; Elson, P; Garcia, JA; George, S; Golshayan, AR; Heng, DY; Mekhail, TM; Rini, BI; Wood, LS; Zhou, M1
Berger, W; Lamm, W; Micksche, M; Pichelmeyer, O; Pirker, C; Schmidinger, M; Vogl, UM; Zielinski, CC1
Mills, EJ; O'Regan, C; Perri, D; Rachlis, B; Thabane, L1
Bergmann, L; Jäger, E; Jakse, G; Keilholz, U; Miller, K; Wirth, M1
Alken, P; Bolenz, C; Häcker, A; Herrmann, E; Honeck, P; Michel, MS; Schöppler, G; Trojan, L1
Hill, KL; Lipson, AC; Sheehan, JM1
Bukowski, RM1
Bellmunt, J; Calvo, E; Castellano, D; Climent, MA; Esteban, E; García del Muro, X; González-Larriba, JL; Maroto, P; Trigo, JM1
Choueiri, TK; Chowdhury, S1
Alfaro, C; Dubrot, J; Erro, L; Gonzalez, A; Grande-Pulido, E; Gurpide, A; Hervas-Stubbs, S; Lopez-Picazo, JM; Melero, I; Palazon, A; Perez-Gracia, JL; Solano, S; Suarez, N1
Mizutani, Y1
Dreyer, C; Faivre, S; Raymond, E1
Asemissen, AM; Keilholz, U; Knoedler, M; Miller, K; Schmittel, A; Steiner, U; Thiel, E; Zimmermann, K1
Jarkowski, A; Wong, MK1
Barnabei, A; Corsello, SM; Gasparini, G; Longo, R; Torino, F2
Bastien, L; Culine, S; de la Taille, A; Ledbai, S; Patard, JJ; Paule, B1
Armand, JP; Domont, J; Lassau, N; Le Cesne, A; Massard, C; Soria, JC1
Horn, L; Sandler, AB1
Dabora, SL; Lee, N; Messina, MP; Nobil, AM; Rauktys, AE; Woodrum, CL1
Maitland, ML; Snider, KL1
Chen, MH1
Ball, SA; Plowman, PN; Reznek, R; Richards, TM1
Ravaud, A; Sire, M1
Secasan, CC1
Billemont, B; Kelly, RJ; Rixe, O1
Balleyguier, C; Celier, C; Escudier, B; Gautier, J; Medioni, J; Negrier, S; Oudard, S; Ravaud, A; Sablin, MP1
Desar, IM; Mulder, SF; Mulders, PF; Stillebroer, AB; van der Graaf, WT; van Herpen, CM; van Spronsen, DJ1
Shibuya, M1
English, BC; Figg, WD; Price, DK1
Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B1
Brower, V1
Berchem, G; Dewilde, S; Mahassen, P1
Alasker, A; Guevremont, C; Karakiewicz, PI1
Abel, EJ; Wood, CG1
Cortés-Funes, H1
Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC1
Chen, HX; Cleck, JN1
Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J1
Campbell, SC; Fergany, A; Garcia, JA; Gill, IS; Klein, EA; Krishnamurthi, V; Novick, AC; Rini, BI; Stephenson, AJ; Thomas, AA; Zhou, M1
Awasthi, S; Rao Lelsani, PC; Sahu, M; Sehrawat, A; Singhal, P; Singhal, SS; Vatsyayan, R; Yadav, S1
Bil, J; Golab, J; Jakobisiak, M; Nowis, D; Zapala, L1
Balis, FM; Kim, A; Widemann, BC1
Aieta, M; Autorino, R; Bruni, G; Cartenì, G; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Ficorella, C; Giannarini, G; Gonnella, A; Imbimbo, C; Longo, N; Mirone, V; Palmieri, G; Perdonà, S; Pignata, S; Rescigno, P; Rizzo, M; Tudini, M1
Samlowski, W; Vogelzang, NJ; Weissman, A1
Benghiat, H; Collins, S; James, N; Karina, M; Oldroyd, A; Parry, H; Pascoe, J; Porfiri, E; Ray, D; Zachariah, A1
Cella, D2
Kuszatal, E; Langiewicz, P; Nurzyński, P; Oborska, S; Obrocka, B; Szczylik, C; Waśko-Grabowska, A; Zołnierek, J1
Gelderblom, H; Guchelaar, HJ; van Erp, NP1
Ivy, SP; Kaufman, BM; Wick, JY1
Carbonell, CE; Coleman, TA; Davis, CH; Davis, WB; La Vine, DB1
Choueiri, TK; Je, Y; Schutz, FA1
Beynat, C; Coudert, B; Diaz, P; Favier, L; Ghiringhelli, F; Ladoire, S1
Baker, SD; Chen, Z; Franke, R; Hu, S; Orwick, S; Rudek, MA; Sparreboom, A; Zhao, M1
Garnock-Jones, KP; Keating, GM1
Atkins, MB; Bukowski, RM; Cheng, T; Chi, KN; Choueiri, TK; Eigl, BJ; Golshayan, AR; Heng, DY; Knox, JJ; Kollmannsberger, C; McDermott, DF; North, S; Oh, WK; Regan, MM; Rini, BI; Ruether, JD; Sahi, C; Venner, P; Warren, MA; Xie, W1
Kuczyk, MA; Merseburger, AS; Simon, A; Waalkes, S1
Crouthamel, MC; Gontarek, RR; King, AG; Kumar, R; Levin, RA; Rominger, DH; Tummino, PJ1
Wilkes, GM1
Goldschmeding, R; Overkleeft, EN; van Reekum, F; Verheul, HM; Voest, EE1
Breau, RH; Leibovich, BC1
Aragon-Ching, JB; Dahut, WL1
Lipworth, AD; Robert, C; Zhu, AX1
Cowey, CL; Fielding, JR; Rathmell, WK1
Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Staehler, M; Varga, Z1
Sherman, SI1
Digue, L; Ravaud, A; Smith, D; Trufflandier, N1
Thompson, JA1
Wood, LS1
Brade, AM; Chung, C; Dawson, LA; Joshua, AM1
Gore, M; Larkin, J1
Baessler, T; Kampa, KM; Krusch, M; Mayer, F; Salih, HR; Salih, J; Schlicke, M1
Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A1
Wang, ZY1
Autorino, R; Di Lorenzo, G1
Green, C; Hoyle, M; Liu, Z; Moxham, T; Stein, K; Thompson Coon, J; Welch, K1
Lieber, ML; Shah, SN; Smith, AD1
Bayer, M; Berdel, WE; Kessler, T; Liersch, R; Mesters, RM; Schwöppe, C1
De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F1
Bukowski, R; Elson, P; Garcia, J; Golshayan, A; Khan, G; Rini, B; Wood, L1
Peter, S; Rohde, D; Tong, TQ1
Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P1
Kurzrock, R; Lenihan, D; Tsimberidou, AM; Vaklavas, C1
Oya, M1
Minor, DR2
Billemont, B; Boccon-Gibod, L; Bompas, E; Camparo, P; Couturier, J; Dutcher, J; Escudier, B; Guillot, A; Malouf, GG; Molinié, V; Oudard, S; Rixe, O; Rustine, A; Schleiermacher, G; Theodore, C1
Gschwend, JE1
Bose, D; Ellis, LM; Flaherty, KT; Hofstetter, W; Meric-Bernstam, F; Reardon, DA1
Fournier, C; Tisman, G1
Bierer, S; Herrmann, E; Wülfing, C1
Amato, AM; Atkins, MB; Cho, DC; Choueiri, TK; Clement, J; McDermott, D; Oh, WK; Regan, MM; Rosenberg, JE; Signoretti, S1
Barbastefano, J; Campbell, SC; Dreicer, R; Elson, P; Garcia, JA; Lane, BR; Rini, BI; Wood, LS1
Kats-Ugurlu, G; Kiemeney, LA; Leenders, WP; Mulders, PF; Old, LJ; Oosterwijk, E; Oosterwijk-Wakka, JC1
Bellmunt, J; Choueiri, TK; Je, Y; Rosenberg, JE; Schutz, FA1
Choueiri, TK1
Bronstein, Y; Busaidy, NL; Cabanillas, ME; Feng, L; Hernandez, M; Lopez, A; Sherman, SI; Waguespack, SG; Williams, MD1
Cuesta Alcalá, JA; De Pablo Cárdenas, A; Millán Serrano, JA; Sánchez Zalabardo, D1
Albouy, B; Escudier, B; Gross Goupil, M; Massard, C1
Ayllon, J; Barrascout, E; Cuenod, CA; Elaidi, R; Medioni, J; Mejean, A; Oudard, S; Scotte, F; Tartour, E1
Escudier, B; Gross-Goupil, M1
Boyle, H; Fléchon, A; Négrier, S1
Kondo, M; Nieder, C; Norum, J1
Vaishampayan, U1
Rini, BI; Shah, SN1
Deville, JL; Duffaud, F; Huynh, T; Salas, S1
Bonvalot, S; Cioffi, A; Dômont, J; Le Cesne, A; Tardieu, M1
Albers, P; Bergmann, L; Gschwend, J; Jäger, E; Keilholz, U; Miller, K1
Lieber, ML; Remer, EM; Rini, BI; Shah, SN; Smith, AD2
Duyster, J; Menzel, H; Peschel, C; Rummelt, C; Sigl, M; von Bubnoff, N1
Billemont, B; Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Massault, PP; Mir, O; Ropert, S; Vignaux, O1
Fagin, JA; Pfister, DG; Tuttle, RM1
Sato, Y1
Brandes, AA; Franceschi, E; Girardi, F1
Balvay, D; Banu, E; Chatellier, G; Cuenod, CA; Fournier, LS; Frija, G; Medioni, J; Oudard, S; Thiam, R; Trinquart, L1
Beck, J; Bellmunt, J; Escudier, B1
Chen, E; Coatney, RW; Davis, CB; Frazier, KS; French, KJ; Gales, TL; Hu, CX; McSurdy-Freed, J; Renninger, JP; Storck, LM; Zhao, S1
Eames, T; Staehler, M; Wollenberg, A1
Herrmann, TR; Kramer, M; Kuczyk, MA; Merseburger, AS; Schrader, AJ; Waalkes, S1
Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J1
An, J; Bilenky, M; Birol, I; Butterfield, YS; Cezard, T; Chuah, E; Corbett, R; Fejes, AP; Griffith, M; Griffith, OL; Hirst, M; Holt, RA; Huntsman, DG; Jones, SJ; Laskin, J; Li, YY; Marra, MA; Martin, M; Mayo, M; Melnyk, N; Moore, RA; Morin, RD; Pugh, TJ; Severson, T; Shah, SP; Sutcliffe, M; Tam, A; Terry, J; Thiessen, N; Thomson, T; Varhol, R; Yee, J; Zeng, T; Zhao, Y1
Hashimoto, Y; Iizuka, J; Kobayashi, H; Kondo, T; Nakano, M; Nishikawa, T; Tanabe, K1
Berros, JP; Blay, P; Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fonseca, PJ; Fra, J; Izquierdo, M; Lacave, ÁJ; Luque, M; Muriel, C; Pardo, P; Sanmamed, M; Vieitez, JM; Villanueva, N1
Castelo, B; Espinosa, E; Pinto, A; Redondo, A; Zamora, P1
Berardi, R; Cascinu, S; Del Prete, M; Di Pietro Paolo, M; Faloppi, L; Maccaroni, E; Scartozzi, M1
Bukowski, RM; Cowey, CL; Dreicer, R; Elson, P; Garcia, JA; Gilligan, T; Hutson, TE; Nemec, C; Rini, BI1
Guo, K; He, Y; Huang, Y; Li, Y; Wang, Y1
Breaker, K; Costa, LJ; Crighton, F; Drabkin, H; Flaig, TW; Gustafson, DL; Kim, FJ; Schultz, MK1
Bojic, M; Clodi, M; Haitel, A; Heinzl, H; Kramer, G; Lamm, W; Schmidinger, M; Vogl, UM; Zielinski, CC1
Aglietta, M; Aieta, M; Buonerba, C; D'Aniello, C; De Placido, S; Di Lorenzo, G; Federico, P; Felici, A; Imbimbo, C; Longo, N; Milella, M; Mirone, V; Ortega, C; Palmieri, G; Rescigno, P; Ruggeri, EM1
Hagymási, K; Tulassay, Z1
Fujisawa, M; Miyake, H1
Figlin, RA; Pal, SK1
Li, H; Shi, GH; Wang, CF; Yang, LF; Yang, ZY; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y1
Bednaríková, D; Kocák, I1
Andersen, JL; Andersson, M; Kamby, C; Nielsen, DL1
Düber, C; Galle, PR; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA1
Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; Lampard, JG; McDermott, DF; North, S; Rini, BI; Xie, W1
Sulkes, A1
Rini, B1
Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A1
Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B1
Oudard, S1
Lolkema, MP; van Hillegersberg, R; Verheul, HM; Voest, EE; Walraven, M; Witteveen, PO1
Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R1
Carroll, AR; Coleman, RL; Sood, AK1
Dunn, RL; Filson, CP; Miller, DC; Redman, BG1
Benedict, A; Charbonneau, C; Figlin, RA; Hariharan, S; Harmenberg, U; Négrier, S; Remák, E; Sandin, R; Sandström, P; Ullén, A1
Akiyama, Y; Fujita, K; Murayama, N; Sasaki, Y; Sugiyama, M; Yamazaki, H1
Andreadis, C; Bamias, A; Dimopoulos, M; Karadimou, A; Kontovinis, L; Laschos, K; Papazisis, K; Paraskevopoulos, P1
Atkins, MB; Choueiri, TK; Guo, M; Heng, DY; Jagannathan, J; Krajewski, KM; McDermott, DF; Pedrosa, I; Ramaiya, N; Schutz, FA; Van den Abbeele, AD; Yap, J1
Poller, B; Schinkel, AH; Tang, SC; Wagenaar, E1
Fukui, I; Hatake, K; Inamura, K; Ishikwa, Y; Kodaira, M; Nakano, K; Takahashi, S; Urakami, S; Yamamoto, S; Yonese, J; Yuasa, T1
Cano Megías, M; Carrasco De La Fuente, M; González Albarrán, O; Menacho Román, M; Pérez López, G1
Hutson, TE1
Ravaud, A1
Demlová, R; Komínek, J; Ondrácková, B1
Allen, GI; Chung, BI; Gill, HS; Harshman, LC; Srinivas, S; Yu, RJ1
Ikeda, R; Iseki, K; Maeda, H; Nakano, K; Shibayama, Y; Sugawara, M; Taguchi, M; Takeda, Y; Yamada, K1
Canipari, C; Chen, K; Duh, MS; Imarisio, I; Neary, M; Paglino, C; Porta, C1
Cohen, EE; Fleming, GF; Gangadhar, TC; Geary, D; House, LK; Janisch, L; Kocherginsky, M; Maitland, ML; Ramirez, J; Ratain, MJ; Undevia, SD; Wu, K1
Blumenstengel, K; Grimm, MO; Groschek, M; Herrmann, E; Hutzschenreuter, U; Marschner, N; Ohlmann, CH; Overkamp, F; Pühse, G; Steiner, T1
Maráz, A1
Duh, MS; Feinberg, BA; Fortner, B; Gilmore, J; Jolly, P; Neary, MP; Scott, J; Wang, ST1
Tanji, N; Yokoyama, M1
Karakiewicz, PI; Maurin, C; Perrotte, P; Sun, M; Thuret, R1
Allen, P; Jonasch, E; Mahajan, A; Tannir, N; Verma, J1
Busch, J; Flörcken, A; Grünwald, V; Johannsen, M; Keilholz, U; Kempkensteffen, C; Miller, K; Weikert, S; Weinkauf, L; Westermann, J; Zimmermann, K1
Abrahamova, J; Brabec, P; Buchler, T; Dusek, L; Klapka, R; Melichar, B; Vyzula, R1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES1
Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Varga, Z1
El-Gamal, MI; Jung, MH; Lee, WS; Oh, CH; Sim, T; Yoo, KH1
Geoerger, B; Leblond, P1
Buonerba, C; Casciano, R; De Placido, S; Di Lorenzo, G; Liu, Z; Malangone, E; Sherman, S; Wang, X; Willet, J1
Bajetta, E; Bearz, A; Calcagno, A; Cartenì, G; Chiappino, I; Guadalupi, V; Imarisio, I; Landi, L; Paglino, C; Porta, C; Procopio, G; Re, GL; Ricotta, R; Rizzo, M; Ruggeri, EM; Sabbatini, R; Verzoni, E; Zustovich, F1
Espinosa, E; González, R; Merino, M; Pinto, A1
Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S1
Fassnacht, M; Kreissl, MC; Schott, M; Spitzweg, C; Willhauck, MJ1
Cunningham, D; Okines, AF; Reynolds, AR1
Blay, JY; Chaigneau, L; Curtit, E; Dobi, E; Kalbacher, E; Mansi, L; Nguyen, T; Pivot, X; Viel, E1
Chan, AL; Leung, HW1
Bloor, A; Cross, NC; Erben, P; Gesk, S; Haferlach, C; Haferlach, T; Hochhaus, A; Hofmann, WK; Metzgeroth, G; Reiter, A; Ritter, M; Score, J; Telford, N; Walz, C1
de Vries, IJ; Desar, IM; Galama, JM; Jacobs, JF; Mulder, SF; Mulders, PF; Olde Nordkamp, MA; Punt, CJ; Teerenstra, S; Torensma, R; van Herpen, CM; Vissers, KC1
Ahn, HK; Kang, WK; Lee, J; Lee, S; Lim, HY; Park, JO; Park, SH; Park, YS; Sun, JM1
Bergmann, L; Gschwend, J; Keilholz, U; Miller, K1
Fujii, M; Fujisawa, M; Kitajima, K; Maeda, T; Miyake, H; Ohno, Y; Sugimura, K; Takahashi, S; Yoshikawa, T1
Busch, J; Grünwald, V; Hinz, S; Kempkensteffen, C; Magheli, A; Miller, K; Seidel, C; Weikert, S; Weinkauf, L; Wolff, I1
Atkinson, B; Choueiri, TK; Chowdhury, S; Matrana, MR; Tannir, NM; Tsang, C1
Budak, K; Pestalozzi, B; Weisshaupt, Ch1
Busch, J; Grünwald, V; Hinz, S; Johannsen, M; Kempkensteffen, C; Magheli, A; Miller, K; Seidel, C; Weikert, S; Wolff, I1
Cunningham, D; Yim, KL1
Atkins, M; Bukowski, R; Choueiri, TK; Dutcher, J; Eisen, T; Elson, P; Escudier, B; Heng, DY; Manola, J; Mazumdar, M; McCormack, JB; Motzer, R; Négrier, S; Royston, P1
Choo, SP; Chow, PK; Chung, AY; Huynh, H; Ong, R; Soo, KC; Tai, WM; Toh, HC1
Calvani, N; Cinefra, M; Cinieri, S; Gnoni, A; Leo, S; Lombardi, L; Lorusso, V; Maiello, E; Morelli, F; Orlando, L1
Ballini, JP; Griffioen, AW; Lovisa, B; Nowak-Sliwinska, P; van Beijnum, JR; van den Bergh, H; Weiss, A; Wong, TJ1
Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K1
Fukui, I; Habuchi, T; Hatake, K; Horikawa, Y; Inoue, T; Nakano, K; Narita, S; Saito, M; Takahashi, S; Tsuchiya, N; Urakami, S; Yamamoto, S; Yonese, J; Yuasa, T1
Joly, F1
Anderson, KC; Podar, K1
Grünberger, B1
Cheng, H; Dicker, AP; Force, T; Kari, G; Koch, WJ; Rodeck, U1
Fiedler, W; Wellbrock, J1
Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V1
Cheng, S; Moslehi, J; Uraizee, I1
Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Mackenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wang, Y; Wood, L1
Adenis, A; Antonescu, CR; Blay, JY; Bompas, E; Bui, B; Casali, P; Cioffi, A; Coco, P; Coindre, JM; Debiec-Rychter, M; Duffaud, F; Isambert, N; Italiano, A; Keohan, ML; Le Cesne, A; Maki, RG; Rutkowski, P; Schöffski, P; Toulmonde, M1
Reed, MW; Young, RJ1
Di Fiore, F; Ménager, C; Michel, P; Pfister, C; Rigal, O1
Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H; Sakai, I1
Calvo Aller, E; Castellano, D; Díaz Cerezo, S; González Larriba, JL; Kreif, N; López-Brea, M; Maroto, P; Martí, B1
Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J1
Dörken, B; Flörcken, A; Hopfenmüller, W; Pezzutto, A; Singh, A; Takvorian, A; Van Lessen, A; Westermann, J1
Chen, X; Guan, W; Hu, Z; Li, Y; Liu, F; Peng, E; Ye, Z; Zhuang, Q1
Hamilton, J; Hong, DS; Ketonen, LM; Kurzrock, R; McCutcheon, IE; Slopis, J; Subbiah, V1
Lanocita, R; Procopio, G; Verzoni, E1
Albiges, L; Caty, A; Dietrich, PY; Duclos, B; Escudier, B; Geoffrois, L; Gravis, G; Guillot, A; Joly, F; Kohser, F; Laguerre, B; Legouffe, E; Negrier, S; Oudard, S; Rolland, F; Theodore, CA1
Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S1
Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C1
Brentani, RR; Cooke, VG; Damascena, A; Duncan, MB; Kalluri, R; Keskin, D; Khan, Z; LeBleu, VS; Maeda, G; O'Connell, JT; Rocha, RM; Sugimoto, H; Teng, Y; Vong, S; Xie, L1
Colecchia, M; Iacovelli, R; Mariani, L; Procopio, G; Torelli, T; Verzoni, E1
Bruyere, F; Carmier, D; Combe, P; D'Arcier, BF; Linassier, C; Narciso, B1
Choueiri, TK; Je, Y; Richards, CJ; Schutz, FA1
Boulanger, G; Edeline, J; Jouan, F; Martin, B; Oger, E; Patard, JJ; Rioux-Leclercq, N; Vigneau, C; Zerrouki, S1
Bellail, AC; Ding, L; Hao, C; Liu, Y; Lu, G; Olson, JJ; Sun, SY; Wang, G; Wei, F; Yuan, C1
Buti, S; Buttitta, F; Calabrese, F; Cavazza, A; Di Chiara, F; Felicioni, L; Garagnani, L; Marchetti, A; Mengoli, MC; Migaldi, M; Nannini, N; Nicoli, D; Rea, F; Rossi, G; Sartori, G; Schirosi, L; Valli, R1
Aste, MG; Buti, S; Conte, PF; Cosmai, L; Del Giovane, C; Di Lorenzo, G; Grosso, F; Iacovelli, R; Invernizzi, R; Lucia Manenti, A; Masini, C; Moscetti, L; Onofri, A; Ortega, C; Pagano, M; Porta, C; Procopio, G; Sabbatini, R1
George, S; Hornick, JL; Jagannathan, JP; Ramaiya, NH; Shinagare, AB1
Czeche, S; Feldt, S; Franzmann, A; Ludwig, WD; Quinzler, R; Schulz, M; Schüssel, K1
Döme, B; Török, S1
Attkisson, E; Aust, MM; Ferreira-Gonzalez, A; Grant, S; Rahmani, M; Williams, DC1
Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Lee, JL; Park, I; Park, K; Park, S; Song, C1
Byun, SS; Hong, SK; Jeong, CW; Jeong, SJ; Kwak, C; Lee, SE; Yoon, CY1
Hayashi, N; Ikeda, I; Inoue, T; Kishida, T; Kobayashi, K; Kubota, Y; Makiyama, K; Minamimoto, R; Miura, T; Murakami, T; Nakaigawa, N; Noguchi, S; Ohgo, Y; Sano, F; Tateishi, U; Ueno, D; Yao, M1
Chung, AS; Ferrara, N; Finkle, D; Komuves, L; Kowanetz, M; Ngu, H; Peale, F; Wu, X; Zhuang, G1
Daimon, M; Kaino, W; Kameda, W; Karasawa, S; Kato, T; Oizumi, T; Susa, S; Takase, K; Tomita, Y; Wada, K1
Kuczyk, MA; Schnoeller, TJ; Schrader, AJ; Schrader, M; Steffens, S1
He, H; Shen, Z; Wang, H; Wang, X; Wu, Y; Zhang, C; Zhao, J; Zhou, W; Zhu, Y1
Buchler, T; Cathomas, R; Chastonay, R; Haile, SR; Knuth, A; Liewen, H; Porta, C; Renner, C; Rothermundt, C; Samaras, P; Siciliano, RD; Stenner, F; Stoll, S1
Agarwala, SS; Chen, CC; Garay, CC; Gesme, DH; Guo, A; Hess, GP; Hill, JW; Liu, Z1
Abrahamova, J; Bortlicek, Z; Buchler, T; Dusek, L; Melichar, B; Pavlik, T; Poprach, A; Puzanov, I; Vyzula, R1
Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D1
Geisberg, C; Pentassuglia, L; Sawyer, DB1
Abrahamova, J; Bortlicek, Z; Buchler, T; Melichar, B; Pavlik, T; Poprach, A; Vyzula, R1
Halfdanarson, TR; Naraev, BG; Strosberg, JR1
Giaccone, G; Killian, KJ; Lee, C; Lee, HS; Luo, J; Meltzer, PS; Petrini, I; Roncalli, M; Santoro, A; Steinberg, SM; Tsokos, M; Wang, Y; Zucali, PA1
Kaklamani, V; Raffin, M; Reddy, S1
Baumann, C; Dahal, BK; Davie, N; Evans, S; Fairman, D; Ghofrani, HA; Grimminger, F; Kilty, I; Kojonazarov, B; Kosanovic, D; Luitel, H; Majewski, M; Phillips, P; Pullamsetti, SS; Schermuly, RT; Seeger, W; Sydykov, A; Tian, X; Wayman, C; Weissmann, N1
Arai, Y; Kawashima, A; Nakai, Y; Nin, M; Nishimura, K; Nonomura, N; Takayama, H; Tanigawa, G; Tsujimura, A; Uemura, M1
Fukui, I; Kitsukawa, S; Saito, K; Takahashi, S; Urakami, S; Yamamoto, S; Yasuda, Y; Yonese, J; Yuasa, T1
Saito, K1
Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S1
Krzemieniecki, K; Sowa-Staszczak, A; Zygulska, AL1
Bottai, G; Santarpia, L1
Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ1
Kondo, T1
Puche-Sanz, I; Vázquez-Alonso, F1
Breaker, K; Clemons, J; Flaig, TW; Gao, D; Garfield, D; Naam, M1
Benekli, M; Buyukberber, S; Cetin, B; Guz, G; Inal, S; Memis, L; Ozturk, SC; Turan, N1
Atkinson, B; Chen, A; Sevin, A1
Albiges, L; Escudier, B; Iacovelli, R; Lanoy, E1
Karakiewicz, PI; Sun, M; Trinh, QD1
Berkers, J; Beuselinck, B; Body, JJ; Debruyne, P; Dumez, H; Elaidi, R; Karadimou, A; Lerut, E; Paridaens, R; Rogiers, A; Schöffski, P; Van Cann, T; Van Poppel, H; Willems, L; Wolter, P1
Hensley, JR; Kulik, L; Lacouture, ME; Mulcahy, M; Nardone, B; Rademaker, A; West, DP1
Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J1
Bex, A; de Bruijn, R; Horenblas, S; Kroon, BK; Powles, T; Prevoo, W1
Lin, CI; Lorch, JH; Ruan, DT; Whang, EE1
Hoekstra, R; Honeywell, RJ; Peters, GJ; van Erp, NP; Verheul, HM; Westgeest, HM1
Chang, AY; Wang, M1
Adenis, A; Alt, M; Caty, A; Fumagalli, I; Penel, N; Vanhuyse, M; Zini, L1
Ambring, A; Björholt, I; Lesén, E; Odén, A; Stierner, U1
Chen, CS; Chen, WM; Cheng, CL; Chiu, KY; Ho, HC; Li, JR; Ou, YC; Su, CK; Wang, SS; Yang, CK; Yang, CR1
Agarwal, S; Chi, M; Dudek, AZ; Elmquist, WF; Mittapalli, RK; Oberoi, R; Raza, A; Singhal, M1
Borker, R; Fonseca, E; Hess, G1
Frampas, E; Koscielny, S; Lassau, N; Vilgrain, V; Vullierme, MP; Zappa, M1
Pal, SK; Vogelzang, NJ1
Alasker, A; Bianchi, M; Hanna, N; Hansen, J; Ismail, S; Karakiewicz, PI; Meskawi, M; Perrotte, P; Sun, M; Tian, Z1
Beuselinck, B; Blesius, A; Chevreau, C; Escudier, B; Oudard, S; Ravaud, A; Rolland, F1
Ashikari, A; Kobayashi, H; Kohno, Y; Namitome, R; Nishiyama, T; Saito, S; Yagi, Y1
Cortesi, E; Iacovelli, R; Mezi, S; Naso, G; Palazzo, A; Pellegrino, D; Trenta, P1
Rose, S1
Abadie-Lacourtoisie, S; Azzouzi, AR; Bigot, P; Chautard, D; Delva, R; Hoarau, N; Latteux, G; Lebdai, S1
Breaker, K; Flaig, IP; Flaig, TW; La Rosa, FG; Naam, M1
de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A1
Albiges, L; Di Palma, M; Escudier, B; Fizazi, K; Levy, A; Loriot, Y; Menard, J1
Omrčen, T; Rini, B; Schmidinger, M; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E1
Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Lee, DH; Lee, JL; Park, I; Park, K; Park, SJ; Song, C1
Andriamanana, I; Duretz, B; Gana, I; Hulin, A1
Robert, C; Sibaud, V1
Buchholz, DE; Clegg, DO; Coffey, PJ; Croze, RH; Hinman, CR; Pennington, BO1
Calvani, N; Chiuri, V; Cinieri, S; Fedele, P; Gnoni, A; Lorusso, V; Maiello, E; Morelli, F; Orlando, L; Scavelli, C1
Ammi, M; Azzouzi, AR; Baumert, H; Beauval, JB; Bensalah, K; Berger, J; Bernhard, JC; Bigot, P; Escudier, B; Fardoun, T; Grenier, N; Hétet, JF; Lagabrielle, S; Lebdai, S; Long, JA; Paparel, P; Patard, JJ; Rioux-Leclercq, N; Rouprêt, M; Soulié, M; Xylinas, E1
Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T1
Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J1
Al-Harbi, H; Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; MacKenzie, M; North, S; Rini, BI; Vickers, MM1
Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY1
Prado, CM1
Itoh, K; Komai, Y; Matsubara, N; Mukai, H; Naito, Y; Sakai, Y1
Dokduang, H; Juntana, S; Khuntikeo, N; Loilome, W; Namwat, N; Riggins, GJ; Techasen, A; Yongvanit, P1
Chang, YC; Cheng, AL; Hsu, C; Lee, BS; Lin, LI; Liou, JY; Ou, DL1
Bianco, R; Damiano, V; Formisano, L; Martignoni, G; Massari, F; Nappi, L; Rosa, R; Scarpa, A; Tortora, G1
Beijnen, JH; de Vries, N; Schinkel, AH; Sparidans, RW; Tang, SC; Wagenaar, E1
Saif, MW; Sarris, EG; Syrigos, KN1
Banerjee, P; Begum, S; Castellanos, MR; Debata, PR; Genzer, O; Kleiner, MJ; Mata, A1
Abernethy, AP; Chen, C; George, DJ; Harrison, MR; Kirkendall, DT; Korytowsky, B; Stepanski, EJ; Walker, MS1
Barney, BM; Bauer, HJ; Laack, NN; Macdonald, OK; Markovic, SN; Miller, RC; Olivier, KR; Sarkaria, JN1
Baker, SD; Buaboonnam, J; Enemark, EJ; Inaba, H; Mullighan, CG; Neale, GA; Olsen, SR; Orwick, S; Rubnitz, JE; Shurtleff, S; Wang, YD; Zatechka, DS; Zimmerman, EI1
Garcia-Donas, J; Jonasch, E; Rodriguez-Antona, C1
Kubota, Y; Makiyama, K; Nakaigawa, N; Nakamura, M; Sakata, R; Sano, F; Tatenuma, T; Yao, M1
Derbel Miled, O; Dionne, C; Droz, JP; Flechon, A; Negrier, S; Neidhart, EM; Segura-Ferlay, C; Terret, C1
Alesini, D; Cascinu, S; Cortesi, E; De Marchis, L; Iacovelli, R; Naso, G; Palazzo, A; Santoni, M; Trenta, P1
Bartz-Schmidt, KU; Bayyoud, T; Hofmann, J; Spitzer, M; Yoeruek, E1
Cheng, AL; Chung, HC; Kang, YK; Kudo, M; Lanzalone, S; Lechuga, MJ; Lin, DY; Omata, M; Park, JW; Pitman Lowenthal, S; Poggi, G; Qin, S; Raymond, E; Song, X; Xu, J; Yang, L1
Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M1
Ding, JF; Zhong, DF1
Bastide, C; Bay, JO; Bruyere, F; Guy, L; Karsenty, G; Mahammedi, H1
Ghavimi, H; Hamishekar, H; Jouyban, A; Shayanfar, A1
Bamias, A; Bearz, A; Bellmunt, J; Imarisio, I; Melichar, B; Paglino, C; Porta, C; Procopio, G; Sabbatini, R; Schmidinger, M; Tinelli, C1
Fischer, JW; Freudenberger, T; Kretschmer, I; Nagy, N; Niedworok, C; Reis, H; Röck, K; Rübben, H; Szarvas, T; Vom Dorp, F1
Novara, G; Zustovich, F1
Ahn, JH; Bellmunt, J; Castellano, D; Chang, YH; Chiang, PH; Chuang, CK; Diaz, JR; Donnellan, P; Duh, MS; Elaidi, R; Feinberg, BA; Hawkins, R; Huang, CY; Korves, C; Levy, A; McCaffrey, J; McDermott, D; McDermott, R; Mehmud, F; Nathan, P; Neary, MP; Oh, WK; Ou, YC; Porta, C; Rha, SY; Scott, J; Scotte, F; Sun, JM; Wagstaff, J1
Fukatsu, A; Gotoh, M; Hattori, R; Kuroda, M; Kuwahara, K; Morikawa, T; Sassa, N; Shimoyama, Y; Shiroki, R; Tsuzuki, T; Yoshino, Y1
Bjarnason, GA; Escudier, B; Esteban, E; Hariharan, S; Hutson, TE; Lim, HY; Lu, DR; Motzer, RJ; Niethammer, A; Pittman, KB; Senico, P1
Afsar, B; Benekli, M; Buyukberber, S; Cetin, B; Coskun, U; Deger, SM; Gonul, II; Gumusay, O; Ozet, A1
A, M; H J, H; L, M; M, K; N, M; P J, G; S, B1
Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Svoboda, M; Vyzula, R1
Garcia-Roig, M; Lokeshwar, V; Ortiz, N1
Hutchinson, L1
Payton, S1
Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M1
Agarwal, N; Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Lee, J; Mackenzie, M; North, S; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Tan, MH; Vaishampayan, UN; Wood, LA; Yuasa, T1
Appleman, LJ; Bass, MB; Friberg, G; Friedland, D; Gordon, MS; Hong, DS; Kurzrock, R; Mendelson, DS; Rasmussen, E; Samlowski, WE; Tannir, N; Vogelzang, NJ; Wu, BM; Zhong, ZD1
El-Gamal, MI; Oh, CH1
Arnaldi, G; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Massari, F; Procopio, G; Rizzo, M; Santoni, M; Tortora, G; Trementino, L1
Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M1
Bougnoux, P; Chantôme, A; Chevalier, S; Clarysse, L; Guéguinou, M; Potier-Cartereau, M; Vandecasteele, G; Vandier, C1
Stadler, WM1
De Lichtenberg, TH; Hermann, GG; Holm, ML; Højer Larsen, MJ; Mansourvar, Z; Rørth, M; Scheike, T1
Bögemann, M; Herrmann, E; Hertle, L; Hoffmeister, I; Krabbe, LM; Moritz, R; Papavassilis, P; Thielen, B1
Bergmann, L; Burkholder, I; Gauler, T; Grünwald, V; Kahl, C; Kube, U; Maute, L; Weikert, S1
Chong, Y; Kim, MK; Shin, H1
Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R1
Ferrari, S; Paioli, A; Palmerini, E1
Bertens, D; Desar, IM; Kessels, RP; Langenhuijsen, JF; Mulder, SF; Mulders, PF; Punt, CJ; van Herpen, CM; van Spronsen, DJ; Vissers, KC1
Croft, SL; Sanderson, L; Yardley, V1
Ambrosetti, D; Amiel, J; Gastaud, L; Grépin, R; Marsaud, A; Pagès, G; Pedeutour, F1
de Vos, R; Koldenhof, JJ; Teunissen, SC; Tillier, CN; Verheul, HM; Walraven, M; Witteveen, PO1
Ahn, H; Hong, JH; Jeong, IG; Kim, CS; Kwon, T; Lee, JL; Song, C; You, D1
Ara, M; Pastushenko, E1
Biondani, P; DE Braud, F; Grassi, P; Porcu, L; Procopio, G; Testa, I; Torri, V; Verzoni, E1
Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ1
Bellmunt, J; Bracarda, S; Cerbone, L; Choueiri, TK; Fay, AP; Foreshew, A; Hutson, TE; Lampron, ME; Pons, F; Porta, C; Powles, T; Sternberg, CN1
Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Khambati, HK; Knox, JJ; Kollmannsberger, CK; MacKenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wood, L1
Beaune, P; de Waziers, I; Favre, A; Figg, WD; Kiehl, P; McMullen, J; Montemurro, M; Narjoz, C; Rochat, B1
Cisar, L; Clark, JI; Escudier, B; Hariharan, S; Hutson, TE; Kannourakis, G; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Porfiri, E; Rini, BI; Rosbrook, B; Staehler, M; Tarazi, J; Zalewski, P1
Elledge, R; Elledge, RO; Raskauskiene, D1
Berkers, J; Beuselinck, B; De Wever, L; Dumez, H; Joniau, S; Lerut, E; Oyen, R; Paridaens, R; Schöffski, P; Strijbos, M; Van Poppel, H; Wolter, P1
Bozcuk, H; Coskun, HS; Gunduz, S; Mutlu, H; Uysal, M1
Fujisawa, M; Furukawa, J; Kusuda, Y; Miyake, H1
Czarnecka, AM; Oborska, S; Rzepecki, P; Szczylik, C1
Blanchard, F; Di Fiore, F; Nouhaud, FX; Pfister, C; Rebibo, JD; Sabourin, JC1
Elsner, A; Fitzner, B; Heuschkel, M; Jaster, R; Krause, BJ; Lange, F1
Bito, T; Hirai, M; Hirano, T; Kume, M; Makimoto, H; Mizumoto, A; Mukai, A; Nakagawa, T; Nishigori, C; Nishimura, K; Uda, A; Yamamoto, K; Yamashita, K1
Anouar, Y; Baudin, E; Denorme, M; Dubessy, C; Gonzalez, BJ; Roux, C; Yon, L1
Blacher, S; Calligaris, D; Cimino, J; De Pauw, E; De Tullio, P; Debois, D; Mari, B; Mazzucchelli, G; Noel, A; Paye, A; Primac, I; Sounni, NE; Truong, A1
Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E1
Chen, IT; Chen, KF; Hsu, CY; Li, YS; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH; Wu, SH1
Coplin, MA; Donahue, RN; Farsaci, B; Grenga, I; Hodge, JW; Lepone, LM; Molinolo, AA1
Kartashova, EA; Romantsov, MG; Sarvilina, IV1
Badalamenti, G; Baldi, GG; Casali, PG; Cominetti, D; Dagrada, GP; Dei Tos, AP; Festinese, F; Fumagalli, E; Grignani, G; Gronchi, A; Morosi, C; Negri, T; Pennacchioli, E; Pilotti, S; Provenzano, S; Spagnuolo, RD; Stacchiotti, S; Tortoreto, M; Toss, A; Zaffaroni, N1
Buonomano, P; Camera, L; Circelli, L; Colao, A; Del Prete, M; Di Somma, C; Faggiano, A; Marciello, F; Marotta, V; Modica, R; Ramundo, V; Rubino, M; Sciammarella, C1
Chen, KF; Chiang, HC; Chu, PY; Hsu, CY; Huang, JW; Ko, CH; Li, YS; Lin, MW; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH1
Ahmed, M; Coleman, CN; Curran, WJ; Dicker, AP; Finkelstein, SE; Houghton, P; Kirsch, DG; Machtay, M; Monjazeb, AM; Teicher, BA; Vikram, B; Wang, D; Wong, P; Xu-Welliver, M1
Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L1
Adenis, A; Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Cassier, P; Chaigneau, L; Chevreau, C; Collard, O; Cropet, C; Cupissol, D; Duffaud, F; Eberst, L; Gentet, JC; Le Cesne, A; Marec-Berard, P; Pautier, P; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Thyss, A1
Mullangi, R; Sharma, K; Srinivas, NR; Suresh, PS1
Galanis, A; Levis, M1
Bartsch, G; Blaheta, RA; Haferkamp, A; Juengel, E; Kim, D; Makarević, J; Reiter, M; Tsaur, I1
Cowen, EW; Massey, PR; Okman, JS; Wilkerson, J1
Bernardini, M; Brossa, A; Bussolati, B; Fiorio Pla, A; Genova, T; Gkika, D; Grolez, G; Leroy, X; Prevarskaya, N; Villers, A1
Götze, L; Hegele, A; Hofmann, R; Keil, C; Nockher, WA; Olbert, P1
Donskov, F; Fode, K; Geertsen, PF; Hermann, GG; Ibsen, R; Jensen, NV; Kjellberg, J; Soerensen, AV1
Chan, JK; Chung, AY; Endaya, BB; Gnecchi, M; Ho, IA; Hui, KM; Huynh, H; Iyer, NG; Lam, PY; Leong, HS; Lim, KH; Newman, JP; Sia, KC; Toh, XY; Yulyana, Y1
Azijli, K; Broxterman, HJ; de Haas, RR; Dekker, H; Gotink, KJ; Honeywell, RJ; Peters, GJ; Poel, D; Rovithi, M; Verheul, HM1
Amir, E; Ethier, JL; Krzyzanowska, MK; Ocana, A; Seruga, B; Srikanthan, A1
Aderhold, C; Birk, R; Faber, A; Hörmann, K; Schultz, JD; Sommer, JU; Umbreit, C; Weiss, C1
Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D1
Kalyan, A; Kulik, L; Nimeiri, H1
Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U1
Akkar, OB; Cetin, A; Kacan, SB; Kacan, T; Karakus, S; Ozer, H; Yildiz, C1
Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; Haas, NB; Jewett, M; Kane, CJ; Ky, B; Manola, J; Uzzo, RG; Wilding, G; Wood, CG; Wood, L1
Thoma, C1
Bensalah, K; Ouzaid, I1
Charbit, D; Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Sabourin, JC1
Di Bella, S; Facchetti, R; Giannattasio, C; Giganti, MO; Maloberti, A; Mancia, G; Meani, P; Moreo, A; Musca, F; Pozzi, M; Ricotta, R; Sartore-Bianchi, A; Siena, S; Stucchi, M; Vallerio, P1
Albuquerque, M; Benhadji, KA; de Gramont, A; Dos Santos, C; Faivre, S; Neuzillet, C; Paradis, V; Raymond, E; Serova, M; Tijeras-Raballand, A1
Iguchi, T; Kato, M; Nakatani, T; Ninomiya, N; Tamada, S; Yamasaki, T1
Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT1
Komarov, YI; Latipova, DH; Novik, AV; Protsenko, SA; Semenova, AI; Teletaeva, GM1
Albiges, L; Escudier, B1
Di Cesare Mannelli, L; Farina, C; Ghelardini, C; Maresca, M; Scherz, MW1
Gemma, A; Miyanaga, A1
Kato, S1
Aliper, A; Borisov, N; Buzdin, A; Kholodenko, R; Malakhova, G; Roumiantsev, S; Shepelin, D; Suntsova, M; Vasilov, R; Venkova, L; Zhavoronkov, A1
Abernethy, AP; George, DJ; Harrison, MR; Hirsch, BR; Mitchell, AP; Walker, MS1
Covell, LL; Ganti, AK1
Fujisawa, M; Harada, K; Imai, S; Miyake, H; Miyazaki, A1
Fujisawa, M; Harada, K; Imai, S; Miyake, H1
Boers-Sonderen, MJ; De Geus-Oei, LF; Desar, IM; Fütterer, JJ; Mulder, SF; Mulders, PF; Oyen, WJ; Van Der Graaf, WT; Van Herpen, CM1
Atkins, MB; Barac, A; Freedman, AN; Fu, AZ; Jang, S; Minasian, L; Potosky, AL; Tsai, HT; Zheng, C1
Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Rebibo, JD1
Fenner, A1
Bandaru, S; Dunna, NR; Girdhar, A; Hussain, T; Kandula, V; Nayarisseri, A; Pudutha, A1
Crawford, K; Dusing, M; Frischer, JS; Knod, JL1
Ahn, JH; Cho, YM; Lee, DH; Lee, JL; Park, I1
Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W1
Grünwald, V; Ivanyi, P1
Cartenì, G; Vitale, MG1
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ1
Ahn, H; Ahn, JH; Hong, B; Hong, JH; Jeong, IG; Koo, DH; Lee, DH; Lee, JL; Park, I; Song, C; You, D1
Koo, V; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ1
Czarnecka, AM; Kornakiewicz, A; Solarek, W; Szczylik, C1
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ; Yang, C1
Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M1
Lin, Z; Shu, M; Wang, R; Zai, X; Zhang, B1
Ha, AS; Imran, TF; Joseph, J; Shah, R; Thomas, R1
Brossart, P; Diehl, L; Garbi, N; Gevensleben, H; Grünwald, B; Heine, A; Held, SA; Höchst, B; Knolle, P; Krüger, A; Kurts, C; Schilling, J1
Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C1
Diekstra, MH; Gelderblom, H; Guchelaar, HJ; Swen, JJ1
Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S1
Chi, Z; Cui, C; Guo, J; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X1
Blumenstengel, K; Busies, S; Hutzschenreuter, U; Marschner, N; Müller, L; Münch, A1
Warren, RB; Yiu, ZZ1
Atkins, MB; Carducci, M; Cella, D; Choueiri, TK; Coomes, R; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Jewett, M; Kane, C; Kohli, M; Kuzel, TM; Manola, J; Matin, S; Pili, R; Pins, M; Puzanov, I; Sexton, WJ; Stadler, W; Uzzo, RG; Wagner, L; Wilding, G; Wong, YN; Wood, CG1
Duensing, S; Hohenfellner, M1
Bodnar, L; Chrom, P; Semeniuk-Wojtas, A; Spencer, NJ; Stec, R; Szczylik, C1
Galsky, MD; Mehrazin, R; Sfakianos, J; Tsao, CK1
Stone, L1
Keck, B; Lieb, V; Lüdecke, G; Sikic, D1
Grünwald, V; Kalanovic, D; Lin, X; Simantov, R1
Bedke, J; Gauler, T; Grünwald, V; Hegele, A; Herrmann, E; Hinz, S; Janssen, J; Miller, K; Schmitz, S; Schostak, M; Tesch, H; Zastrow, S1
Bai, Q; Guo, J; Liu, L; Long, Q; Qu, Y; Wang, J; Xi, W; Xia, Y; Xiong, Y; Xu, J1
Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME1
Chagin, K; Djousse, L; Fraeman, KH; Gagnon, DR; Hall, SA; Nelson, J; Nordstrom, BL; Shantakumar, S; van Herk-Sukel, M1
Aziz, SA; Bhat, GM; Changal, KH; Lone, AR; Mir, MH1
Jalkanen, S; Joensuu, H; Laukkanen, MO; Laurila, JP; Salmi, M1
Bruno, R; Chanu, P; Chen, Y; Claret, L; Mercier, F; Milligan, PA; Rosbrook, B; Yazdi, P; Zheng, J1
Chung, J; Joo, J; Joung, JY; Kim, S; Kim, SH; Lee, KH; Seo, HK1
Gao, Y; Guo, G; Li, H; Liu, K; Ma, X; Meng, Q; Song, Z; Wang, D; Wang, L; Zhang, X; Zhang, Y; Zhao, C1
Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yagisawa, T1
Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M1
Bourlon, MT; Breaker, K; Clemons, JE; Flaig, TW; Gao, D; Lam, ET; Trigero, S1
Anai, S; Fujimoto, K; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y1
Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH1
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A1
Campitiello, M; Eid, N; Hennequin, L; Longo, R; Plastino, F; Quétin, P; Wendel, C1
Chi, ZH; Guo, J; He, ZS; Li, XS; Sheng, XN; Wang, HK; Ye, DW; Zhang, HL1
Joshi, A; Kannan, RA; Kothari, R; Menon, S; Noronha, V; Patil, VM; Popat, P; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A1
Bonsignore, R; Gentile, C; Lauria, A; Martorana, A1
Bedke, J; Burchardt, M; Kroeger, N; Stenzl, A1
Huang, L; Luo, C; Wen, T; Xiao, H; Xiong, M1
Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Xi, W; Xiong, Y; Xu, J; Yao, J1
Kong, W; Liu, G; Liu, X; Qu, J; Suo, S; Wu, G; Xu, J; Zhang, J1
Agarwal, N; Ghate, SR; Li, N; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML1
Afriansyah, A; Hamid, AR; Mochtar, CA; Umbas, R1
Aubert, RE; Clore, G; Epstein, RS; Herrera, V; Kourlas, H; La-Beck, NM; McLeod, HL; Walko, CM1
Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhou, L2
Abe, K; Iwata, T; Kakoki, K; Miyata, Y; Mochizuki, Y; Nagayasu, T; Obatake, M; Sakai, H1
Gobe, GC; He, Y; Hooper, J; Jeffery, PL; Lourie, R; McGuckin, MA; Morais, C; Ng, CP; Oancea, I; Seim, I; Shah, ET; Sheng, Y; Wong, KY1
Affolter, A; Brenner, W; Brieger, J; Heimes, AS; Jensen, A; Mann, WJ; Mayer, A; Samosny, G; Schneider, J; Sommer, K; Stenzinger, A; Weichert, W1
Bauer, J; Grimm, D; Magnusson, NE; Randrup Hansen, C; Wehland, M1
Dragomir, A; Edqvist, PH; Enblad, G; Niinivirta, M; Pontén, F; Ullenhag, GJ1
Albiges, L; Ficarra, V; Heng, DY; Hsieh, JJ; Larkin, J; Purdue, MP; Schmidinger, M; Signoretti, S; Swanton, C1
Atkins, MB; Choueiri, TK; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Manola, J; Uzzo, RG1
Cho, A; Choi, YD; Hwang, SH; Kang, WJ; Rha, SY; Yun, M1
Alivon, M; Boutouyrie, P; De Lepper, AG; Delhaas, T; Giroux, J; Goldwasser, F; Reesink, KD; Spronck, B1
Ambert, V; Cambon-Thomsen, A; Castellano, D; Diekstra, MHM; Eisen, T; Fritsch, A; Garcia Donas, J; Guarch Troyas, R; Guchelaar, HJ; Hartmann, A; Hulsbergen-van de Kaa, C; Jaehde, U; Junker, K; Kiemeney, LALM; Martinez-Cardus, A; Masson, G; Maurits, JSF; Oosterwijk, E; Oosterwijk-Wakka, J; Oskarsdottir, A; Radu, MT; Rafnar, T; Rodriguez-Antona, C; Roessler, M; Ruijtenbeek, R; Stefansson, K; van der Zanden, LFM; Vermeulen, SH; Warren, A; Wessels, L1
Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Bonneville-Levard, A; Chauffert, B; Chevreau, C; Cupissol, D; Duffaud, F; Fabbro, M; Feuvret, L; Le Cesne, A; Lebellec, L; Mir, O; Noel, G; Penel, N; Saada-Bouzid, E; Vauleon, E; Vinceneux, A1
Antonuzzo, L; Balestri, V; Brugia, M; Costanzo, FD; Giommoni, E; Laffi, A; Lunghi, A; Mazzoni, F; Mela, MM; Petreni, P1
Cai, W; Chen, Y; Huang, J; Huang, Y; Kong, W; Zhang, J; Zhou, L1
Agarwal, N; Gill, DM; Vaishampayan, U1
Goto, H; Goto, S; Hamanoue, S; Iwasaki, F; Keino, D; Kitagawa, N; Miyagawa, N; Miyagi, Y; Sarashina, T; Sekiguchi, H; Shiomi, M; Sugiyama, M; Tanaka, Y; Yokosuka, T1
Choueiri, TK; Kaymakcalan, MD; Lalani, AA; Lin, X; McKay, RR; Simantov, R1
Bortlicek, Z; Buchler, T; Chloupková, R; Dusek, L; Fiala, O; Finek, J; Hornova, J; Kiss, I; Kopeckova, K; Kopecky, J; Lakomy, R; Melichar, B; Poprach, A; Slaby, O; Studentova, H; Svoboda, M; Vyzula, R; Zemanova, M1
Fujii, Y; Ishioka, J; Kawamura, N; Kihara, K; Matsuoka, Y; Okuno, T; Saito, K; Uehara, S; Yamamoto, S; Yasuda, Y; Yokoyama, M; Yonese, J; Yuasa, T1
Durand-Zaleski, I; Fleury, L; Maroun, R; Maunoury, F; Nachbaur, G; Vanhille, JL1
Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhong, H; Zhou, L1
Hu, D; Huang, M; Li, Z; Wu, S; Yu, W; Zhang, A; Zhang, H; Zhang, K; Zheng, K1
Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C1
Bersanelli, M; Buti, S; DiPaola, RS; Haas, NB; Manola, J; Puligandla, M; Taguchi, S1
Angus, SP; Beak, JY; Chen, X; Hicks, ST; Huang, W; Jensen, BC; Johnson, GL; Parry, TL; Sciaky, N; Stuhlmiller, TJ; Willis, MS; Zawistowski, JS1
He, HL; Yao, WX1
Alonso, V; Asensio, E; Camps, J; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Feliu, J; Fernández-Martos, C; Gaba, L; Gallego, J; García-Albéniz, X; Horndler, C; Jares, P; Marín-Aguilera, M; Martín-Richard, M; Martínez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Méndez, JC; Méndez, M; Montironi, C; Prat, A; Reig, O; Rojo, F; Rosell, R; Rubini, M; Salud, A; Victoria, I1
Fukuda, H; Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yoshida, K1
Cardwell, LA; Cline, A; Feldman, SR1
Cheng, IG; Hespel, L; Kato, K; Kobayashi, M; Lee, E; Matsunaga, YT; Nakajima, H; Pauty, J; Soncin, F; Takahashi, H; Usuba, R; Yger, F1
Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Wang, Z; Xiong, Y; Xu, J; Yang, Y1
Abdel-Rahman, O1
Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG1
Golinelli, G; Pia, F; Rosa, MS; Toso, A; Valletti, PA1
Carlisle, B; Federico, CA; Kimmelman, J1
Cao, YW; Dong, Z; Guo, L; Kang, EH; Liu, Y; Niu, HT; Wang, YH; Zhang, W1
Cai, W; Chen, YH; Dong, BJ; Huang, JW; Huang, YR; Kong, W; Li, MY; Xue, W; Yuan, YC; Zhang, J; Zhou, LX1
Chen, LJ; Li, BT; Mai, HX; Mei, GH; Tang, YY; Xu, XJ; Zhang, B; Zhao, FL1
Hikasa, Y; Leong, ZP1
Fuss, H; Jung, S; Lademann, J1
Adnan, M; Lin, Y; Luo, CX; Shang, Y; Yin, WX1
Westhovens, R1
Aykara, I; Diller, M; Frommer, K; Hasseli, R; Hülser, ML; Müller-Ladner, U; Neumann, E; Rehart, S1
Feng, Q; Guo, M; Qiu, Q; Tan, X1
Georgiou, S; Plachouri, KM1
Morinobu, A1
Kim, JW; Kim, SY1

Reviews

240 review(s) available for niacinamide and pyrroles

ArticleYear
[Advance in pharmacology of potassium channels in cardiovascular system and their clinical use].
    Zhonghua yi xue za zhi, 1992, Volume: 72, Issue:3

    Topics: Benzopyrans; Cromakalim; Guanidines; Humans; Muscle, Smooth, Vascular; Myocardium; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Vasodilator Agents

1992
Potassium channel openers: pharmacological and clinical aspects.
    Fundamental & clinical pharmacology, 1992, Volume: 6, Issue:7

    Topics: Animals; Benzopyrans; Cardiovascular Diseases; Cromakalim; Heart; Humans; Muscle, Smooth; Nervous System; Niacinamide; Nicorandil; Potassium Channels; Pyrroles; Vasodilator Agents

1992
Clinical pharmacology of potassium channel openers.
    Pharmacology & toxicology, 1992, Volume: 70, Issue:4

    Topics: Antihypertensive Agents; Benzopyrans; Cardiovascular System; Cromakalim; Guanidines; Humans; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Respiratory System

1992
Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential.
    Medicinal research reviews, 1992, Volume: 12, Issue:2

    Topics: Animals; Antihypertensive Agents; Benzopyrans; Cardiovascular System; Central Nervous System; Clinical Trials as Topic; Cromakalim; Disease Models, Animal; Guanidines; Humans; Muscle, Smooth, Vascular; Muscles; Neurons; Niacinamide; Nicorandil; Pancreas; Pinacidil; Potassium Channels; Pyrroles; Vasodilator Agents

1992
[Nitrogen compounds of tobacco smoke].
    Arzneimittel-Forschung, 1969, Volume: 19, Issue:7

    Topics: Acridines; Alkaloids; Alkanes; Amines; Amino Acids; Aniline Compounds; Carbazoles; Cyanates; Indoles; Isoquinolines; Ketones; Niacinamide; Nicotiana; Nicotine; Nicotinic Acids; Nitriles; Nitrites; Nitrosamines; Piperidines; Plants, Toxic; Pyrazines; Pyridines; Pyrroles; Pyrrolidines; Quinolines; Quinoxalines; Smoking

1969
Pharmacology and structure-activity relationships for KATP modulators: tissue-selective KATP openers.
    Journal of cardiovascular pharmacology, 1994, Volume: 24 Suppl 4

    Topics: Action Potentials; Adenosine Triphosphate; Animals; Antihypertensive Agents; Benzopyrans; Cardiovascular Diseases; Cromakalim; Diazoxide; Guanidines; Guinea Pigs; Minoxidil; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Picolines; Pinacidil; Potassium Channels; Pyrans; Pyrroles; Radioligand Assay; Rats; Structure-Activity Relationship; Vasodilator Agents

1994
Cerebral vascular smooth muscle potassium channels and their possible role in the management of vasospasm.
    Pharmacology & toxicology, 1994, Volume: 75, Issue:6

    Topics: Adenosine Triphosphate; Animals; Benzopyrans; Calcium; Cromakalim; Electrophysiology; Guanidines; Ischemic Attack, Transient; Muscle, Smooth, Vascular; Neuropeptides; Niacinamide; Nicorandil; Nitric Oxide; Pinacidil; Potassium Channels; Pyrroles; Vasoconstriction; Vasodilator Agents

1994
[Potassium agonists].
    Medizinische Monatsschrift fur Pharmazeuten, 1994, Volume: 17, Issue:6

    Topics: Animals; Benzopyrans; Calcium; Cromakalim; Humans; Membrane Potentials; Muscle, Smooth, Vascular; Myocardial Ischemia; Neuromuscular Junction; Niacinamide; Nicorandil; Potassium; Potassium Channels; Pyrroles; Vascular Resistance; Vasodilator Agents

1994
Do the K+ channel openers relax smooth muscle by opening K+ channels?
    Trends in pharmacological sciences, 1993, Volume: 14, Issue:9

    Topics: Adenosine Triphosphate; Animals; Benzopyrans; Calcium; Cromakalim; Humans; Inositol 1,4,5-Trisphosphate; Membrane Potentials; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Potassium; Potassium Channels; Pyrroles; Vasodilator Agents

1993
[Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
    Nihon rinsho. Japanese journal of clinical medicine, 1993, Volume: 51, Issue:5

    Topics: Animals; Benzopyrans; Calcium Channel Blockers; Cromakalim; Guanidines; Heart Failure; Hemodynamics; Humans; In Vitro Techniques; Ion Channel Gating; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Vasodilator Agents

1993
[Potential role of ATP-sensitive K+ channels in ischemia- and reperfusion-induced arrhythmias].
    Kokyu to junkan. Respiration & circulation, 1993, Volume: 41, Issue:6

    Topics: Action Potentials; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Benzopyrans; Cromakalim; Glyburide; Guanidines; Humans; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Niacinamide; Nicorandil; Pinacidil; Potassium; Potassium Channels; Pyrroles; Tolbutamide

1993
Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion.
    Canadian journal of physiology and pharmacology, 1997, Volume: 75, Issue:4

    Topics: Animals; ATP-Binding Cassette Transporters; Benzopyrans; Cromakalim; Guanidines; Humans; Ischemic Preconditioning, Myocardial; KATP Channels; Mitochondria, Heart; Models, Cardiovascular; Myocardial Ischemia; Myocardial Reperfusion; Niacinamide; Nicorandil; Picolines; Pinacidil; Potassium Channels; Potassium Channels, Inwardly Rectifying; Pyrans; Pyrroles; Rats

1997
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
    Current oncology reports, 2005, Volume: 7, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2005
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
    BJU international, 2005, Volume: 96, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2005
Promising systemic therapy for renal cell carcinoma.
    Current treatment options in oncology, 2005, Volume: 6, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide

2005
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
    Clinical lung cancer, 2005, Volume: 7 Suppl 1

    Topics: Benzenesulfonates; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2005
Novel agents for the treatment of advanced kidney cancer.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Epothilones; Gefitinib; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide

2004
Targeted therapy for metastatic renal cell carcinoma.
    British journal of cancer, 2006, Mar-13, Volume: 94, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib

2006
[Progress in therapeutic strategy for renal cell carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Female; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Minimally Invasive Surgical Procedures; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2006
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
    Current oncology reports, 2006, Volume: 8, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein

2006
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 2

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib

2006
Molecular targeting therapy for renal cell carcinoma.
    International journal of clinical oncology, 2006, Volume: 11, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib

2006
New treatment approaches in metastatic renal cell carcinoma.
    Current opinion in urology, 2006, Volume: 16, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2006
Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
    ONS news, 2006, Volume: 21, Issue:8 Suppl

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Niacinamide; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Education as Topic; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib

2006
[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
    Der Urologe. Ausg. A, 2006, Volume: 45, Issue:10

    Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Female; Gastrointestinal Diseases; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2006
Molecular biology of renal cell carcinoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Exons; Humans; Indoles; Kidney Neoplasms; Molecular Biology; Mutation; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease

2006
New weapons to snuff out kidney cancer.
    Nursing, 2006, Volume: 36, Issue:12 Pt.1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib

2006
Targeted therapy for metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Dec-10, Volume: 24, Issue:35

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein

2006
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
    Expert review of anticancer therapy, 2006, Volume: 6, Issue:12

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Case Management; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2006
Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
    Expert review of anticancer therapy, 2006, Volume: 6, Issue:12

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Forecasting; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2006
Targeting von Hippel-Lindau pathway in renal cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Dec-15, Volume: 12, Issue:24

    Topics: Benzenesulfonates; Biomedical Research; Carcinoma, Renal Cell; Enzyme Inhibitors; Everolimus; Humans; Indoles; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein

2006
Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.
    Clinical genitourinary cancer, 2006, Volume: 5 Suppl 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib

2006
Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.
    Clinical genitourinary cancer, 2006, Volume: 5 Suppl 1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2006
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
    Clinical lung cancer, 2006, Volume: 8 Suppl 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors

2006
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-15, Volume: 13, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
    Clinical colorectal cancer, 2006, Volume: 6 Suppl 1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles

2006
[Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot].
    Der Urologe. Ausg. A, 2007, Volume: 46, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Drug Approval; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
    BJU international, 2007, Volume: 99, Issue:5 Pt B

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Leiomyomatosis; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; von Hippel-Lindau Disease

2007
Combination of target agents: challenges and opportunities.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:5 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Drug Resistance, Neoplasm; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib

2007
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
    Nature reviews. Cancer, 2007, Volume: 7, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab

2007
Angiogenesis in cancer: molecular mechanisms, clinical impact.
    Langenbeck's archives of surgery, 2007, Volume: 392, Issue:3

    Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Indoles; Microcirculation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Design of clinical trials of radiation combined with antiangiogenic therapy.
    The oncologist, 2007, Volume: 12, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Combined Modality Therapy; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiation Dosage; raf Kinases; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
    British journal of cancer, 2007, Jun-18, Volume: 96, Issue:12

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Thrombosis; Vascular Endothelial Growth Factor A; Wound Healing

2007
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jul-01, Volume: 13, Issue:13

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2007
The effect of recent drug approvals on translational research and drug development.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomedical Research; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Approval; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; United States; United States Food and Drug Administration

2007
The role of targeted therapy in metastatic renal cell carcinoma.
    TheScientificWorldJournal, 2007, Mar-02, Volume: 7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Current treatment options in oncology, 2007, Volume: 8, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1

2007
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Pharmacotherapy, 2007, Volume: 27, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Growth Factor; Sorafenib; Sunitinib

2007
[Effect of angiogenesis inhibitors on renal cell carcinoma].
    Magyar onkologia, 2007, Volume: 51, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A

2007
Treatment options in renal cell carcinoma: past, present and future.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18 Suppl 10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cytokines; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2007
[Oral drugs inhibiting the VEGF pathway].
    Bulletin du cancer, 2007, Volume: 94 Spec No

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
[Angiogenesis and renal cell carcinoma].
    Bulletin du cancer, 2007, Volume: 94 Spec No

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors

2007
[Cutaneous side effects of antiangiogenic agents].
    Bulletin du cancer, 2007, Volume: 94 Spec No

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Pyridines; Pyrroles; Skin Diseases; Sorafenib; Sunitinib

2007
Managing side effects of angiogenesis inhibitors in renal cell carcinoma.
    Onkologie, 2007, Volume: 30, Issue:10

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
    BioEssays : news and reviews in molecular, cellular and developmental biology, 2007, Volume: 29, Issue:11

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2007, Volume: 12 Suppl 1

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome

2007
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
    Bulletin du cancer, 2007, Volume: 94, Issue:10

    Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles

2007
[Angiogenesis targeting in renal carcinomas].
    Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib

2007
New developments in multitargeted therapy for patients with solid tumours.
    Cancer treatment reviews, 2008, Volume: 34, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles

2008
[Renal cell carcinoma and antiangiogenic therapies].
    Presse medicale (Paris, France : 1983), 2008, Volume: 37, Issue:4 Pt 2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2008
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
    European urology, 2008, Volume: 53, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib

2008
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
    Clinical and experimental medicine, 2007, Volume: 7, Issue:4

    Topics: Acneiform Eruptions; Antineoplastic Agents; Benzenesulfonates; Erythema; Esophagitis; Exanthema; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jan-15, Volume: 65, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Bulletin du cancer, 2008, Volume: 95, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles

2008
[Molecular targeted therapy for renal cell carcinoma].
    Hinyokika kiyo. Acta urologica Japonica, 2008, Volume: 54, Issue:1

    Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indoles; Interferon-beta; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Liposomes; Mitochondrial Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2008
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
    Clinical lymphoma & myeloma, 2007, Volume: 8 Suppl 1

    Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib

2007
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
    Current medicinal chemistry, 2008, Volume: 15, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab

2008
[Cutaneous side effects of sorafenib and sunitinib].
    Annales de dermatologie et de venereologie, 2008, Volume: 135, Issue:2

    Topics: Acrodermatitis; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Hair Diseases; Humans; Indoles; Nail Diseases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib; Sunitinib

2008
[Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
    Annales de dermatologie et de venereologie, 2008, Volume: Spec No 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib

2008
Chemotherapeutic agents and the skin: An update.
    Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids

2008
[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
    Nederlands tijdschrift voor geneeskunde, 2008, Feb-16, Volume: 152, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2008
Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
    Reviews on recent clinical trials, 2006, Volume: 1, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dioxoles; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Niacinamide; Oligonucleotides; Phthalazines; Piperazines; Proto-Oncogene Mas; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Tetrahydroisoquinolines; Trabectedin

2006
Treatment options for metastatic renal cell carcinoma: a review.
    The Canadian journal of urology, 2008, Volume: 15, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Graft vs Host Disease; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2008
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
    Reviews on recent clinical trials, 2007, Volume: 2, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome

2007
[Lung cancer].
    Medizinische Klinik (Munich, Germany : 1983), 2008, May-15, Volume: 103, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib

2008
Targeted therapy in advanced non-small-cell lung cancer.
    Seminars in respiratory and critical care medicine, 2008, Volume: 29, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2008
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
    Nature clinical practice. Oncology, 2008, Volume: 5, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials as Topic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
[Value of targeted therapies for renal cell cancer].
    Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Survival Rate

2008
Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications.
    Oncology nursing forum, 2008, Volume: 35, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Diffusion of Innovation; Humans; Incidence; Indoles; Interferon-alpha; Interleukin-2; Molecular Biology; Neoplasm Staging; Nephrectomy; Niacinamide; Oncology Nursing; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Rare Diseases; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2008
An update on the medical therapy of advanced metastatic renal cell carcinoma.
    Scandinavian journal of urology and nephrology, 2008, Volume: 42, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Severity of Illness Index; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2008
Targeted therapy in renal cell carcinoma.
    Current opinion in urology, 2008, Volume: 18, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2008
New therapies in renal cell carcinoma.
    Current opinion in supportive and palliative care, 2007, Volume: 1, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
[Molecular basis of targeted therapy in metastatic renal cancer].
    Der Pathologe, 2008, Volume: 29 Suppl 2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein

2008
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    The oncologist, 2008, Volume: 13, Issue:9

    Topics: Benzenesulfonates; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2008
[Molecular targeted therapy for renal cell carcinoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2008, Volume: 49, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Gene Targeting; Humans; Indoles; Kidney Neoplasms; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein

2008
Exploring the role of novel agents in the treatment of renal cell carcinoma.
    Cancer treatment reviews, 2008, Volume: 34, Issue:8

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome

2008
Novel drugs for renal cell carcinoma.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2008
Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:15

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2008
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
    The oncologist, 2008, Volume: 13, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recombinant Proteins; Sirolimus; Sorafenib; Sunitinib

2008
Vascular complications of selected cancer therapies.
    Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cisplatin; Fluorouracil; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Thrombosis; Vascular Diseases

2008
Systemic therapy for metastatic renal cell carcinoma.
    The Urologic clinics of North America, 2008, Volume: 35, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cytotoxins; Disease-Free Survival; Drug Therapy, Combination; Everolimus; Humans; Immunosuppressive Agents; Immunotherapy; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Stem Cell Transplantation; Sunitinib; TOR Serine-Threonine Kinases; Transplantation, Homologous

2008
Molecular therapy for the treatment of hepatocellular carcinoma.
    British journal of cancer, 2009, Jan-13, Volume: 100, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
    BMC cancer, 2009, Jan-27, Volume: 9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib

2009
Recent advances in the systemic treatment of metastatic papillary renal cancer.
    Expert review of anticancer therapy, 2009, Volume: 9, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Papillary; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2009
Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
    International journal of urology : official journal of the Japanese Urological Association, 2009, Volume: 16, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2009
[Targeted therapies and their indications in solid neoplasias].
    La Revue de medecine interne, 2009, Volume: 30, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
    Pharmacotherapy, 2009, Volume: 29, Issue:4

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Case-Control Studies; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Therapy, Combination; Humans; Hypothyroidism; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Thyroid Function Tests; Treatment Outcome

2009
Targeted therapies in metastatic renal cancer in 2009.
    BJU international, 2009, Volume: 103, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factors

2009
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
    Clinical lung cancer, 2009, Volume: 10 Suppl 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A

2009
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
    Targeted oncology, 2009, Volume: 4, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Routes; Female; Hemorrhage; Humans; Hypertension; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
    Current cardiology reports, 2009, Volume: 11, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Heart; Heart Diseases; Heart Failure; Humans; Indoles; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Trastuzumab

2009
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
    Cancer, 2009, May-15, Volume: 115, Issue:10 Suppl

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2009
Prognostic markers and new, innovative treatments in renal cell carcinoma.
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2009, Volume: 20, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cancer Vaccines; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2009
Renal toxicity of targeted therapies.
    Targeted oncology, 2009, Volume: 4, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hypertension; Indoles; Kidney; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
Angiogenesis regulated by VEGF and its receptors and its clinical application.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Design; Humans; Indoles; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
    Current opinion in supportive and palliative care, 2009, Volume: 3, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2009
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.
    Nature reviews. Urology, 2009, Volume: 6, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib

2009
The role of antiangiogenesis therapy: bevacizumab and beyond.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2009, Volume: 11, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Forecasting; Humans; Indoles; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
Adverse effects of anticancer agents that target the VEGF pathway.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Brain Diseases; Capillary Leak Syndrome; Cardiovascular Diseases; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Forecasting; Gastrointestinal Diseases; Hemorrhage; Humans; Indoles; Kidney Diseases; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing

2009
Targeted therapies in the treatment of advanced/metastatic NSCLC.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:14

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome

2009
Sorafenib and sunitinib.
    The oncologist, 2009, Volume: 14, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Interactions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes.
    Cancer treatment reviews, 2009, Volume: 35, Issue:8

    Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Health Status; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Patient Satisfaction; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2009
Clinical pharmacokinetics of tyrosine kinase inhibitors.
    Cancer treatment reviews, 2009, Volume: 35, Issue:8

    Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution

2009
An overview of small-molecule inhibitors of VEGFR signaling.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cadherins; Clinical Trials, Phase III as Topic; Extracellular Matrix Proteins; Humans; Indoles; Integrins; Intercellular Signaling Peptides and Proteins; National Cancer Institute (U.S.); Neoplasms; Niacinamide; Peptide Hydrolases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Structure-Activity Relationship; Sunitinib; Transcription Factors; United States

2009
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    The Lancet. Oncology, 2009, Volume: 10, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Hemorrhage; Humans; Incidence; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sorafenib; Sunitinib

2009
Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer.
    Expert review of anticancer therapy, 2009, Volume: 9, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
    Oncology, 2009, Volume: 77, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Niacinamide; Paresthesia; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Syndrome

2009
Tyrosine kinase inhibitors and the thyroid.
    Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:6

    Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms

2009
Metastatic renal cell carcinoma: current standards of care.
    Clinical journal of oncology nursing, 2009, Volume: 13 Suppl

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2009
Management of vascular endothelial growth factor and multikinase inhibitor side effects.
    Clinical journal of oncology nursing, 2009, Volume: 13 Suppl

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Drug Eruptions; Drug Monitoring; Fatigue; Humans; Indoles; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2009
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2009
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2010, Volume: 14, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2010
Compounds in clinical Phase III and beyond.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 180

    Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostatins; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A

2010
Progress in the management of advanced renal cell carcinoma (RCC).
    Aktuelle Urologie, 2010, Volume: 41 Suppl 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Everolimus; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein

2010
Targeted molecular therapies in thyroid carcinoma.
    Arquivos brasileiros de endocrinologia e metabologia, 2009, Volume: 53, Issue:9

    Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms

2009
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
    The oncologist, 2010, Volume: 15, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Cardiovascular Diseases; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2010
[Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
    Onkologie, 2010, Volume: 33 Suppl 1

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Drugs, Investigational; Everolimus; Evidence-Based Medicine; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate

2010
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
    The Lancet. Oncology, 2010, Volume: 11, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Chemotherapy, Adjuvant; Humans; Indoles; Neoadjuvant Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing

2010
Update on systemic therapies of metastatic renal cell carcinoma.
    World journal of urology, 2010, Volume: 28, Issue:3

    Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biopsy, Needle; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Everolimus; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sirolimus; Sorafenib; Sunitinib; Survival Analysis

2010
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13

    Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Arterial Occlusive Diseases; Benzenesulfonates; Humans; Incidence; Indoles; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thromboembolism

2010
[Treatment of locally advanced renal tumors].
    Actas urologicas espanolas, 2010, Volume: 34, Issue:2

    Topics: Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2010
[Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
    Bulletin du cancer, 2010, Volume: 97

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2010
Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
    Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Kidney Neoplasms; Markov Chains; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sirolimus; Sorafenib; Sunitinib

2010
[Antiangionic drugs in soft tissue sarcoma].
    Bulletin du cancer, 2010, Volume: 97, Issue:6

    Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Doxorubicin; Humans; Indazoles; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2010
[Focus on GIST management].
    Bulletin du cancer, 2010, Volume: 97, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles

2010
[Anti-angiogenic drugs].
    Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Hypoxia-Inducible Factor 1; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2010
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
    The oncologist, 2010, Volume: 15, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cardiovascular Diseases; Female; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2010
[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2010, Volume: 61, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Drug Eruptions; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Structure-Activity Relationship; Sunitinib

2010
Present state of target therapy for disseminated renal cell carcinoma.
    Immunotherapy, 2010, Volume: 2, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2010
Angiogenesis as a therapeutic target in urothelial carcinoma.
    Anti-cancer drugs, 2010, Volume: 21, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Matrix Metalloproteinases; Neoadjuvant Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays

2010
Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.
    Cancer treatment reviews, 2011, Volume: 37, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2011
[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
    Orvosi hetilap, 2010, Oct-24, Volume: 151, Issue:43

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Cell Cycle; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hepatectomy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Wnt Proteins

2010
[Molecular targeted therapy for renal cell carcinoma and other urological cancers].
    Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Urologic Neoplasms

2010
[Hand-foot syndrome after administration of tyrosinkinase inhibitors].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2010, Volume: 23, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Syndrome

2010
Antiangiogenic therapy for breast cancer.
    Breast cancer research : BCR, 2010, Volume: 12, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2010
Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
    The Israel Medical Association journal : IMAJ, 2010, Volume: 12, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
    Breast (Edinburgh, Scotland), 2011, Volume: 20, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab

2011
Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.
    Angiogenesis, 2011, Volume: 14, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Endoscopy; Female; Humans; Indoles; Intestinal Perforation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib

2011
In pursuit of new anti-angiogenic therapies for cancer treatment.
    Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment

2011
Therapeutic advances in women's cancers.
    Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cetuximab; ErbB Receptors; Female; Genital Neoplasms, Female; Humans; Indoles; Intestinal Perforation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2011
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
    The oncologist, 2011, Volume: 16 Suppl 2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Everolimus; Humans; Immunotherapy; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2011
Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
    The oncologist, 2011, Volume: 16 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2011
Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
    The oncologist, 2011, Volume: 16 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Everolimus; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2011
[Novelties in the treatment for advanced renal-cell cancer].
    Orvosi hetilap, 2011, Apr-24, Volume: 152, Issue:17

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2011
Treatment of metastatic renal cell carcinoma and renal pelvic cancer.
    Clinical and experimental nephrology, 2011, Volume: 15, Issue:3

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Everolimus; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2011
[Treatment of metastatic renal cell carcinoma].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2011, Volume: 21, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2011
Novel molecular targeted therapies for refractory thyroid cancer.
    Head & neck, 2012, Volume: 34, Issue:5

    Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat

2012
[Indications and current development of new targeted therapies in pediatric oncology].
    Bulletin du cancer, 2011, Volume: 98, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases

2011
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:12

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A

2011
Targeting angiogenesis in esophagogastric adenocarcinoma.
    The oncologist, 2011, Volume: 16, Issue:6

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Disease Models, Animal; Disease-Free Survival; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2011
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Clinical therapeutics, 2011, Volume: 33, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib

2011
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
    Hematology/oncology clinics of North America, 2011, Volume: 25, Issue:4

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome

2011
Targeted drug therapies and cancer.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 185

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Drug Delivery Systems; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gefitinib; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2011
[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
    Bulletin du cancer, 2011, Volume: 98, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Fatigue; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Sunitinib

2011
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
    Current cancer drug targets, 2011, Volume: 11, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway

2011
[Systemic treatment of renal cell carcinoma - recent update].
    Wiener medizinische Wochenschrift (1946), 2011, Volume: 161, Issue:15-16

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Evidence-Based Medicine; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Palliative Care; Phenylurea Compounds; Practice Guidelines as Topic; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib

2011
Clinical experience with antiangiogenic therapy in leukemia.
    Current cancer drug targets, 2011, Volume: 11, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2011
[Dermatologic side effects induced by new angiogenesis inhibitors].
    Bulletin du cancer, 2011, Volume: 98, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib

2011
Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Drug and therapeutics bulletin, 2011, Volume: 49, Issue:11

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2011
Anti-angiogenic therapy: concept to clinic.
    Microcirculation (New York, N.Y. : 1994), 2012, Volume: 19, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2012
VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2011, Volume: 31, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2011
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
    Journal of the National Cancer Institute, 2012, Jan-18, Volume: 104, Issue:2

    Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular System; Drug Eruptions; Europe; Everolimus; Evidence-Based Medicine; Gastrointestinal Tract; Humans; Hypothyroidism; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Weight Loss; Wound Healing

2012
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-10, Volume: 30, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib

2012
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
    Magyar onkologia, 2012, Volume: 56, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib

2012
Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?
    International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:10

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vena Cava, Inferior

2012
Cardiac side effects of anticancer treatments: new mechanistic insights.
    Current heart failure reports, 2012, Volume: 9, Issue:3

    Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Daunorubicin; Doxorubicin; Heart Failure; Humans; Indoles; Myocardial Contraction; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Trastuzumab

2012
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
    Oncology, 2012, Volume: 83, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Differentiation; ErbB Receptors; Everolimus; Histone Deacetylases; Humans; Immunologic Factors; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Somatostatin; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2012
Evidence for therapeutic drug monitoring of targeted anticancer therapies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-10, Volume: 30, Issue:32

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles

2012
Hypothyroidism during treatment with tyrosine kinase inhibitors.
    Endokrynologia Polska, 2012, Volume: 63, Issue:4

    Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyroid Neoplasms

2012
Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.
    Current pharmaceutical design, 2013, Volume: 19, Issue:5

    Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib

2013
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Current topics in medicinal chemistry, 2012, Volume: 12, Issue:15

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome

2012
[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Nihon Jinzo Gakkai shi, 2012, Volume: 54, Issue:5

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2012
Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation.
    Urology, 2013, Volume: 81, Issue:1

    Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Probability; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Tumor Burden

2013
Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    American journal of clinical oncology, 2014, Volume: 37, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2

2014
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2013, Volume: 39, Issue:7

    Topics: Adult; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Sorafenib; Sunitinib

2013
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
    Anti-cancer drugs, 2013, Volume: 24, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Zoledronic Acid

2013
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
    Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles

2013
Body composition in chemotherapy: the promising role of CT scans.
    Current opinion in clinical nutrition and metabolic care, 2013, Volume: 16, Issue:5

    Topics: Anthracyclines; Body Composition; Body Weight; Chemotherapy, Adjuvant; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Muscle, Skeletal; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Tomography, X-Ray Computed

2013
Molecular markers to predict response to therapy.
    Seminars in oncology, 2013, Volume: 40, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Bevacizumab; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Gene Dosage; Humans; Immunotherapy; Indazoles; Indoles; Kidney Neoplasms; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Genetic; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein

2013
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
    Cancer treatment reviews, 2014, Volume: 40, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Induction Chemotherapy; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome

2014
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
    International journal of cancer, 2014, Aug-15, Volume: 135, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting

2014
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2013, Volume: 48, Issue:7

    Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib

2013
[Medical treatment of renal cell carcinoma].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2013, Volume: 23, Issue:15

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Immunotherapy; Indoles; Interferon alpha-2; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Sirolimus; Societies, Medical; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2013
Advanced kidney cancer: treating the elderly.
    Expert review of anticancer therapy, 2013, Volume: 13, Issue:12

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2013
Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?
    Current urology reports, 2014, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2014
Kidney cancer: Temsirolimus fails to expand its role in patients with mRCC.
    Nature reviews. Urology, 2014, Volume: 11, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus

2014
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
    Annales d'endocrinologie, 2013, Volume: 74 Suppl 1

    Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome

2013
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
    International journal of cancer, 2015, Jan-01, Volume: 136, Issue:1

    Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Incidence; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Risk; Sorafenib; Sulfonamides; Sunitinib

2015
Emerging therapeutic targets for synovial sarcoma.
    Expert review of anticancer therapy, 2014, Volume: 14, Issue:7

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sarcoma, Synovial; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases

2014
Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.
    Actas dermo-sifiliograficas, 2014, Volume: 105, Issue:10

    Topics: Administration, Cutaneous; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2014
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    Angiogenesis, 2014, Volume: 17, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2014
Combining targeted agents with modern radiotherapy in soft tissue sarcomas.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:11

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; Cyclin-Dependent Kinase 4; Humans; Indazoles; Indoles; Ipilimumab; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment

2014
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A

2015
Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.
    Biomedical chromatography : BMC, 2015, Volume: 29, Issue:6

    Topics: Animals; Chromatography, Liquid; Humans; Indoles; Mass Spectrometry; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-2

2015
Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:6

    Topics: Antineoplastic Agents; Humans; Incidence; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2015
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:3

    Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hemorrhage; Humans; Hypertension; Indoles; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Niacinamide; Pain; Pancytopenia; Phenylurea Compounds; Protease Inhibitors; Pyrroles; Salvage Therapy; Sepsis; Sorafenib; Sunitinib

2015
Systemic therapy of hepatocellular carcinoma: current and promising.
    Clinics in liver disease, 2015, Volume: 19, Issue:2

    Topics: Alanine; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Indoles; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Preoperative Care; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Triazines

2015
[Anti-angiogenesis and molecular targeted therapies].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2015
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2015
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
    Targeted oncology, 2015, Volume: 10, Issue:3

    Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A

2015
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
    Aktuelle Urologie, 2015, Volume: 46, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Immunotherapy; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis

2015
Clinical management of metastatic kidney cancer: the role of new molecular drugs.
    Future oncology (London, England), 2016, Volume: 12, Issue:1

    Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2016
Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
    Clinical genitourinary cancer, 2016, Volume: 14, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome

2016
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
    Bulletin du cancer, 2016, Volume: 103, Issue:3

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2016
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.
    Expert review of molecular diagnostics, 2016, Volume: 16, Issue:5

    Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Gene Expression; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2016
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Anti-cancer drugs, 2016, Volume: 27, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2016
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
    American journal of clinical dermatology, 2016, Volume: 17, Issue:3

    Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles

2016
Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?
    Urologic oncology, 2016, Volume: 34, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Forecasting; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2016
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
    Der Urologe. Ausg. A, 2016, Volume: 55, Issue:5

    Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib

2016
Systemic therapy in metastatic renal cell carcinoma.
    World journal of urology, 2017, Volume: 35, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Decision Trees; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Nivolumab; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2017
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
    World journal of urology, 2017, Volume: 35, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms

2017
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Cancer treatment reviews, 2016, Volume: 50

    Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein

2016
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    European urology, 2017, Volume: 71, Issue:3

    Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2017
Kinase Inhibitors in Multitargeted Cancer Therapy.
    Current medicinal chemistry, 2017, Volume: 24, Issue:16

    Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib

2017
Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Oncotarget, 2017, Mar-21, Volume: 8, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2017
Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Acta medica Indonesiana, 2016, Volume: 48, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2016
Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:3

    Topics: Adult; Age of Onset; Antineoplastic Agents; Axitinib; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Catheter Ablation; Child; Combined Modality Therapy; Everolimus; Fatal Outcome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Oncogene Fusion; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Translocation, Genetic; Young Adult

2017
Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
    International journal of molecular sciences, 2017, Feb-21, Volume: 18, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Management; Drug Resistance, Neoplasm; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2017
Renal cell carcinoma.
    Nature reviews. Disease primers, 2017, Mar-09, Volume: 3

    Topics: Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Diseases; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2017
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
    Current medicinal chemistry, 2017, Volume: 24, Issue:28

    Topics: Angiogenesis Inhibitors; Bevacizumab; Humans; Indoles; Jaw Diseases; Niacinamide; Osteonecrosis; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib

2017
Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2017, Volume: 37

    Topics: Carcinoma, Renal Cell; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolines; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein

2017
Angiogenesis Inhibitors in NSCLC.
    International journal of molecular sciences, 2017, Sep-21, Volume: 18, Issue:10

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids

2017
A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma.
    Bioscience reports, 2017, Dec-22, Volume: 37, Issue:6

    Topics: Anilides; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Network Meta-Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2017
Advances in treating psoriasis in the elderly with small molecule inhibitors.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:18

    Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Small Molecule Libraries; Sulfonamides; Thalidomide

2017
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
    Rheumatology (Oxford, England), 2019, 02-01, Volume: 58, Issue:Suppl 1

    Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles; Valine

2019
JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
    Expert review of clinical pharmacology, 2019, Volume: 12, Issue:6

    Topics: Adamantane; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Proliferation; Humans; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Niacinamide; Piperidines; Pyrimidines; Pyrroles

2019
JAK inhibitors in chronic plaque psoriasis: What is known so far.
    Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:2

    Topics: Adamantane; Azetidines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Nitriles; Piperidines; Prospective Studies; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles

2020
JAK inhibitors for the treatment of rheumatoid arthritis.
    Immunological medicine, 2020, Volume: 43, Issue:4

    Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Diseases; Herpes Zoster; Humans; Janus Kinases; Molecular Targeted Therapy; Neutropenia; Niacinamide; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Venous Thromboembolism

2020
The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.
    International journal of molecular sciences, 2021, Oct-20, Volume: 22, Issue:21

    Topics: Adamantane; Colitis; Colitis, Ulcerative; Crohn Disease; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Piperidines; Pyridines; Pyrimidines; Pyrroles; Triazoles

2021

Trials

38 trial(s) available for niacinamide and pyrroles

ArticleYear
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
    Radiology, 2010, Volume: 256, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome

2010
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
    Cancer, 2010, Dec-01, Volume: 116, Issue:23

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2010
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Drug Interactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult

2011
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival; Treatment Outcome

2011
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Clinical therapeutics, 2011, Volume: 33, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib

2011
Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Immunity, Cellular; Immunity, Humoral; Indoles; Influenza Vaccines; Influenza, Human; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Vaccination

2011
Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
    European journal of radiology, 2012, Volume: 81, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Organ Size; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Gland; Tomography, X-Ray Computed; Treatment Outcome

2012
Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
    Anti-cancer drugs, 2012, Volume: 23, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; CD3 Complex; CD4 Antigens; Female; Forkhead Transcription Factors; Humans; Indoles; Interleukin-2 Receptor alpha Subunit; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Treatment Outcome

2012
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Feb-10, Volume: 30, Issue:5

    Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Child; Child, Preschool; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Valproic Acid; Vascular Endothelial Growth Factor A; Young Adult

2012
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Urologic oncology, 2013, Volume: 31, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Treatment Outcome

2013
Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
    BJU international, 2012, Volume: 110, Issue:11

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden

2012
The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
    Journal of drugs in dermatology : JDD, 2012, Volume: 11, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Severity of Illness Index; Sorafenib; Sunitinib

2012
Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:3

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Axitinib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hand-Foot Syndrome; Heparin; Humans; Imidazoles; Indazoles; Indoles; Male; Middle Aged; Niacinamide; Ointments; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrroles; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Outcome

2013
Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
    European journal of radiology, 2013, Volume: 82, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Early Detection of Cancer; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Pilot Projects; Prognosis; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2013
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolones; Salvage Therapy; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome

2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid

2013
"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:4

    Topics: Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2013
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Nov-10, Volume: 31, Issue:32

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib; Young Adult

2013
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, 03-10, Volume: 32, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Time Factors; TOR Serine-Threonine Kinases; Treatment Failure; Young Adult

2014
A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
    Urologic oncology, 2014, Volume: 32, Issue:3

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cross-Sectional Studies; Everolimus; Fatigue; Female; Humans; Incidence; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Physicians; Pyrroles; Quality of Life; Self Report; Sirolimus; Sorafenib; Sunitinib; Surveys and Questionnaires

2014
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
    Clinical genitourinary cancer, 2014, Volume: 12, Issue:3

    Topics: Adult; Aged; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Treatment Outcome

2014
Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study.
    BMC cancer, 2014, Mar-24, Volume: 14

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cognition; Cognition Disorders; Cross-Sectional Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Memory; Middle Aged; Neoplasm Metastasis; Neuropsychological Tests; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib

2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
    British journal of cancer, 2014, Jun-10, Volume: 110, Issue:12

    Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden

2014
[The influence of citoflavin on molecular mechanisms of hypertensive encephalopathy development in patients with systolic arterial hypertension].
    Eksperimental'naia i klinicheskaia farmakologiia, 2014, Volume: 77, Issue:6

    Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Atorvastatin; Blood Pressure; Blood Proteins; Drug Combinations; Drug Therapy, Combination; Echocardiography; Female; Flavin Mononucleotide; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Hypertensive Encephalopathy; Inosine Diphosphate; Male; Neuroprotective Agents; Niacinamide; Pyrroles; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Succinates; Systole; Tetrazoles; Valine; Valsartan

2014
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:17

    Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; Male; MAP Kinase Signaling System; Mice, SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2

2014
The off-label use of targeted therapies in sarcomas: the OUTC'S program.
    BMC cancer, 2014, Nov-24, Volume: 14

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Off-Label Use; Phenylurea Compounds; Pyrroles; Registries; Sarcoma; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult

2014
[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
    Der Urologe. Ausg. A, 2015, Volume: 54, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sulfonamides; Sunitinib

2015
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    European urology, 2015, Volume: 68, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib

2015
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Sep-15, Volume: 21, Issue:18

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Chemotherapy, Adjuvant; Double-Blind Method; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Ventricular Function, Left

2015
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer.
    Anticancer research, 2015, Volume: 35, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Withholding Treatment

2015
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
    Lancet (London, England), 2016, May-14, Volume: 387, Issue:10032

    Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2016
Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Tertiary Care Centers; Treatment Outcome; Young Adult

2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate

2017
Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
    Chinese journal of cancer, 2017, May-18, Volume: 36, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypoalbuminemia; Indoles; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2017
Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    International journal of clinical oncology, 2017, Volume: 22, Issue:6

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2017
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 11-01, Volume: 28, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Health Status Indicators; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate

2017
Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study.
    Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:5

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib

2018

Other Studies

473 other study(ies) available for niacinamide and pyrroles

ArticleYear
Molecular mechanism of action of nicorandil.
    Journal of cardiovascular pharmacology, 1992, Volume: 20 Suppl 3

    Topics: Animals; Benzopyrans; Cattle; Coronary Vessels; Cromakalim; Cyclic GMP; Dose-Response Relationship, Drug; In Vitro Techniques; Niacinamide; Nicorandil; Nitroglycerin; Nitroprusside; Pyrroles; Vasodilation; Vasodilator Agents

1992
Differential effects of nitrovasodilators, K(+)-channel openers, and nicorandil on large and small coronary arteries in conscious dogs.
    Journal of cardiovascular pharmacology, 1992, Volume: 20 Suppl 3

    Topics: Animals; Benzopyrans; Coronary Vessels; Cromakalim; Dogs; Dose-Response Relationship, Drug; Injections, Intravenous; Molsidomine; Niacinamide; Nicorandil; Nifedipine; Nitroglycerin; Potassium Channels; Pyrroles; Vasodilation; Vasodilator Agents

1992
Pharmacological characterization of nicorandil by 86Rb efflux and isometric vasorelaxation studies in vascular smooth muscle.
    Journal of cardiovascular pharmacology, 1992, Volume: 20 Suppl 3

    Topics: Animals; Aorta; Benzopyrans; Cromakalim; Glyburide; In Vitro Techniques; Niacinamide; Nicorandil; Nitroprusside; Potassium Channels; Pyrroles; Rabbits; Rubidium Radioisotopes; Vasodilation; Vasodilator Agents

1992
Changes in responsiveness of the aorta to vasorelaxant agents in genetically diabetic rats: a study in WBN/Kob rats.
    Life sciences, 1992, Volume: 50, Issue:18

    Topics: Animals; Aorta, Thoracic; Benzopyrans; Colforsin; Cromakalim; Diabetes Mellitus, Experimental; Endothelium, Vascular; Isoproterenol; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Pyrroles; Rats; Rats, Inbred Strains; Receptors, Adrenergic, beta; Vasodilator Agents

1992
Pharmacological interaction experiments differentiate between glibenclamide-sensitive K+ channels and cyclic GMP as components of vasodilation by nicorandil.
    European journal of pharmacology, 1992, Apr-29, Volume: 215, Issue:1

    Topics: Animals; Benzopyrans; Cattle; Coronary Vessels; Cromakalim; Cyclic GMP; Drug Interactions; Glyburide; Guanidines; In Vitro Techniques; Methylene Blue; Molsidomine; Muscle Relaxation; Niacinamide; Nicorandil; Nitroprusside; Pinacidil; Potassium Channels; Pyrroles; Sensitivity and Specificity; Vasodilator Agents

1992
Vasodilatation of canine cerebral arteries by nicorandil, pinacidil and lemakalim.
    General pharmacology, 1992, Volume: 23, Issue:2

    Topics: Animals; Basilar Artery; Benzopyrans; Cerebral Arteries; Cromakalim; Dogs; Female; Glyburide; Guanidines; Guanylate Cyclase; In Vitro Techniques; Male; Methylene Blue; Muscle Contraction; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Vasodilation; Vasodilator Agents

1992
Spasmolytic action of nicorandil in canine conductive coronary arteries in vivo is not modified by glibenclamide.
    Journal of cardiovascular pharmacology, 1992, Volume: 19, Issue:1

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiocardiography; Animals; Benzopyrans; Coronary Circulation; Coronary Vasospasm; Coronary Vessels; Cromakalim; Dogs; Female; Glyburide; Male; Niacinamide; Nicorandil; Nitroglycerin; Parasympatholytics; Potassium Channels; Prostaglandin Endoperoxides, Synthetic; Pyrroles; Vasodilator Agents

1992
Effects of imidazoline-related compounds on the mechanical response to nicorandil in the rat portal vein.
    European journal of pharmacology, 1992, May-14, Volume: 215, Issue:2-3

    Topics: Animals; Benzopyrans; Cromakalim; Imidazoles; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Portal Vein; Potassium Channels; Pyrroles; Rats; Rats, Wistar

1992
Comparison of the in vitro effects of K+ channel modulators on detrusor and portal vein strips from guinea pigs.
    Pharmacology, 1992, Volume: 45, Issue:4

    Topics: Animals; Benzopyrans; Cromakalim; Dose-Response Relationship, Drug; Glyburide; Guanidines; Guinea Pigs; In Vitro Techniques; Male; Minoxidil; Muscle, Smooth; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Pinacidil; Portal Vein; Potassium Channels; Potassium Chloride; Pyrroles; Vasoconstriction; Vasodilator Agents

1992
[The vasospasmolytic effects of nicorandil, cromakalim and pinacidil on 3,4-diaminopyridine-induced phasic contractions in canine coronary arteries as an experimental vasospasm model].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1992, Volume: 100, Issue:4

    Topics: 4-Aminopyridine; Amifampridine; Animals; Benzopyrans; Coronary Vasospasm; Cromakalim; Disease Models, Animal; Dogs; Female; Glyburide; Guanidines; In Vitro Techniques; Ion Channel Gating; Male; Methylene Blue; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Vasodilator Agents

1992
The resistance of some rat cerebral arteries to the vasorelaxant effect of cromakalim and other K+ channel openers.
    British journal of pharmacology, 1992, Volume: 105, Issue:1

    Topics: Acetylcholine; Animals; Antihypertensive Agents; Benzopyrans; Cerebellum; Cerebral Arteries; Cromakalim; Guanidines; Guinea Pigs; Niacinamide; Nicorandil; Nitric Oxide; Nitroglycerin; Pinacidil; Potassium Channels; Pyrroles; Rabbits; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Vascular Resistance; Vasodilator Agents

1992
Nicorandil improves postischemic contractile function independently of direct myocardial effects.
    Journal of cardiovascular pharmacology, 1990, Volume: 15, Issue:5

    Topics: Animals; Benzopyrans; Coronary Circulation; Coronary Disease; Cromakalim; Dogs; Heart Function Tests; Heart Rate; In Vitro Techniques; L-Lactate Dehydrogenase; Male; Myocardial Contraction; Myocardium; Niacinamide; Nicorandil; Perfusion; Pyrroles; Rats; Rats, Inbred Strains

1990
[Potassium channel activators. Perspectives in the treatment of arterial hypertension].
    Presse medicale (Paris, France : 1983), 1991, Jan-19, Volume: 20, Issue:2

    Topics: Antihypertensive Agents; Benzopyrans; Cromakalim; Guanidines; Humans; Hypertension; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles

1991
Analysis of pulmonary and systemic vascular responses to cromakalim, an activator of K+ATP channels.
    The American journal of physiology, 1991, Volume: 260, Issue:3 Pt 2

    Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Benzopyrans; Blood Circulation; Cats; Cromakalim; Endothelins; Glyburide; Guanidines; Heart Rate; Hindlimb; Myocardial Contraction; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pulmonary Circulation; Pyrroles; Vascular Resistance; Vasodilator Agents; Ventricular Function, Right

1991
The dualistic mode of action of the vasodilator drug, nicorandil, differentiated by glibenclamide in 86Rb flux studies in rabbit isolated vascular smooth muscle.
    Naunyn-Schmiedeberg's archives of pharmacology, 1991, Volume: 343, Issue:1

    Topics: Animals; Aorta; Benzopyrans; Cromakalim; Glyburide; Membranes; Muscle Contraction; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Norepinephrine; Potassium; Potassium Channels; Pyrroles; Rabbits; Rubidium Radioisotopes; Stimulation, Chemical; Vasodilator Agents

1991
Differential antagonism by glibenclamide of the relaxant effects of cromakalim, pinacidil and nicorandil on canine large coronary arteries.
    Naunyn-Schmiedeberg's archives of pharmacology, 1991, Volume: 343, Issue:1

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Arteries; Benzopyrans; Coronary Vessels; Cromakalim; Dogs; Dose-Response Relationship, Drug; Female; Glyburide; Guanidines; Male; Methylene Blue; Muscle Contraction; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Nitroglycerin; Pinacidil; Potassium; Prostaglandin Endoperoxides, Synthetic; Pyrroles; Vasodilator Agents

1991
Analysis of cromakalim-, pinacidil-, and nicorandil-induced relaxation of the 5-hydroxytryptamine precontracted rat isolated basilar artery.
    Naunyn-Schmiedeberg's archives of pharmacology, 1991, Volume: 343, Issue:4

    Topics: Animals; Basilar Artery; Benzopyrans; Cromakalim; Drug Interactions; Glyburide; Guanidines; Male; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Rats; Rats, Inbred Strains; Serotonin; Serotonin Antagonists; Vasoconstriction; Vasodilation; Vasodilator Agents

1991
Potassium channel opening properties of a novel compound, NIP-121, cromakalim and nicorandil in rat aorta and portal vein.
    European journal of pharmacology, 1991, Apr-03, Volume: 195, Issue:3

    Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Benzopyrans; Cromakalim; Glyburide; In Vitro Techniques; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Oxadiazoles; Phentolamine; Piperidines; Portal Vein; Potassium Channels; Potassium Chloride; Pyrroles; Rats; Rats, Inbred Strains; Rubidium Radioisotopes

1991
Effect of three novel K+ channel openers, cromakalim, pinacidil and nicorandil on allergic reaction and experimental asthma.
    Japanese journal of pharmacology, 1991, Volume: 56, Issue:1

    Topics: Airway Resistance; Animals; Asthma; Benzopyrans; Bronchodilator Agents; Cromakalim; Guanidines; Guinea Pigs; In Vitro Techniques; Mice; Mice, Inbred Strains; Niacinamide; Nicorandil; Passive Cutaneous Anaphylaxis; Pinacidil; Potassium Channels; Pyrroles; Rats; Trachea; Vasculitis

1991
Essential role of nucleotide diphosphates in nicorandil-mediated activation of cardiac ATP-sensitive K+ channel. A comparison with pinacidil and lemakalim.
    Circulation research, 1991, Volume: 69, Issue:4

    Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Guanidines; Myocardium; Niacinamide; Nicorandil; Phosphorylation; Pinacidil; Potassium Channels; Pyrroles; Vasodilator Agents

1991
K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system.
    Zeitschrift fur Kardiologie, 1991, Volume: 80 Suppl 7

    Topics: Animals; Benzopyrans; Cromakalim; Dogs; Dose-Response Relationship, Drug; Female; Male; Membrane Potentials; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Potassium Channels; Pyrroles; Rats; Rats, Inbred SHR; Vasoconstriction; Vasodilation; Vasodilator Agents

1991
Effects of pinacidil, cromakalim, and nicorandil on potassium currents of rat basilar artery smooth muscle.
    Advances in experimental medicine and biology, 1991, Volume: 304

    Topics: Animals; Antihypertensive Agents; Basilar Artery; Benzopyrans; Calcium; Cerebrovascular Circulation; Cromakalim; Electrophysiology; Guanidines; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Rats; Rats, Inbred Strains

1991
Effects of cromakalim, pinacidil and nicorandil on cardiac refractoriness and arterial pressure in open-chest dogs.
    European journal of pharmacology, 1990, Apr-25, Volume: 179, Issue:3

    Topics: Animals; Atrioventricular Node; Benzopyrans; Blood Pressure; Cromakalim; Dogs; Dose-Response Relationship, Drug; Electrocardiography; Female; Guanidines; Heart Conduction System; Heart Rate; Male; Neural Conduction; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Refractory Period, Electrophysiological

1990
Specific but differential antagonism by glibenclamide of the vasodepressor effects of cromakalim and nicorandil in spinally-anaesthetized dogs.
    British journal of pharmacology, 1990, Volume: 100, Issue:3

    Topics: Anesthesia, Spinal; Animals; Benzopyrans; Blood Pressure; Calcium Channel Blockers; Cromakalim; Diltiazem; Dogs; Dose-Response Relationship, Drug; Female; Glyburide; Heart Rate; Hemodynamics; Male; Myocardial Contraction; Niacinamide; Nicorandil; Nitroglycerin; Norepinephrine; Potassium Channels; Pyrroles

1990
Cytoplasmic calcium and the relaxation of canine coronary arterial smooth muscle produced by cromakalim, pinacidil and nicorandil.
    British journal of pharmacology, 1990, Volume: 101, Issue:1

    Topics: Adenosine Triphosphate; Animals; Benzopyrans; Calcium; Coronary Vessels; Cromakalim; Cytoplasm; Dogs; Female; Fluorescence; Glyburide; Guanidines; In Vitro Techniques; Male; Muscle Contraction; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Pinacidil; Potassium Chloride; Pyrroles; Quaternary Ammonium Compounds

1990
Specific antagonism by glibenclamide of negative inotropic effects of potassium channel openers in canine atrial muscle.
    Japanese journal of pharmacology, 1990, Volume: 54, Issue:2

    Topics: Animals; Benzopyrans; Carbachol; Cromakalim; Dogs; Female; Glyburide; Guanidines; Heart Atria; Male; Myocardial Contraction; Niacinamide; Nicorandil; Nifedipine; Pinacidil; Potassium Channels; Pyrroles; Vasodilator Agents

1990
Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism.
    Cardiovascular drugs and therapy, 1990, Volume: 4, Issue:4

    Topics: Adenosine Triphosphate; Animals; Benzopyrans; Coronary Circulation; Cromakalim; Dogs; Dose-Response Relationship, Drug; Female; Glyburide; In Vitro Techniques; Male; Myocardial Contraction; Niacinamide; Nicorandil; Nitroglycerin; Potassium Channels; Pyrroles; Vasodilator Agents

1990
Effect of apamin on responses to BRL 34915, nicorandil and other relaxants in the guinea-pig taenia caeci.
    British journal of pharmacology, 1986, Volume: 88, Issue:1

    Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Apamin; Bee Venoms; Benzopyrans; Cecum; Cromakalim; Female; Guinea Pigs; In Vitro Techniques; Ion Channels; Isoproterenol; Male; Muscle Relaxants, Central; Muscle Tonus; Muscle, Smooth; Niacinamide; Nicorandil; Norepinephrine; Pyrroles

1986
The effects of BRL 34915 and nicorandil on electrical and mechanical activity and on 86Rb efflux in rat blood vessels.
    British journal of pharmacology, 1986, Volume: 88, Issue:1

    Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Benzopyrans; Cromakalim; In Vitro Techniques; Ion Channels; Male; Membrane Potentials; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Norepinephrine; Portal Vein; Pyrroles; Radioisotopes; Rats; Rats, Inbred Strains; Rubidium; Time Factors

1986
Specificity of action of the novel antihypertensive agent, BRL 34915, as a potassium channel activator. Comparison with nicorandil.
    Biochemical pharmacology, 1987, Nov-01, Volume: 36, Issue:21

    Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Animals; Antihypertensive Agents; Apamin; Benzopyrans; Binding Sites; Cromakalim; Cyclic AMP; Cyclic GMP; Inositol Phosphates; Ion Channels; Male; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Nitrendipine; Potassium; Pyrroles; Rats; Rats, Inbred Strains; Rubidium; Tetraethylammonium Compounds

1987
Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
    Journal of cardiovascular pharmacology, 1988, Volume: 12, Issue:5

    Topics: Animals; Antihypertensive Agents; Benzopyrans; Cats; Coronary Circulation; Cromakalim; Female; Guanidines; Hemodynamics; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Organ Specificity; Papillary Muscles; Pinacidil; Portal Vein; Potassium Channels; Pyrroles; Rabbits

1988
Effects of valinomycin on calcium mobilization in vascular smooth muscle cells induced by angiotensin II.
    Biochemical and biophysical research communications, 1989, Jul-14, Volume: 162, Issue:1

    Topics: Angiotensin II; Animals; Benzopyrans; Calcium; Cromakalim; Endothelium, Vascular; Ethers; Female; Inositol 1,4,5-Trisphosphate; Inositol Phosphates; Ionomycin; Ionophores; Monensin; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Pyrroles; Rats; Valinomycin

1989
Glibenclamide is a competitive antagonist of cromakalim, pinacidil and RP 49356 in guinea-pig pulmonary artery.
    European journal of pharmacology, 1989, Jun-20, Volume: 165, Issue:2-3

    Topics: Animals; Benzopyrans; Cromakalim; Glyburide; Guanidines; Guinea Pigs; In Vitro Techniques; Male; Methylene Blue; Muscle Contraction; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Picolines; Pinacidil; Potassium Channels; Potassium Chloride; Pulmonary Artery; Purinones; Pyrans; Pyrroles; Tetraethylammonium Compounds

1989
Comparison of the effects of putative activators of K+ channels on pancreatic B-cell function.
    Pflugers Archiv : European journal of physiology, 1989, Volume: 414 Suppl 1

    Topics: Animals; Benzopyrans; Cromakalim; Diazoxide; Guanidines; In Vitro Techniques; Islets of Langerhans; Mice; Minoxidil; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Vasodilator Agents

1989
Functional changes in potassium channels in aortas from rats with streptozotocin-induced diabetes.
    European journal of pharmacology, 1989, Jul-18, Volume: 166, Issue:2

    Topics: Animals; Aorta, Thoracic; Benzopyrans; Blood Glucose; Cromakalim; Diabetes Mellitus, Experimental; In Vitro Techniques; Male; Muscle Contraction; Muscle Relaxation; Niacinamide; Nicorandil; Norepinephrine; Parasympatholytics; Potassium Channels; Pyrroles; Rats; Rats, Inbred Strains

1989
Effects of putative activators of K+ channels in mouse pancreatic beta-cells.
    British journal of pharmacology, 1989, Volume: 98, Issue:3

    Topics: Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Diazoxide; Electrophysiology; Female; Glucose; Guanidines; Homeostasis; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Membrane Potentials; Mice; Minoxidil; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Rubidium Radioisotopes

1989
Comparative effects of K+ channel blockade on the vasorelaxant activity of cromakalim, pinacidil and nicorandil.
    European journal of pharmacology, 1988, Aug-02, Volume: 152, Issue:3

    Topics: 4-Aminopyridine; Aminopyridines; Animals; Benzopyrans; Cardiovascular Agents; Cromakalim; Guanidines; In Vitro Techniques; Male; Mesenteric Arteries; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Procaine; Pyrroles; Rabbits; Rubidium Radioisotopes; Tetraethylammonium Compounds; Vasodilator Agents

1988
The negative inotropic effect of nicorandil is independent of cyclic GMP changes: a comparison with pinacidil and cromakalim in canine atrial muscle.
    British journal of pharmacology, 1988, Volume: 95, Issue:2

    Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzopyrans; Cromakalim; Cyclic AMP; Cyclic GMP; Dogs; Female; Guanidines; In Vitro Techniques; Male; Monoamine Oxidase Inhibitors; Myocardial Contraction; Myocardium; Niacinamide; Nicorandil; Nifedipine; Pinacidil; Potassium Channels; Pyrroles; Tetraethylammonium Compounds; Vasodilator Agents

1988
Anti-spasmogenic and spasmolytic effects of BRL 34915: a comparison with nifedipine and nicorandil.
    Journal of autonomic pharmacology, 1987, Volume: 7, Issue:3

    Topics: Animals; Benzopyrans; Cromakalim; Electric Stimulation; In Vitro Techniques; Male; Mesenteric Arteries; Muscle Contraction; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Nifedipine; Norepinephrine; Parasympatholytics; Potassium Chloride; Pyrroles; Rabbits

1987
Characteristics of cromakalim-induced relaxations in the smooth muscle cells of guinea-pig mesenteric artery and vein.
    British journal of pharmacology, 1988, Volume: 95, Issue:3

    Topics: Action Potentials; Animals; Antihypertensive Agents; Benzopyrans; Cromakalim; Female; Guinea Pigs; In Vitro Techniques; Male; Membrane Potentials; Mesenteric Arteries; Mesenteric Veins; Microelectrodes; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Potassium Channels; Pyrroles; Vasodilator Agents

1988
The conversion of pyrrolizidine alkaloids to N-oxides and to dihydropyrrolizine derivatives by rat-liver microsomes in vitro.
    Chemico-biological interactions, 1971, Volume: 3, Issue:5

    Topics: Alkaloids; Animals; Calcium; Carbon Monoxide; DDT; Diet; Kinetics; Lung; Magnesium; Manganese; Microsomes; Microsomes, Liver; Models, Biological; NADP; Niacinamide; Oxides; Oxygen; Phenobarbital; Proadifen; Proteins; Pyrroles; Pyrrolizidine Alkaloids; Rats; Rats, Inbred Strains

1971
Effects of ATP-sensitive K+ channel openers on pacemaker activity in isolated single rabbit sino-atrial node cells.
    Journal of cardiovascular pharmacology, 1993, Volume: 22, Issue:6

    Topics: Action Potentials; Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Electrophysiology; Glyburide; Guanidines; Heart Rate; In Vitro Techniques; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Rabbits; Sinoatrial Node; Vasodilator Agents

1993
Glibenclamide-induced oscillation of canine coronary artery is independent of myocardial ischemia.
    Journal of cardiovascular pharmacology, 1994, Volume: 23, Issue:3

    Topics: Adenosine Triphosphate; Animals; Arginine; Benzopyrans; Coronary Circulation; Coronary Vessels; Cromakalim; Diltiazem; Dogs; Female; Glyburide; In Vitro Techniques; Male; Muscle Tonus; Muscle, Smooth, Vascular; Myocardial Ischemia; Niacinamide; Nicorandil; Nitroarginine; Nitroglycerin; Potassium Channels; Pyrroles; Vasodilator Agents

1994
Effect of four potassium channel agonists on bupivacaine-induced toxicity in mice.
    Life sciences, 1995, Volume: 57, Issue:10

    Topics: Animals; Benzopyrans; Bupivacaine; Cromakalim; Diazoxide; Dose-Response Relationship, Drug; Guanidines; Male; Mice; Mice, Inbred Strains; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Seizures

1995
Effect of KRN2391 on venous return: comparison with other vasodilators.
    Journal of cardiovascular pharmacology, 1993, Volume: 22, Issue:1

    Topics: Animals; Benzopyrans; Cromakalim; Dogs; Female; Glyburide; Hemodynamics; Male; Niacinamide; Nicorandil; Nifedipine; Nitroglycerin; Potassium Channels; Pyridines; Pyrroles; Vasodilator Agents; Veins

1993
The inhibitory mechanisms of nicorandil in isolated rat urinary bladder and femoral artery.
    European journal of pharmacology, 1995, Jan-24, Volume: 273, Issue:1-2

    Topics: Acetylcholine; Animals; Benzopyrans; Cromakalim; Cyclic GMP; Electric Stimulation; Femoral Artery; Guanylate Cyclase; Male; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Nitroglycerin; Potassium Channels; Potassium Chloride; Pyrroles; Rats; Rats, Wistar; Urinary Bladder; Vasodilator Agents

1995
Ionic dependence of adenosine uptake into cultured astrocytes.
    Brain research, 1994, Oct-24, Volume: 661, Issue:1-2

    Topics: Adenosine; Animals; Animals, Newborn; Astrocytes; Benzopyrans; Biological Transport; Calcimycin; Calcium; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cells, Cultured; Cerebral Cortex; Cromakalim; Furosemide; Glyburide; Ionophores; Kinetics; Mice; Niacinamide; Nicorandil; Nigericin; Omeprazole; Potassium; Pyrroles; Sodium; Valinomycin; Vasodilator Agents

1994
Potassium channel openers relax A23187-induced nifedipine-resistant contraction of rat aorta.
    Journal of cardiovascular pharmacology, 1994, Volume: 24, Issue:6

    Topics: Animals; Aorta; Benzopyrans; Calcimycin; Cromakalim; In Vitro Techniques; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Nifedipine; Oxadiazoles; Piperidines; Pyrroles; Rats; Rats, Wistar; Vasoconstriction; Vasodilator Agents

1994
[Potassium channel openers. A new possible therapeutic principle in several diseases].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1994, Feb-10, Volume: 114, Issue:4

    Topics: Antihypertensive Agents; Benzopyrans; Bronchodilator Agents; Cromakalim; Guanidines; Humans; Minoxidil; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Vasodilator Agents

1994
Mechanisms of vasodilation of cerebral vessels induced by the potassium channel opener nicorandil in canine in vivo experiments.
    Stroke, 1994, Volume: 25, Issue:8

    Topics: Administration, Topical; Animals; Arterioles; Benzopyrans; Cromakalim; Dimethyl Sulfoxide; Dogs; Glyburide; Methylene Blue; Microcirculation; Niacinamide; Nicorandil; Nitroglycerin; Pia Mater; Pyrroles; Vasodilation; Vasodilator Agents; Venules

1994
Prejunctional effects of cromakalim, nicorandil and pinacidil on noradrenergic transmission in rat isolated mesenteric artery.
    Journal of autonomic pharmacology, 1994, Volume: 14, Issue:2

    Topics: Animals; Benzopyrans; Calcium; Cromakalim; Desipramine; Electric Stimulation; Extracellular Space; Female; Guanidines; In Vitro Techniques; Male; Mesenteric Arteries; Neuromuscular Junction; Niacinamide; Nicorandil; Norepinephrine; Pargyline; Phentolamine; Pinacidil; Pyrroles; Rats; Rats, Sprague-Dawley; Sympathetic Nervous System; Synaptic Transmission; Vasodilator Agents

1994
Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs.
    Cardiovascular drugs and therapy, 1994, Volume: 8, Issue:1

    Topics: Animals; Benzopyrans; Coronary Circulation; Coronary Vessels; Cromakalim; Dogs; Dose-Response Relationship, Drug; Female; Glyburide; Hemodynamics; Injections, Intravenous; Male; Niacinamide; Nicorandil; Nitroglycerin; Potassium Channels; Pyrroles; Vasodilator Agents

1994
Dissimilarity in the mechanisms of action of KRN2391, nicorandil and cromakalim in canine renal artery.
    The Journal of pharmacy and pharmacology, 1993, Volume: 45, Issue:3

    Topics: Animals; Benzopyrans; Cromakalim; Dogs; Female; Glyburide; In Vitro Techniques; Male; Methylene Blue; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Nitrates; Potassium Channels; Potassium Chloride; Pyridines; Pyrroles; Renal Artery; Vasodilator Agents

1993
Mechanism of action of KRN2391 in canine coronary vascular bed.
    Japanese journal of pharmacology, 1993, Volume: 63, Issue:3

    Topics: Animals; Antihypertensive Agents; Arteries; Benzopyrans; Coronary Circulation; Coronary Vessels; Cromakalim; Dogs; Drug Interactions; Female; Glyburide; In Vitro Techniques; Male; Methylene Blue; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Pyridines; Pyrroles; Vasodilator Agents

1993
ATP sensitive potassium channel openers are of potential benefit in ischaemic heart disease.
    Cardiovascular research, 1994, Volume: 28, Issue:1

    Topics: Benzopyrans; Cromakalim; Dihydropyridines; Guanidines; Humans; Myocardial Ischemia; Myocardium; Niacinamide; Nicorandil; Picolines; Pinacidil; Potassium Channels; Pyrans; Pyrroles; Sodium-Potassium-Exchanging ATPase; Vasodilator Agents

1994
Effects of nicorandil on cytosolic calcium concentrations and on tension development in the rabbit femoral artery.
    The Journal of pharmacology and experimental therapeutics, 1994, Volume: 268, Issue:2

    Topics: Animals; Benzopyrans; Calcium; Cromakalim; Cyclic GMP; Femoral Artery; Glyburide; In Vitro Techniques; Male; Niacinamide; Nicorandil; Nitroglycerin; Norepinephrine; Potassium; Potassium Channels; Pyrroles; Rabbits; Vasodilation; Vasodilator Agents

1994
Effects of nicorandil on human isolated corpus cavernosum and cavernous artery.
    The Journal of urology, 1994, Volume: 151, Issue:4

    Topics: Adult; Aged; Benzopyrans; Cromakalim; Humans; In Vitro Techniques; Male; Middle Aged; Molsidomine; Niacinamide; Nicorandil; Penis; Potassium Channels; Pyrroles; Vasodilator Agents

1994
Effects of K-channel openers on the contractility and electrical activity of antral circular muscle in guinea-pig stomach.
    Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi, 1993, Volume: 29, Issue:5

    Topics: Action Potentials; Animals; Benzopyrans; Cromakalim; Glyburide; Guinea Pigs; In Vitro Techniques; Ion Channel Gating; Muscle Contraction; Muscle, Smooth; Niacinamide; Nicorandil; Potassium Channels; Pyrroles; Stomach

1993
Regulation of ATP-sensitive K+ channels by ATP and nucleotide diphosphate in rabbit portal vein.
    The American journal of physiology, 1994, Volume: 266, Issue:5 Pt 2

    Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Egtazic Acid; Guanidines; In Vitro Techniques; Ion Channel Gating; Magnesium; Male; Membrane Potentials; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Pinacidil; Portal Vein; Potassium Channels; Probability; Pyrroles; Rabbits; Ribonucleotides; Time Factors; Vasodilator Agents

1994
Nicorandil as a nitrate, and cromakalim as a potassium channel opener, dilate isolated porcine large coronary arteries in an agonist-nonselective manner.
    Cardiovascular drugs and therapy, 1993, Volume: 7, Issue:4

    Topics: Animals; Benzopyrans; Coronary Vessels; Cromakalim; Glyburide; In Vitro Techniques; Niacinamide; Nicorandil; Nitrates; Potassium Channels; Pyrroles; Swine; Vasodilator Agents

1993
Mechanism of action of KRN2391, a novel vasodilator, in canine mesenteric artery.
    Japanese journal of pharmacology, 1993, Volume: 61, Issue:4

    Topics: Animals; Arterioles; Benzopyrans; Cromakalim; Dogs; Female; Glyburide; In Vitro Techniques; Male; Mesenteric Arteries; Methylene Blue; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Pyridines; Pyrroles; Splanchnic Circulation; Vascular Resistance; Vasodilator Agents

1993
Vasorelaxant mechanism of KRN2391 and nicorandil in porcine coronary arteries of different sizes.
    British journal of pharmacology, 1993, Volume: 109, Issue:3

    Topics: Animals; Benzopyrans; Coronary Vessels; Cromakalim; Glyburide; In Vitro Techniques; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Nitroglycerin; Oxyhemoglobins; Potassium Channels; Pyridines; Pyrroles; Swine; Vasodilator Agents

1993
Pharmacological properties of ATP-sensitive K+ channels in mammalian skeletal muscle cells.
    European journal of pharmacology, 1993, Jun-04, Volume: 236, Issue:3

    Topics: Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Electrophysiology; Glyburide; Guanidines; In Vitro Techniques; Mice; Muscles; Niacinamide; Nicorandil; Organic Chemicals; Pinacidil; Potassium Channels; Pyrroles; Vasodilator Agents

1993
Comparative electrophysiological and mechanical actions of ATP-sensitive potassium channel openers in canine Purkinje fibers.
    General pharmacology, 1993, Volume: 24, Issue:3

    Topics: Action Potentials; Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Dogs; Electrophysiology; Glyburide; Guanidines; In Vitro Techniques; Myocardial Contraction; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Purkinje Fibers; Pyrroles; Tetraethylammonium Compounds; Vasodilator Agents

1993
Modification by cGMP of glibenclamide-sensitive K+ currents in Xenopus oocytes.
    Japanese journal of pharmacology, 1993, Volume: 61, Issue:3

    Topics: Animals; Benzopyrans; Cromakalim; Cyclic GMP; Female; Glyburide; In Vitro Techniques; Membrane Potentials; Methylene Blue; Niacinamide; Nicorandil; Nitroprusside; Oocytes; Potassium Channels; Pyridines; Pyrroles; Xenopus laevis

1993
K+ channel openers prevent global ischemia-induced expression of c-fos, c-jun, heat shock protein, and amyloid beta-protein precursor genes and neuronal death in rat hippocampus.
    Proceedings of the National Academy of Sciences of the United States of America, 1993, Oct-15, Volume: 90, Issue:20

    Topics: Alternative Splicing; Amyloid beta-Protein Precursor; Animals; Base Sequence; Benzopyrans; Brain Ischemia; Cell Death; Cromakalim; Gene Expression Regulation; Guanidines; Heat-Shock Proteins; Hippocampus; In Situ Hybridization; Male; Molecular Sequence Data; Neurons; Niacinamide; Nicorandil; Oligonucleotide Probes; Pinacidil; Potassium Channels; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Pyrroles; Rats; Rats, Wistar; RNA, Messenger

1993
Activation by KRN2391 and nicorandil of glibenclamide-sensitive K+ channels in Xenopus oocytes.
    European journal of pharmacology, 1993, Feb-15, Volume: 244, Issue:3

    Topics: Animals; Benzopyrans; Cromakalim; Electrophysiology; Epinephrine; Female; Glyburide; Niacinamide; Nicorandil; Oocytes; Phentolamine; Potassium Channels; Pyridines; Pyrroles; Trifluoperazine; Vasodilator Agents; Xenopus laevis

1993
Effects of cromakalim and nicorandil on intraocular pressure after topical administration in rabbit eyes.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 1995,Fall, Volume: 11, Issue:3

    Topics: Administration, Topical; Animals; Antihypertensive Agents; Benzopyrans; Blood Flow Velocity; Chymotrypsin; Cromakalim; Eye; Female; Intraocular Pressure; Male; Niacinamide; Nicorandil; Ocular Hypertension; Ophthalmic Solutions; Potassium Channels; Pyrroles; Rabbits

1995
Endothelin-1 partially inhibits ATP-sensitive K+ current in guinea pig ventricular cells.
    Journal of cardiovascular pharmacology, 1996, Volume: 27, Issue:1

    Topics: Action Potentials; Adenosine Triphosphate; Alkaloids; Animals; Azepines; Benzopyrans; Cromakalim; Endothelin Receptor Antagonists; Endothelins; Female; Glyburide; Guinea Pigs; Heart; Heart Ventricles; Hypoglycemic Agents; Male; Niacinamide; Nicorandil; Oligopeptides; Papillary Muscles; Potassium Channels; Protein Kinase C; Pyrroles; Staurosporine; Sulfonamides; Vasodilator Agents

1996
ATP-sensitive K+ channel openers block sulpiride-induced dopamine release in the rat striatum.
    European journal of pharmacology, 1996, Feb-15, Volume: 297, Issue:1-2

    Topics: Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Male; Microdialysis; Monoamine Oxidase Inhibitors; Neostriatum; Nerve Endings; Niacinamide; Nicorandil; Potassium Channels; Pyrroles; Rats; Rats, Wistar; Substantia Nigra; Sulpiride; Vasodilator Agents

1996
Role of activation of ectosolic 5'-nucleotidase in the cardioprotection mediated by opening of K+c channels.
    The American journal of physiology, 1996, Volume: 270, Issue:5 Pt 2

    Topics: 5'-Nucleotidase; Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Dogs; Enzyme Activation; Glyburide; Heart; Hemodynamics; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Niacinamide; Nicorandil; Potassium Channels; Pyrroles; Recurrence

1996
alpha 1-Adrenoceptor stimulation partially inhibits ATP-sensitive K+ current in guinea pig ventricular cells: attenuation of the action potential shortening induced by hypoxia and K+ channel openers.
    Journal of cardiovascular pharmacology, 1996, Volume: 28, Issue:6

    Topics: Action Potentials; Adrenergic alpha-Agonists; Animals; Benzopyrans; Cells, Cultured; Cromakalim; Female; Guinea Pigs; Heart; Heart Ventricles; Hypoxia; Male; Methoxamine; Niacinamide; Nicorandil; Papillary Muscles; Patch-Clamp Techniques; Potassium Channels; Pyrroles; Ventricular Function

1996
Analysis of relaxation and repolarization mechanisms of nicorandil in rat mesenteric artery.
    British journal of pharmacology, 1996, Volume: 119, Issue:8

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Benzopyrans; Calcium Channel Blockers; Cromakalim; Electrophysiology; Glyburide; Hypoglycemic Agents; In Vitro Techniques; Male; Membrane Potentials; Mesenteric Arteries; Methylene Blue; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Nifedipine; Potassium Channels; Prostaglandin Endoperoxides, Synthetic; Pyrroles; Rats; Rats, Sprague-Dawley; Thromboxane A2; Vasoconstrictor Agents; Vasodilator Agents

1996
Nicorandil activates glibenclamide-sensitive K+ channels in smooth muscle cells of pig proximal urethra.
    The Journal of pharmacology and experimental therapeutics, 1997, Volume: 280, Issue:1

    Topics: Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Cyclic GMP; Female; Glyburide; Membrane Potentials; Muscle, Smooth; Niacinamide; Nicorandil; Potassium Channels; Pyrroles; Swine; Urethra

1997
Comparison of proarrhythmogenic effects of two potassium channel openers, levcromakalim (BRL 38227) and nicorandil (RP 46417): a high-resolution mapping study on rabbit heart.
    Journal of cardiovascular pharmacology, 1997, Volume: 29, Issue:1

    Topics: Animals; Arrhythmias, Cardiac; Benzopyrans; Bradycardia; Cromakalim; Dose-Response Relationship, Drug; Electrophysiology; Heart; In Vitro Techniques; Isosorbide Dinitrate; Niacinamide; Nicorandil; Potassium Channels; Pyrroles; Rabbits; Tachycardia; Vasodilator Agents; Ventricular Fibrillation

1997
Effect of JTV-506, a novel vasodilator, on coronary blood flow in conscious dogs.
    Journal of cardiovascular pharmacology, 1997, Volume: 29, Issue:3

    Topics: Administration, Oral; Animals; Benzopyrans; Blood Pressure; Chromans; Coronary Circulation; Cromakalim; Diltiazem; Dogs; Dose-Response Relationship, Drug; Female; Heart Rate; Injections, Intravenous; Male; Niacinamide; Nicorandil; Nitroglycerin; Pyrroles; Vasodilator Agents

1997
Heterogeneity in the vasorelaxing effect of nicorandil on dog epicardial coronary arteries: comparison with other NO donors.
    Journal of cardiovascular pharmacology, 1997, Volume: 29, Issue:6

    Topics: Animals; Atrial Natriuretic Factor; Benzopyrans; Coronary Vessels; Cromakalim; Cyclic GMP; Dogs; Female; Glyburide; In Vitro Techniques; Male; Methylene Blue; Molsidomine; Muscle Contraction; Muscle Relaxation; Muscle, Smooth, Vascular; Niacinamide; Nicorandil; Nitric Oxide; Nitroglycerin; Nitroprusside; Oxyhemoglobins; Pyrroles; Vasodilator Agents

1997
[ADDITIONAL CLASSES OF COMPOUNDS INHIBITING TUMORS. I. CYTOSTATIC EFFECTS OF N- AND S-HYDROXYMETHYL COMPOUNDS].
    Hoppe-Seyler's Zeitschrift fur physiologische Chemie, 1963, Volume: 334

    Topics: Amides; Animals; Antineoplastic Agents; Benzimidazoles; Carbohydrate Metabolism; Carcinoma, Ehrlich Tumor; Cytostatic Agents; Formaldehyde; Hydantoins; Imidazoles; Isonicotinic Acids; Mice; Morpholines; Neoplasms, Experimental; Niacin; Niacinamide; Piperazines; Piperidines; Pyrroles; Research; Urea

1963
Multi-kinase inhibitors create buzz at ASCO.
    Nature biotechnology, 2005, Volume: 23, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Biotechnology; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Phosphotransferases; Pyridines; Pyrroles; Sorafenib; Sunitinib

2005
Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
    Annals of internal medicine, 2005, Aug-16, Volume: 143, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Nail Diseases; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2005
Trials probe new agents for kidney cancer.
    JAMA, 2006, Jul-12, Volume: 296, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Lapatinib; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib

2006
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
    Clinical genitourinary cancer, 2006, Volume: 5, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2006
Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes.
    ONS news, 2006, Volume: 21, Issue:8 Suppl

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Delivery Systems; Humans; Indoles; Interleukin-2; Karnofsky Performance Status; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Niacinamide; Nurse's Role; Oncology Nursing; Patient Education as Topic; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Risk Assessment; Safety Management; Sorafenib; Sunitinib; Survival Analysis

2006
New therapeutic options for renal cell carcinoma.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2006
Pharmacy benefit spending on oral chemotherapy drugs.
    Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:7

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States

2006
Current and future management of GIST.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2006
Renal-cell carcinoma--molecular pathways and therapies.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Gene Silencing; Humans; Hypoxia-Inducible Factor 1; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein

2007
New drugs 07, part I.
    Nursing, 2007, Volume: 37, Issue:2

    Topics: Abatacept; Acetanilides; Alprostadil; Anidulafungin; Antidiuretic Hormone Receptor Antagonists; Antifungal Agents; Antineoplastic Agents; Arabinonucleosides; Benzazepines; Benzenesulfonates; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Echinocandins; Fatty Acids; Humans; Hypoglycemic Agents; Immunoconjugates; Immunosuppressive Agents; Indoles; Insulin; Insulin Detemir; Insulin, Long-Acting; Intercellular Signaling Peptides and Proteins; Lenalidomide; Lubiprostone; Niacinamide; Patient Education as Topic; Peptides, Cyclic; Phenylurea Compounds; Piperazines; Pyridines; Pyrroles; Ranolazine; Sorafenib; Sunitinib; Thalidomide; United States

2007
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    The oncologist, 2007, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2007
Two new drugs for renal cell carcinoma.
    The Medical letter on drugs and therapeutics, 2007, Feb-26, Volume: 49, Issue:1255

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Drug Interactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Newly approved therapies for RCC and their effect on the standard of care.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Interferons; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein

2007
ASCO 2006 highlights: targeted therapy for renal cell carcinoma.
    Cancer treatment reviews, 2007, Volume: 33, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2007
Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
    Medical hypotheses, 2007, Volume: 69, Issue:4

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urinary Bladder Neoplasms

2007
Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
    Onkologie, 2007, Volume: 30, Issue:5

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cytokines; Drug Costs; Humans; Indoles; Kidney Neoplasms; Long-Term Care; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate

2007
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
    Praxis, 2007, May-02, Volume: 96, Issue:18

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed

2007
Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
    European urology, 2007, Volume: 52, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunologic Factors; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Survival Rate

2007
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Cancer, 2007, Aug-01, Volume: 110, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A

2007
[Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
    Aktuelle Urologie, 2007, Volume: 38, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Controlled Clinical Trials as Topic; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Kidney; Kidney Neoplasms; Meta-Analysis as Topic; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors

2007
American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
    IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Technology Transfer; Treatment Outcome

2007
High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
    European urology, 2008, Volume: 53, Issue:2

    Topics: Adult; Aged; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2008
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
    Experimental hematology, 2007, Volume: 35, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib

2007
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:11

    Topics: Aged; Atrial Fibrillation; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Chest Pain; Drug Interactions; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sampling Studies; Severity of Illness Index; Sorafenib; Sunitinib

2007
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    The Journal of urology, 2008, Volume: 179, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2008
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
    Cancer, 2008, Jan-15, Volume: 112, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2008
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-01, Volume: 26, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome

2008
[New drugs; sunitinib and sorafenib].
    Nederlands tijdschrift voor geneeskunde, 2007, Dec-29, Volume: 151, Issue:52

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome

2007
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
    Journal of the National Cancer Institute, 2008, Feb-20, Volume: 100, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib

2008
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.
    Blood, 2008, Jun-15, Volume: 111, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; CD8-Positive T-Lymphocytes; Cell Division; Cell Movement; Cells, Cultured; Cytokines; Dendritic Cells; Dextrans; Endocytosis; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indoles; Interleukin-4; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Toll-Like Receptor 4

2008
[New drugs; sunitinib and sorafenib].
    Nederlands tijdschrift voor geneeskunde, 2008, Feb-23, Volume: 152, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Heart; Humans; Indoles; Myocardium; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
    BJU international, 2008, Volume: 102, Issue:6

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2008
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib

2008
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
    The Journal of urology, 2008, Volume: 180, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nicotinic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urea

2008
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
    Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Health Surveys; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Quality of Life; Salvage Therapy; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome; Young Adult

2009
Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-10, Volume: 26, Issue:20

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Multicenter Studies as Topic; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome

2008
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
    Cancer, 2008, Sep-15, Volume: 113, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythrocyte Indices; Female; Hematologic Tests; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib

2008
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    The Journal of urology, 2008, Volume: 180, Issue:3

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chi-Square Distribution; DNA Primers; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease

2008
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
    Toxicological sciences : an official journal of the Society of Toxicology, 2008, Volume: 106, Issue:1

    Topics: Adenosine Triphosphate; Animals; Benzamides; Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Electron Transport; Galactose; Glucose; Imatinib Mesylate; Indoles; Male; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocytes, Cardiac; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Thiazoles

2008
[Targeted therapy - point blank or single shot].
    Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2008
Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
    European urology, 2008, Volume: 54, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Time Factors; Treatment Outcome; Young Adult

2008
Watchdog set to reject four drugs for kidney cancer on the NHS.
    BMJ (Clinical research ed.), 2008, Aug-14, Volume: 337

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Approval; Drug Costs; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; State Medicine; Sunitinib; United Kingdom

2008
[New therapeutic regimes in metastasic renal-cell carcinoma].
    Der Internist, 2008, Volume: 49, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2008
[Antiangiogenics: new therapeutic standards in metastatic kidney cancer].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18 Suppl 4

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-20, Volume: 26, Issue:24

    Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polycythemia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients.
    Oncology, 2008, Volume: 74, Issue:3-4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Sample Size; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome

2008
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proctocolitis; Pyridines; Pyrroles; Sorafenib; Sunitinib

2008
Major treatment improvements encourage kidney cancer researchers to seek further gains.
    Journal of the National Cancer Institute, 2008, Sep-03, Volume: 100, Issue:17

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2008
[Renal cell carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2008
[Systemic therapy of metastasizing renal cell carcinoma].
    Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Tomography, X-Ray Computed

2008
[Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
    Bulletin du cancer, 2008, Volume: 95, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2008
Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-10, Volume: 26, Issue:32

    Topics: Antineoplastic Agents; Benzenesulfonates; Cardiovascular Diseases; Humans; Indoles; Neoplasms; Niacinamide; Patient Care Team; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome

2008
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-10, Volume: 26, Issue:32

    Topics: Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Cardiovascular Diseases; Echocardiography; Electrocardiography; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome

2008
Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    European urology, 2009, Volume: 55, Issue:6

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Withholding Treatment

2009
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    European urology, 2009, Volume: 55, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Withholding Treatment

2009
[Vascular and renal effects of anti-angiogenic therapy].
    Nephrologie & therapeutique, 2008, Volume: 4, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Glomerular Filtration Rate; Glomerulonephritis; Humans; Indoles; Kidney; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2008
Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature.
    Cancer science, 2009, Volume: 100, Issue:1

    Topics: Animals; Benzamides; Benzenesulfonates; Cell Line, Tumor; Extravasation of Diagnostic and Therapeutic Materials; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Transforming Growth Factor beta; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2009
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
    Cancer, 2009, Jan-01, Volume: 115, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Analysis

2009
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-10, Volume: 27, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Delivery Systems; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
    Cancer letters, 2009, May-18, Volume: 277, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase C; Protein Kinase C beta; Pyridines; Pyrroles; Ribosomal Protein S6 Kinases; Signal Transduction; Sorafenib; Sunitinib

2009
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Aktuelle Urologie, 2009, Volume: 40, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney; Kidney Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Time Factors

2009
[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Aktuelle Urologie, 2009, Volume: 40, Issue:1

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Cohort Studies; Data Interpretation, Statistical; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Surveys and Questionnaires; Time Factors; Urology

2009
Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.
    Journal of neurosurgery, 2009, Volume: 111, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain; Brain Edema; Brain Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Seizures; Sorafenib; Sunitinib

2009
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Clinical genitourinary cancer, 2009, Volume: 7, Issue:1

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Foot Diseases; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Niacinamide; Paresthesia; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63 Suppl 1

    Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Linear Models; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors

2009
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
    British journal of cancer, 2009, Apr-07, Volume: 100, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Cell Line, Tumor; Dendritic Cells; Humans; Indoles; Interleukin-12; Kidney Neoplasms; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Monocytes; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes; Vascular Endothelial Growth Factor A

2009
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Oncology, 2009, Volume: 76, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Salvage Therapy; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome

2009
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
    Investigational new drugs, 2010, Volume: 28, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Fatal Outcome; Female; Hemangiopericytoma; Humans; Indoles; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recurrence; Solitary Fibrous Tumors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Ultrasonography

2010
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
    BMC pharmacology, 2009, Apr-15, Volume: 9

    Topics: Animals; Atorvastatin; Benzenesulfonates; Cystadenoma; Disease Models, Animal; Doxycycline; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Heptanoic Acids; Immunosuppressive Agents; Interferon-gamma; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Burden; Tumor Suppressor Proteins

2009
A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2009, Volume: 21, Issue:8

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2009
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Pressure; Carcinoma, Renal Cell; Humans; Hypertension; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2009
Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
    Thyroid : official journal of the American Thyroid Association, 2009, Volume: 19, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypothyroidism; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib

2009
Sequential sorafenib and sunitinib for renal cell carcinoma.
    The Journal of urology, 2009, Volume: 182, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome

2009
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
    Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2009
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
    Cancer biology & therapy, 2009, Volume: 8, Issue:13

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Disease Models, Animal; Humans; Indoles; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Jul-15, Volume: 877, Issue:22

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles

2009
How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
    Journal of the National Cancer Institute, 2009, Jun-16, Volume: 101, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Cytokines; Disease-Free Survival; Endothelial Cells; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A

2009
A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
    Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg, 2009, Issue:1

    Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hemoglobins; Hemolysis; Humans; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    The British journal of dermatology, 2009, Volume: 161, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Gastrointestinal Stromal Tumors; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Skin Diseases; Sorafenib; Stomatitis; Sunitinib; Young Adult

2009
Surgical resection of renal cell carcinoma after targeted therapy.
    The Journal of urology, 2009, Volume: 182, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2009
Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.
    International journal of cancer, 2010, Mar-15, Volume: 126, Issue:6

    Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; DNA, Antisense; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; GTPase-Activating Proteins; Humans; Indoles; Kidney Neoplasms; Kinetics; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pyridines; Pyrroles; RNA, Small Interfering; Sorafenib; Sunitinib; Transfection; Tumor Burden

2010
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
    Cancer letters, 2010, Feb-01, Volume: 288, Issue:1

    Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Mice; Myocytes, Cardiac; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Prenylation; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib

2010
Long-term response in primary renal cancer to sequential antiangiogenic therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-10, Volume: 27, Issue:26

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors

2009
Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2009, Volume: 21, Issue:8

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Medical Audit; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; United Kingdom

2009
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
    Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Disease Progression; Drug Delivery Systems; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2010
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    American journal of clinical oncology, 2010, Volume: 33, Issue:3

    Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2010
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcitonin; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Susceptibility; Everolimus; Fatal Outcome; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonia, Bacterial; Pneumothorax; Protein Precursors; Pyridines; Pyrroles; Rupture, Spontaneous; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2010
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Oct-01, Volume: 15, Issue:19

    Topics: Adenosine Triphosphatases; Animals; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blood-Brain Barrier; Carrier Proteins; Cells, Cultured; Drug Evaluation, Preclinical; Humans; Hydrolysis; Indoles; Mice; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Swine; Xenopus laevis

2009
Everolimus: in advanced renal cell carcinoma.
    Drugs, 2009, Oct-22, Volume: 69, Issue:15

    Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A

2009
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
    British journal of cancer, 2009, Nov-17, Volume: 101, Issue:10

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Hematologic Diseases; Hematopoietic Stem Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Myelopoiesis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Substrate Specificity; Sulfonamides; Sunitinib

2009
Drug essentials. Small molecule multitargeted TKI therapy.
    Oncology (Williston Park, N.Y.), 2008, Volume: 22, Issue:11 Suppl N

    Topics: Benzenesulfonates; Drug Interactions; Humans; Indoles; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2008
Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:1

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
Therapy for metastatic RCC--questions remain.
    Nature reviews. Urology, 2009, Volume: 6, Issue:11

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2009
About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Humans; Indoles; Male; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.
    Urology, 2010, Volume: 75, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiographic Image Enhancement; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2010
[Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
    Aktuelle Urologie, 2010, Volume: 41, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Benzenesulfonates; Carcinoma, Renal Cell; Cooperative Behavior; Data Collection; Drug Delivery Systems; Drug Utilization; Germany; Humans; Immunotherapy; Indoles; Interdisciplinary Communication; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Medical Oncology; Niacinamide; Patient Care Team; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Urology

2010
VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Time Factors

2010
Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.
    Anti-cancer drugs, 2010, Volume: 21, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiodermatitis; Sorafenib; Sunitinib; Treatment Outcome

2010
Health policy: The UK 'postcode lottery' in renal cell carcinoma.
    Nature reviews. Urology, 2009, Volume: 6, Issue:12

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Health Care Rationing; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Regional Health Planning; Sorafenib; Sunitinib; Survival Rate; United Kingdom

2009
The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro.
    Journal of immunology (Baltimore, Md. : 1950), 2009, Dec-15, Volume: 183, Issue:12

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Indoles; K562 Cells; Killer Cells, Natural; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib

2009
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
    Blood, 2010, Feb-18, Volume: 115, Issue:7

    Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib

2010
Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
    The Journal of urology, 2010, Volume: 183, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
    AJR. American journal of roentgenology, 2010, Volume: 194, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome

2010
Tyrosine kinase inhibitor-induced macrocytosis.
    Anticancer research, 2009, Volume: 29, Issue:12

    Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate

2009
Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:8

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Renal Insufficiency; Sorafenib; Sunitinib

2010
[Renal cell carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
Risk of bleeding not increased by sorafenib or sunitinib.
    The Lancet. Oncology, 2010, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib

2010
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Agents; Antiviral Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates; Carcinoma, Renal Cell; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, X; Everolimus; Female; Gene Fusion; Humans; Immunosuppressive Agents; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Research Report; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Translocation, Genetic; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult

2010
Sorafenib-associated remission of psoriasis in hypernephroma: case report.
    Dermatology online journal, 2010, Feb-15, Volume: 16, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psoriasis; Pyridines; Pyrroles; Retreatment; Sorafenib; Sunitinib; Treatment Outcome

2010
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
    BJU international, 2010, Volume: 106, Issue:6

    Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Epidemiologic Methods; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2010
Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    BJU international, 2010, Volume: 106, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A

2010
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
    BJU international, 2011, Volume: 107, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrases; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib

2011
Prognostic factors in patients treated with VEGF-targeted therapies.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factors

2010
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Off-Label Use; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Thyroglobulin; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome

2010
[Renal cell carcinoma management and therapies in 2010].
    Bulletin du cancer, 2010, Volume: 97

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Everolimus; Humans; Indoles; Interferons; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Metabolic Networks and Pathways; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2010
[Targeted therapies: sequential and combined treatments].
    Bulletin du cancer, 2010, Volume: 97

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Combined Modality Therapy; Cytokines; ErbB Receptors; Humans; Indoles; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2010
[Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
    Bulletin du cancer, 2010, Volume: 97

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Digestive System; Heart; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Lung Injury; Mucous Membrane; Muscle Fatigue; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2010
[Advanced renal carcinomas with special situations. How to treat them?].
    Bulletin du cancer, 2010, Volume: 97

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2010
Editorial comment.
    Urology, 2010, Volume: 75, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome

2010
Editorial comment.
    Urology, 2010, Volume: 75, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome

2010
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Aktuelle Urologie, 2010, Volume: 41, Issue:3

    Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Drug Delivery Systems; Everolimus; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2010
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
    AJR. American journal of roentgenology, 2010, Volume: 194, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome

2010
Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
    Leukemia, 2010, Volume: 24, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myelomonocytic, Chronic; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
    Investigational new drugs, 2011, Volume: 29, Issue:5

    Topics: Adult; Benzenesulfonates; Disease Progression; Fatal Outcome; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2011
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:6

    Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms

2010
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib

2011
Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity.
    Toxicologic pathology, 2010, Volume: 38, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Echocardiography; Heart; Immunohistochemistry; In Situ Nick-End Labeling; Indazoles; Indoles; Male; Microscopy, Electron, Transmission; Mitochondria; Myocardium; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Rats; Sorafenib; Sulfonamides; Sunitinib; Troponin I

2010
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2011, Volume: 17, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome

2011
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.
    Genome biology, 2010, Volume: 11, Issue:8

    Topics: Adenocarcinoma; Benzenesulfonates; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Indoles; Lung Neoplasms; Mitogen-Activated Protein Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Selection, Genetic; Sorafenib; Sunitinib; Tongue Neoplasms

2010
Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2010
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2010, Volume: 12, Issue:8

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2010
Risk of arterial thrombosis not increased by sorafenib or sunitinib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30

    Topics: Angiogenesis Inhibitors; Arterial Occlusive Diseases; Benzenesulfonates; Evidence-Based Medicine; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Reproducibility of Results; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thromboembolism

2010
Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2.
    Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:5

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; GPI-Linked Proteins; Humans; Immunomagnetic Separation; Immunotherapy, Adoptive; Indoles; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Linear Models; Nasopharyngeal Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib

2011
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
    British journal of cancer, 2010, Sep-07, Volume: 103, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chromatography, Liquid; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Tandem Mass Spectrometry

2010
Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Cancer, 2011, Feb-01, Volume: 117, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyrotropin; Treatment Outcome

2011
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    European urology, 2010, Volume: 58, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Feasibility Studies; Female; Humans; Indoles; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome

2010
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules.
    Expert opinion on biological therapy, 2010, Volume: 10, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis

2010
Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report.
    Urologia internationalis, 2010, Volume: 85, Issue:3

    Topics: Adult; Antigens, CD34; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Penile Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Pyrroles; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome

2010
Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
    Oncology, 2010, Volume: 79, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Retrospective Studies; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Failure; Treatment Outcome

2010
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
    The Journal of urology, 2011, Volume: 185, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factors

2011
Kidney cancer: Does hypothyroidism predict clinical outcome?
    Nature reviews. Urology, 2011, Volume: 8, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib

2011
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
    World journal of urology, 2011, Volume: 29, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine

2011
More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.
    Anticancer research, 2010, Volume: 30, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Everolimus; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2010
Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.
    Urology, 2011, Volume: 77, Issue:4

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Young Adult

2011
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
    BJU international, 2011, Volume: 108, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Markov Chains; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib; Sweden; United States

2011
Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Hydroxylation; Indoles; Liver; Microsomes, Liver; Midazolam; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib

2011
Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors

2012
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell ca
    European urology, 2011, Volume: 59, Issue:5

    Topics: Academic Medical Centers; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Boston; Carcinoma, Renal Cell; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Observer Variation; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Pyrroles; Reproducibility of Results; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A

2011
Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Molecular pharmaceutics, 2011, Apr-04, Volume: 8, Issue:2

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blood-Brain Barrier; Cells, Cultured; Dogs; Humans; Indoles; Mice; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Topoisomerase I Inhibitors; Topotecan

2011
Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
    Urology, 2011, Volume: 77, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2011
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2011, Volume: 58, Issue:2

    Topics: Adult; Benzamides; Benzenesulfonates; Carcinoma, Renal Cell; Choristoma; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Pleural Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thymus Gland; Thyroxine

2011
[Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2010, Volume: 23, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cost-Benefit Analysis; Drug Costs; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2010
Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
    Urologic oncology, 2013, Volume: 31, Issue:3

    Topics: Aged; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Urinary Bladder

2013
Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.
    Biological & pharmaceutical bulletin, 2011, Volume: 34, Issue:3

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Substrate Specificity; Sunitinib; Swine; Transfection

2011
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
    BMC cancer, 2011, Mar-24, Volume: 11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Fatigue; Female; Humans; Indoles; Italy; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Oncology Service, Hospital; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2011
Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
    World journal of urology, 2011, Volume: 29, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2011
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Cancer Care Facilities; Carcinoma, Renal Cell; Community Health Services; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Practice Patterns, Physicians'; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; United States

2012
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
    Cancer, 2011, Nov-01, Volume: 117, Issue:21

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib

2011
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
    World journal of urology, 2013, Volume: 31, Issue:4

    Topics: Adult; Aged; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome

2013
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2012
[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
    Der Urologe. Ausg. A, 2011, Volume: 50, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Data Collection; Disease Progression; Drug Delivery Systems; Everolimus; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2011
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Melanoma; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Skin Neoplasms; Sorafenib; Structure-Activity Relationship

2011
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
    BJU international, 2011, Volume: 108, Issue:8 Pt 2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indoles; Italy; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2011
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Thrombocytopenia

2011
[New therapeutic options for advanced thyroid cancer].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:22

    Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms

2011
[KIT and KIT: from biology to clinical use].
    Bulletin du cancer, 2012, Feb-01, Volume: 99, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles

2012
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
    Blood, 2011, Aug-25, Volume: 118, Issue:8

    Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzenesulfonates; DNA, Neoplasm; Drug Resistance, Neoplasm; Eosinophilia; ETS Translocation Variant 6 Protein; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Indoles; Male; Middle Aged; Molecular Sequence Data; Niacinamide; Oncogene Fusion; Oncogene Proteins, Fusion; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ets; Pyridines; Pyrroles; Repressor Proteins; Sorafenib; Sunitinib

2011
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Treatment Outcome

2012
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Aktuelle Urologie, 2011, Volume: 42, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cooperative Behavior; Cytokines; Disease Progression; Everolimus; Evidence-Based Medicine; Humans; Indazoles; Indoles; Interdisciplinary Communication; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Care Team; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2011
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.
    BMC cancer, 2011, Jul-14, Volume: 11

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Time Factors; Treatment Outcome

2011
[Adverse effects of new oncologic therapies].
    Praxis, 2011, Jul-27, Volume: 100, Issue:15

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab

2011
Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
    European urology, 2011, Volume: 60, Issue:6

    Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chi-Square Distribution; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Everolimus; Female; Germany; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Time Factors; Treatment Failure

2011
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Aug-15, Volume: 17, Issue:16

    Topics: Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; International Cooperation; Kidney Neoplasms; Logistic Models; Male; Models, Biological; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Survival Analysis; Time Factors

2011
Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Current cancer drug targets, 2011, Volume: 11, Issue:8

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Random Allocation; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays

2011
Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2012
Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion.
    Journal of cellular and molecular medicine, 2012, Volume: 16, Issue:7

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cell Line; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Erlotinib Hydrochloride; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Photochemotherapy; Porphyrins; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Verteporfin; Wet Macular Degeneration

2012
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
    Journal of biochemistry, 2012, Volume: 151, Issue:1

    Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection

2012
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    BJU international, 2012, Volume: 109, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2012
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Urologic oncology, 2013, Volume: 31, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A

2013
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
    Circulation research, 2011, Dec-09, Volume: 109, Issue:12

    Topics: Animals; Animals, Genetically Modified; Apoptosis; Benzenesulfonates; Cardiotoxins; Cell Survival; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Indoles; Male; Models, Animal; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; Sunitinib; Zebrafish

2011
Reversible cardiomyopathy associated with sunitinib and sorafenib.
    The New England journal of medicine, 2011, Oct-27, Volume: 365, Issue:17

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cardiomyopathies; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2011
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2012
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Annals of surgical oncology, 2012, Volume: 19, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Risk Factors; Serum Albumin; Sorafenib; Sunitinib; Survival Rate; Young Adult

2012
Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
    British journal of cancer, 2011, Dec-06, Volume: 105, Issue:12

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate

2011
Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
    International journal of clinical oncology, 2013, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2013
Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2011, Volume: 13, Issue:12

    Topics: Angiogenesis Inhibitors; Antiviral Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib

2011
[Renal tolerance of targeted therapies].
    Bulletin du cancer, 2012, Mar-01, Volume: 99, Issue:3

    Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib

2012
Sorafenib: muscle wasting.
    Prescrire international, 2011, Volume: 20, Issue:122

    Topics: Benzamides; Benzenesulfonates; Humans; Imatinib Mesylate; Indoles; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Rhabdomyolysis; Sorafenib; Sunitinib

2011
Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
    Clinical genitourinary cancer, 2012, Volume: 10, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden

2012
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Feb-10, Volume: 30, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Remission Induction; Retrospective Studies; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome

2012
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult

2012
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.
    Cancer cell, 2012, Jan-17, Volume: 21, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Crizotinib; Epithelial-Mesenchymal Transition; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Niacinamide; Pericytes; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Tumor Cells, Cultured

2012
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
    Clinical and experimental nephrology, 2012, Volume: 16, Issue:3

    Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib

2012
Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
    Anticancer research, 2012, Volume: 32, Issue:2

    Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib

2012
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:6

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2012
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
    Cancer letters, 2012, Sep-01, Volume: 322, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Humans; Insulin-Like Growth Factor I; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Mutation; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Pyrroles; ras Proteins; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2012
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Benzenesulfonates; Carcinoid Tumor; Carcinoma, Squamous Cell; CD5 Antigens; DNA Mutational Analysis; Enzyme Activation; Female; Genetic Association Studies; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thymoma; Thymus Neoplasms; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins

2012
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
    BJU international, 2012, Volume: 110, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Contraindications; Female; Humans; Indoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Renal Dialysis; Retrospective Studies; Sorafenib; Sunitinib

2012
Intracranial metastasis from pediatric GI stromal tumor.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Apr-01, Volume: 30, Issue:10

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Stomach Neoplasms; Sunitinib; Treatment Outcome

2012
Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Databases as Topic; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Hormones

2012
Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Blood, 2012, Jun-21, Volume: 119, Issue:25

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzenesulfonates; Cells, Cultured; Drug Synergism; Female; HL-60 Cells; Humans; Indoles; Leukemia, Myeloid; Membrane Proteins; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; Sorafenib; U937 Cells; Up-Regulation; Xenograft Model Antitumor Assays

2012
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VE
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Enzyme Inhibitors; ErbB Receptors; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrroles; Salvage Therapy; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome

2012
The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.
    Urologic oncology, 2013, Volume: 31, Issue:8

    Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Insulin-Like Growth Factor I; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-met; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Sunitinib; Taxoids; Zinc Sulfate

2013
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
    BMC cancer, 2012, May-02, Volume: 12

    Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Indoles; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome

2012
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
    The Journal of pathology, 2012, Volume: 227, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Imatinib Mesylate; In Vitro Techniques; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2012
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Gland; Thyrotoxicosis

2012
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.
    Oncology, 2012, Volume: 82, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2012
Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
    Clinical genitourinary cancer, 2012, Volume: 10, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2012
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:12

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Exanthema; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Registries; Retrospective Studies; Skin; Sorafenib; Sunitinib; Treatment Outcome

2012
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:9

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed

2012
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2012
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.
    Cell death & disease, 2012, Jul-19, Volume: 3

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Aniline Compounds; Animals; Apoptosis Regulatory Proteins; Autophagy; bcl-X Protein; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; DNA Copy Number Variations; Female; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; RNA Interference; RNA, Small Interfering; Sorafenib; Sulfonamides; Thymus Neoplasms; TOR Serine-Threonine Kinases; Transplantation, Heterologous

2012
Targeting angiogenesis in metastatic breast cancer.
    The oncologist, 2012, Volume: 17, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2012
Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling.
    International journal of cardiology, 2013, Sep-10, Volume: 167, Issue:6

    Topics: Animals; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Ventricular Function, Right; Ventricular Remodeling

2013
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
    International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; C-Reactive Protein; Carcinoma, Renal Cell; Confidence Intervals; Female; Humans; Hyponatremia; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Leukocytosis; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Severity of Illness Index; Sodium; Sorafenib; Sunitinib

2012
Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    International journal of clinical oncology, 2013, Volume: 18, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; C-Reactive Protein; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib

2013
Editorial comment from Dr Saito to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
    International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:12

    Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2012
Editorial comment from Dr Vázquez-Alonso and Dr Puche-Sanz to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
    International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:12

    Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2012
Thyroid dysfunction in patients treated with sunitinib or sorafenib.
    Clinical genitourinary cancer, 2012, Volume: 10, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Gland; Thyroid Hormones

2012
Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
    The Annals of pharmacotherapy, 2012, Volume: 46, Issue:10

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2012
Tyrosine kinase inhibitor induced pancreatitis.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2013, Volume: 19, Issue:3

    Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Pancreatitis; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib

2013
Conditional survival of patients with metastatic renal-cell carcinoma.
    The Lancet. Oncology, 2012, Volume: 13, Issue:11

    Topics: Carcinoma, Renal Cell; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Analysis

2012
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
    British journal of cancer, 2012, Nov-06, Volume: 107, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Osteonecrosis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2012
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sorafenib; Sunitinib; Treatment Outcome; Young Adult

2013
Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
    Surgery, 2012, Volume: 152, Issue:6

    Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Benzimidazoles; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Humans; Immunosuppressive Agents; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms

2012
Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-20, Volume: 31, Issue:6

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Humans; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2013
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
    Anti-cancer drugs, 2013, Volume: 24, Issue:3

    Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines

2013
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
    Bulletin du cancer, 2012, Volume: 99, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Cancer Care Facilities; Carcinoma, Renal Cell; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2012
Drugmakers struggle with Indian patents.
    Cancer discovery, 2012, Volume: 2, Issue:12

    Topics: Antineoplastic Agents; Benzamides; Drug Design; Drug Industry; Humans; Imatinib Mesylate; India; Indoles; Niacinamide; Patents as Topic; Phenylurea Compounds; Piperazines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib

2012
Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Sweden; Young Adult

2013
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:2

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Knockout; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2013
Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; United States

2013
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome

2013
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
    Cancer treatment reviews, 2013, Volume: 39, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2013
[Two cases of bowel perforation in patients with metastatic renal cancer treated with a molecularly targeted drug].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2012, Volume: 103, Issue:5

    Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2012
Taking cancer-drug toxicity to heart.
    Cancer discovery, 2013, Volume: 3, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Doxorubicin; Heart Failure; Heart Function Tests; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Trastuzumab

2013
[Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2013, Volume: 23, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome

2013
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2013
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult

2013
Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Chemotherapy, 2012, Volume: 58, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Young Adult

2012
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, May-01, Volume: 926

    Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles

2013
Rapid and efficient directed differentiation of human pluripotent stem cells into retinal pigmented epithelium.
    Stem cells translational medicine, 2013, Volume: 2, Issue:5

    Topics: Activins; Cell Differentiation; Cell Line; Cell Lineage; Cell Proliferation; Cells, Cultured; Gene Expression Regulation; Humans; Niacinamide; Pluripotent Stem Cells; Pyrroles; Retinal Pigment Epithelium; RNA, Messenger; Time Factors; Vasoactive Intestinal Peptide; Visual Fields

2013
Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib

2013
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?
    World journal of urology, 2014, Volume: 32, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Comorbidity; Dose-Response Relationship, Drug; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thrombectomy; Thrombosis; Treatment Outcome; Vena Cava, Inferior

2014
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2013, Volume: 71, Issue:9

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid

2013
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Databases, Factual; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival; Treatment Outcome

2013
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
    Angiogenesis, 2013, Volume: 16, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid

2013
First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
    Urology, 2013, Volume: 82, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Asymptomatic Diseases; Blood Cell Count; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Function Tests; Kidney Neoplasms; Liver Function Tests; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Patient Preference; Phenylurea Compounds; Population Surveillance; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors

2013
Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013, Volume: 34, Issue:6

    Topics: Angiogenesis Inhibitors; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Communication; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Enzyme Activation; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sorafenib; Sunitinib

2013
Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cells, Cultured; Checkpoint Kinase 2; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays

2013
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
    British journal of cancer, 2013, Aug-06, Volume: 109, Issue:3

    Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Growth Processes; Everolimus; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Random Allocation; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays

2013
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
    The Journal of pharmacology and experimental therapeutics, 2013, Volume: 346, Issue:3

    Topics: Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain; Dasatinib; DNA, Complementary; Female; Gene Dosage; Half-Life; Indoles; Male; Maternal-Fetal Exchange; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Pregnancy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; RNA; Sex Characteristics; Sorafenib; Sunitinib; Thiazoles

2013
Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.
    JOP : Journal of the pancreas, 2013, Jul-10, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Indoles; Niacinamide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sunitinib; Treatment Outcome

2013
Curcumin potentiates the ability of sunitinib to eliminate the VHL-lacking renal cancer cells 786-O: rapid inhibition of Rb phosphorylation as a preamble to cyclin D1 inhibition.
    Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:10

    Topics: Antineoplastic Agents; CDC2 Protein Kinase; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Curcumin; Cyclin D1; Cyclin-Dependent Kinase 4; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Retinoblastoma Protein; Signal Transduction; Sorafenib; Sunitinib

2013
Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT).
    International journal of radiation oncology, biology, physics, 2013, Sep-01, Volume: 87, Issue:1

    Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Bevacizumab; Duodenal Diseases; Humans; Indazoles; Indoles; Intestinal Diseases; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography; Radiosurgery; Radiotherapy Dosage; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Stomach Ulcer; Sulfonamides; Sunitinib; Ulcer

2013
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Oct-15, Volume: 19, Issue:20

    Topics: Adolescent; Alleles; Animals; Antineoplastic Agents; Cell Line, Tumor; Child; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Mice; Models, Molecular; Molecular Conformation; Mutation; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2013
[A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents].
    Hinyokika kiyo. Acta urologica Japonica, 2013, Volume: 59, Issue:8

    Topics: Animals; Antineoplastic Agents; Birt-Hogg-Dube Syndrome; Carcinoma, Renal Cell; Everolimus; Humans; In Vitro Techniques; Indoles; Kidney Neoplasms; Male; Mice, Knockout; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2013
Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
    Journal of geriatric oncology, 2013, Volume: 4, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Disease-Free Survival; Drug Eruptions; Female; Humans; Indoles; Kidney Neoplasms; Male; Neutropenia; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2013
Cytotoxic properties of sunitinib and sorafenib on human corneal epithelial cells.
    Current eye research, 2014, Volume: 39, Issue:2

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers; Cell Line; Cell Survival; Enzyme-Linked Immunosorbent Assay; Epithelium, Corneal; Humans; Immunohistochemistry; Indoles; Membrane Proteins; Microscopy, Fluorescence; Microscopy, Phase-Contrast; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Sunitinib; Tetrazolium Salts; Thiazoles

2014
Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties.
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2013, Volume: 16, Issue:4

    Topics: Animals; Atorvastatin; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacinamide; Pyrroles; Rats; Rats, Wistar; Solubility

2013
A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.
    Anticancer research, 2013, Volume: 33, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases

2013
Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Animals; Biglycan; Gene Expression Regulation, Neoplastic; Humans; Indoles; Leucine; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyrroles; RNA, Messenger; Sorafenib; Sunitinib; Urinary Bladder Neoplasms

2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
    International journal of oncology, 2014, Volume: 44, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Asia; Bevacizumab; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; United States

2014
Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
    Histopathology, 2014, Volume: 64, Issue:4

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sunitinib

2014
Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma.
    International urology and nephrology, 2014, Volume: 46, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hemoglobin A; Humans; Indazoles; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A

2014
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
    Urologic oncology, 2014, Volume: 32, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cytokines; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate

2014
Targeted therapies: Juggling combinations--not the way forward.
    Nature reviews. Clinical oncology, 2014, Volume: 11, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus

2014
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Eligibility Determination; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome

2014
Diarylureas and diarylamides with pyrrolo[2,3-d]pyrimidine scaffold as broad-spectrum anticancer agents.
    Chemical & pharmaceutical bulletin, 2014, Volume: 62, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Niacinamide; Phenylurea Compounds; Piperazines; Pyrimidines; Pyrroles; Sorafenib

2014
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    European journal of endocrinology, 2014, Volume: 170, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome

2014
cAMP-PKA inhibition of SK3 channel reduced both Ca2+ entry and cancer cell migration by regulation of SK3-Orai1 complex.
    Pflugers Archiv : European journal of physiology, 2014, Volume: 466, Issue:10

    Topics: Adrenergic beta-Agonists; Azepines; Calcium; Calcium Channels; Carbazoles; Cell Line, Tumor; Cell Movement; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; HEK293 Cells; Humans; Isoproterenol; Membrane Microdomains; Niacinamide; ORAI1 Protein; Phosphodiesterase 4 Inhibitors; Protein Binding; Protein Kinase Inhibitors; Pyrroles; Small-Conductance Calcium-Activated Potassium Channels

2014
Maturing of renal cancer therapeutics.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-10, Volume: 32, Issue:8

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2014
Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
    Scandinavian journal of urology, 2014, Volume: 48, Issue:4

    Topics: Aged; Algorithms; Carcinoma, Renal Cell; Combined Modality Therapy; Denmark; Enzyme Inhibitors; Female; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Survival Rate; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome

2014
[Systemic treatment of metastatic renal cell carcinoma: change of paradigms after introduction of targeted therapy].
    Der Urologe. Ausg. A, 2014, Volume: 53, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate

2014
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
    Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:5

    Topics: Adult; Aged; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases

2014
4-Amino-pyrrolopyridine-5-carboxamide: a novel scaffold for JAK1-selective inhibitors.
    Chemical & pharmaceutical bulletin, 2014, Volume: 62, Issue:3

    Topics: In Vitro Techniques; Janus Kinase 1; Janus Kinase 2; Niacinamide; Protein Kinase Inhibitors; Pyrroles; Structure-Activity Relationship

2014
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
    European urology, 2014, Volume: 66, Issue:3

    Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid

2014
Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:7

    Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Disease Models, Animal; Drug Repositioning; Indoles; Inhibitory Concentration 50; Lapatinib; Leishmania; Leishmaniasis; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome

2014
The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Indoles; Kidney Neoplasms; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Pyrroles; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cohort Studies; Decision Making; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Netherlands; Niacinamide; Phenylurea Compounds; Pyrroles; Quality of Life; Self Report; Sorafenib; Sunitinib; Treatment Outcome

2014
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
    Journal of surgical oncology, 2014, Volume: 110, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombectomy; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis

2014
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients.
    Anticancer research, 2014, Volume: 34, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2014
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Clinical genitourinary cancer, 2014, Volume: 12, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2014
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
    Clinical genitourinary cancer, 2014, Volume: 12, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A

2014
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dasatinib; Hep G2 Cells; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib; Thiazoles

2014
Metastatic involvement of the maxillary antrum from an uncommon source.
    Dental update, 2014, Volume: 41, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemoradiotherapy, Adjuvant; Embolization, Therapeutic; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Maxillary Sinus Neoplasms; Nephrectomy; Niacinamide; Palatal Neoplasms; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2014
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
    Clinical genitourinary cancer, 2014, Volume: 12, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome

2014
Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Eosinophils; Female; Hemoglobins; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib

2014
Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor.
    International journal of clinical oncology, 2015, Volume: 20, Issue:2

    Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Hyponatremia; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Risk Factors; Serum Albumin; Sodium; Sorafenib; Sunitinib; Survival Rate

2015
Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.
    Future oncology (London, England), 2015, Volume: 11, Issue:1

    Topics: Adult; Aged; Bone Marrow Cells; Carcinoma, Renal Cell; Humans; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2015
[Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2014, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate

2014
Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.
    World journal of gastroenterology, 2014, Jun-28, Volume: 20, Issue:24

    Topics: Actins; Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Indoles; Male; Matrix Metalloproteinase 2; Niacinamide; Pancreas; Pancreatic Stellate Cells; Phenotype; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Rats, Inbred Lew; RNA, Messenger; Signal Transduction; Sorafenib; Sunitinib; Time Factors; Transforming Growth Factor beta1

2014
Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3).
    PloS one, 2014, Volume: 9, Issue:7

    Topics: Antineoplastic Agents; Cell Line, Transformed; Cell Proliferation; Cyclic S-Oxides; Gene Expression Regulation; Humans; Indoles; Inhibitor of Apoptosis Proteins; Keratinocytes; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Sunitinib; Survivin; Tetrazolium Salts

2014
Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
    Cancer letters, 2014, Oct-01, Volume: 352, Issue:2

    Topics: Administration, Oral; Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Survival; Dose-Response Relationship, Drug; Heterografts; Indoles; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; PC12 Cells; Phenylurea Compounds; Pheochromocytoma; Protein Kinase Inhibitors; Pyrroles; Rats; Sorafenib; Sunitinib; Time Factors; Tumor Burden

2014
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.
    Cell metabolism, 2014, Aug-05, Volume: 20, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Progression; Fatty Acid Synthases; Homeodomain Proteins; Humans; Indoles; Lipids; Metabolomics; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteomics; Pyrroles; RNA Interference; Sorafenib; Sunitinib; Transplantation, Heterologous

2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    The Journal of urology, 2015, Volume: 193, Issue:1

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib

2015
SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
    Neoplasia (New York, N.Y.), 2014, Volume: 16, Issue:7

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Regulatory Factor X Transcription Factors; Regulatory Factor X1; Sorafenib; STAT3 Transcription Factor; Transcription Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays

2014
Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
    Cancer immunology research, 2014, Volume: 2, Issue:11

    Topics: Angiogenesis Inhibitors; Animals; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Female; Flow Cytometry; Humans; Indoles; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib; Vaccines, Synthetic

2014
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib.
    Endocrine, 2015, Volume: 49, Issue:3

    Topics: Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Indoles; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Failure

2015
RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Carcinogenesis, 2014, Volume: 35, Issue:12

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Chromatin Immunoprecipitation; DNA-Binding Proteins; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Liver Neoplasms; Luciferases; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Real-Time Polymerase Chain Reaction; Regulatory Factor X Transcription Factors; Regulatory Factor X1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
Inhibition of c-Kit by tyrosine kinase inhibitors.
    Haematologica, 2015, Volume: 100, Issue:3

    Topics: Aminopyridines; Antineoplastic Agents; Benzothiazoles; Biomarkers; Bone Marrow; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; fms-Like Tyrosine Kinase 3; Gene Expression; Hair; Hematopoietic Stem Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pigmentation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Thiazoles

2015
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
    Journal of cellular and molecular medicine, 2015, Volume: 19, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2015
Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    BMC cancer, 2014, Dec-12, Volume: 14

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Indoles; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-2

2014
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
    European urology, 2015, Volume: 68, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Costs and Cost Analysis; Denmark; Drug Costs; Efficiency; Employment; Everolimus; Female; Fluorouracil; Health Care Costs; Hospitalization; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Radiography; Radiotherapy; Registries; Sirolimus; Sorafenib; Sunitinib

2015
Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2015, Volume: 23, Issue:4

    Topics: Carcinoma, Hepatocellular; Cell Proliferation; Culture Media, Conditioned; Fetus; Gene Knockdown Techniques; Humans; Indoles; Liver Neoplasms; Mesenchymal Stem Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib; Sunitinib

2015
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
    Cellular oncology (Dordrecht), 2015, Volume: 38, Issue:2

    Topics: Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Tandem Mass Spectrometry

2015
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Adult; Aged, 80 and over; Canada; Cardiovascular Diseases; Female; Humans; Indoles; Male; Middle Aged; Myocardial Ischemia; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib

2015
Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Anticancer research, 2015, Volume: 35, Issue:4

    Topics: Amphiregulin; Carcinoma, Squamous Cell; EGF Family of Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Indoles; Molecular Targeted Therapy; Niacinamide; Papillomaviridae; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Sunitinib; TOR Serine-Threonine Kinases

2015
Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
    Reproductive sciences (Thousand Oaks, Calif.), 2015, Volume: 22, Issue:11

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Proliferation; Disease Models, Animal; Endometriosis; Endometrium; Female; Indazoles; Indoles; Niacinamide; Ovarian Reserve; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2015
Kidney cancer: SWITCHing inconsequential.
    Nature reviews. Urology, 2015, Volume: 12, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles

2015
Results of the first trial assessing adjuvant tyrosine kinase inhibitors in renal cell carcinoma do not reASSURE.
    European urology, 2015, Volume: 68, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Early Termination of Clinical Trials; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Treatment Outcome

2015
Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
    Anti-cancer drugs, 2015, Volume: 26, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chronic Disease; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Diseases; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate

2015
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System.
    American journal of hypertension, 2016, Volume: 29, Issue:2

    Topics: Aged; Antineoplastic Agents; Arteries; Blood Pressure; Carcinoma, Renal Cell; Female; Heart; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pulse Wave Analysis; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; Vascular Stiffness

2016
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
    Oncotarget, 2015, Aug-28, Volume: 6, Issue:25

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hep G2 Cells; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyrroles; Quinolines; Signal Transduction; Sorafenib; Sunitinib; Transforming Growth Factor beta1

2015
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
    The Canadian journal of urology, 2015, Volume: 22, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Life Style; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate

2015
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
    Journal of translational medicine, 2015, Jun-13, Volume: 13

    Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays

2015
[Systemic therapy of soft tissue sarcomas].
    Voprosy onkologii, 2015, Volume: 61, Issue:2

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ifosfamide; Indazoles; Indoles; Male; Molecular Targeted Therapy; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Polyethylene Glycols; Pyrimidines; Pyrroles; Radiography; Sarcoma; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome

2015
Sorafenib-Sunitinib Sequence: The Jury Is Out.
    European urology, 2015, Volume: 68, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2015
A model of neuropathic pain induced by sorafenib in the rat: Effect of dimiracetam.
    Neurotoxicology, 2015, Volume: 50

    Topics: Analgesics; Analysis of Variance; Animals; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Imidazoles; Male; Neuralgia; Niacinamide; Pain Measurement; Pain Threshold; Phenylurea Compounds; Pyrroles; Rats; Rats, Sprague-Dawley; Reaction Time; Sorafenib; Time Factors

2015
Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.
    Oncotarget, 2015, Sep-29, Volume: 6, Issue:29

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; HeLa Cells; Hep G2 Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Jurkat Cells; MCF-7 Cells; Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcriptome

2015
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.
    Journal of oncology practice, 2015, Volume: 11, Issue:6

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Patients; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2015
Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
    Targeted oncology, 2016, Volume: 11, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2016
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Clinical genitourinary cancer, 2016, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib

2016
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
    Cancer, 2016, Jan-01, Volume: 122, Issue:1

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cardiovascular Diseases; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Risk Factors; SEER Program; Sorafenib; Sunitinib; Survival Analysis; United States

2016
[Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2016, Volume: 26, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome

2016
Kidney cancer: TKIs associated with stroke risk.
    Nature reviews. Urology, 2015, Volume: 12, Issue:11

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cardiovascular Diseases; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles

2015
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:16

    Topics: Angiogenesis Inhibitors; Anilides; Carcinoma, Neuroendocrine; Databases, Chemical; Drug Discovery; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Molecular Structure; Niacinamide; Oligonucleotides; Piperidines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2

2015
Murine colitis treated with multitargeted tyrosine kinase inhibitors.
    The Journal of surgical research, 2016, Volume: 200, Issue:2

    Topics: Animals; Axitinib; Colitis; Imidazoles; Indazoles; Indoles; Male; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2016
Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-1

2016
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
    Cancer, 2016, Feb-01, Volume: 122, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2016
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Journal of medical economics, 2016, Volume: 19, Issue:5

    Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comorbidity; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Fees, Pharmaceutical; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib

2016
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Time Factors; Withholding Treatment

2016
Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer.
    Oncology reports, 2016, Volume: 35, Issue:3

    Topics: Axitinib; Carcinoma, Renal Cell; Cell Communication; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Neoplastic Stem Cells; Niacinamide; Oxygen; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Tumor Microenvironment

2016
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Current medical research and opinion, 2016, Volume: 32, Issue:4

    Topics: Aged; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; United States

2016
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
    European urology, 2016, Volume: 70, Issue:3

    Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment

2016
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC).
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Singapore; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2015
Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Models, Molecular; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma; Retinoid X Receptor alpha; Sorafenib; Sunitinib

2016
Heart failure associated with small molecule tyrosine kinase inhibitors.
    International journal of cardiology, 2016, Mar-01, Volume: 206

    Topics: Aged; Aged, 80 and over; Dasatinib; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib

2016
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
    Cancer immunology, immunotherapy : CII, 2016, Volume: 65, Issue:3

    Topics: Celecoxib; Cell Differentiation; Cells, Cultured; Dasatinib; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Humans; Immune Tolerance; Indoles; Monocytes; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sunitinib

2016
Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Oncotarget, 2016, May-10, Volume: 7, Issue:19

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2016
Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2017, Volume: 23, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Documentation; Fatigue; Female; Germany; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Registries; Sirolimus; Sorafenib; Stomatitis; Sunitinib

2017
Adjuvant therapy for renal-cell carcinoma: settled for now.
    Lancet (London, England), 2016, May-14, Volume: 387, Issue:10032

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles

2016
Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
    Clinical genitourinary cancer, 2016, Volume: 14, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult

2016
Kidney cancer: No advantage of adjuvant sunitinib or sorafenib.
    Nature reviews. Urology, 2016, Volume: 13, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2016
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    European urology, 2016, Volume: 70, Issue:6

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden

2016
Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
    The Journal of urology, 2016, Volume: 196, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Young Adult

2016
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:3

    Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Cohort Studies; Computer Communication Networks; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A

2016
Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
    International urology and nephrology, 2016, Volume: 48, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Developing Countries; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Prospective Studies; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; White People; Young Adult

2016
Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.
    International journal of cancer, 2016, 11-15, Volume: 139, Issue:10

    Topics: Animals; Cell Movement; Female; Indoles; Leukocytes; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Transendothelial and Transepithelial Migration

2016
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:3

    Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Logistic Models; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Time Factors

2016
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
    BMC cancer, 2016, 08-02, Volume: 16

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome

2016
Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
    Scientific reports, 2016, 08-04, Volume: 6

    Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Prospective Studies; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Sunitinib; Tissue Array Analysis; Vascular Endothelial Growth Factor Receptor-1

2016
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
    International journal of clinical oncology, 2017, Volume: 22, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Time Factors

2017
Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
    Cancer medicine, 2016, Volume: 5, Issue:12

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Erythrocyte Indices; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2016
Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
    Oncology reports, 2017, Volume: 37, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Cycle Proteins; Cell Line, Tumor; Disease-Free Survival; Everolimus; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphoproteins; Protein Kinase Inhibitors; Pyrroles; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Sunitinib; Treatment Outcome

2017
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
    Yonsei medical journal, 2017, Volume: 58, Issue:1

    Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib

2017
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
    The American journal of case reports, 2017, Jan-03, Volume: 18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neurosurgical Procedures; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Sorafenib; Sunitinib; Treatment Outcome

2017
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.
    BMC cancer, 2017, 01-05, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2017
Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?
    European urology, 2017, Volume: 71, Issue:5

    Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk; Risk Assessment; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome

2017
Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
    Oncotarget, 2017, Feb-28, Volume: 8, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; N-Acetylgalactosaminyltransferases; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polypeptide N-acetylgalactosaminyltransferase; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate

2017
Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
    European radiology, 2017, Volume: 27, Issue:9

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Observer Variation; Phenylurea Compounds; Pyrroles; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome

2017
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; SEER Program; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome

2017
Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.
    The oncologist, 2017, Volume: 22, Issue:2

    Topics: Cohort Studies; Female; Humans; Hypertension; Hypothyroidism; Indoles; Male; Middle Aged; Niacinamide; Pharmacoepidemiology; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2017
Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prealbumin; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Serum Albumin, Human; Sorafenib; Sunitinib; Treatment Outcome

2017
MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.
    International journal of cancer, 2017, 05-15, Volume: 140, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Renal Cell; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Immunoenzyme Techniques; Indoles; Kidney Neoplasms; Mucins; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Tumor Cells, Cultured

2017
Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
    Head & neck, 2017, Volume: 39, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Disease-Free Survival; Head and Neck Neoplasms; Humans; Immunohistochemistry; Indoles; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Radiation-Sensitizing Agents; Risk Assessment; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Sunitinib

2017
Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib.
    Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Receptors, Cell Surface; Sorafenib; Sunitinib; Treatment Outcome

2017
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Clinical nuclear medicine, 2017, Volume: 42, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sorafenib; Sulfonamides; Sunitinib

2017
Patient-specific blood pressure correction technique for arterial stiffness: evaluation in a cohort on anti-angiogenic medication.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2017, Volume: 40, Issue:8

    Topics: Adult; Aged; Algorithms; Angiogenesis Inhibitors; Blood Pressure; Carotid Arteries; Cohort Studies; Cross-Sectional Studies; Female; Humans; Indoles; Male; Manometry; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pulse Wave Analysis; Pyrroles; Sorafenib; Sunitinib; Vascular Stiffness

2017
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
    Urologic oncology, 2017, Volume: 35, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Young Adult

2017
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 79

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chordoma; Erlotinib Hydrochloride; Female; France; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Skull Base Neoplasms; Sorafenib; Sunitinib; Treatment Outcome; Young Adult

2017
The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma.
    Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:5

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Collagen; Drug Screening Assays, Antitumor; Drug Synergism; Female; Hepatoblastoma; Humans; Indoles; Infant; Inhibitory Concentration 50; Irinotecan; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Recurrence; Sorafenib; Sunitinib

2017
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:6

    Topics: Aged; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Female; Gastrointestinal Diseases; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome

2017
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A

2017
Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
    Current medical research and opinion, 2017, Volume: 33, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Databases, Factual; Disease-Free Survival; Everolimus; Female; France; Humans; Imidazoles; Indazoles; Indoles; Insurance, Health; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib

2017
Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
    Chinese journal of cancer, 2017, Aug-08, Volume: 36, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Treatment Outcome

2017
Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    International urology and nephrology, 2017, Volume: 49, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphocyte Count; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Neutrophils; Niacinamide; Nutritional Status; Phenylurea Compounds; Preoperative Period; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Young Adult

2017
Simultaneous determination of boscalid and fludioxonil in grape and soil under field conditions by gas chromatography/tandem triple quadrupole mass spectrometry.
    Biomedical chromatography : BMC, 2018, Volume: 32, Issue:2

    Topics: Analysis of Variance; Biphenyl Compounds; Dioxoles; Fungicides, Industrial; Gas Chromatography-Mass Spectrometry; Limit of Detection; Linear Models; Niacinamide; Pesticide Residues; Pyrroles; Reproducibility of Results; Soil; Tandem Mass Spectrometry; Vitis

2018
Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Recepto
    Journal of the American Heart Association, 2017, Oct-19, Volume: 6, Issue:10

    Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Cells, Cultured; Dose-Response Relationship, Drug; Echocardiography; ErbB Receptors; Erlotinib Hydrochloride; Fatty Acids; Female; Gene Expression Profiling; Heart; Heart Diseases; Indoles; Mice; Molecular Targeted Therapy; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Protein Interaction Maps; Protein Kinase Inhibitors; Proteomics; Pyrroles; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Sunitinib; Time Factors

2017
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
    British journal of cancer, 2017, Dec-05, Volume: 117, Issue:12

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Nucleus; Cell Survival; Cetuximab; Colorectal Neoplasms; Curcumin; Dasatinib; Drug Resistance, Neoplasm; Fatty Acids, Unsaturated; Female; Fluorouracil; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Leucovorin; Male; Middle Aged; Molecular Chaperones; Molecular Targeted Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Protein Inhibitors of Activated STAT; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib

2017
Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
    Japanese journal of clinical oncology, 2017, Dec-01, Volume: 47, Issue:12

    Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib

2017
A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs.
    EBioMedicine, 2018, Volume: 27

    Topics: Angiogenesis Inhibitors; Biological Assay; Blood Vessels; Gene Knockdown Techniques; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Microvessels; Models, Biological; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A

2018
CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma.
    Urologic oncology, 2018, Volume: 36, Issue:5

    Topics: Aged; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Receptors, Interleukin-8A; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate

2018
Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    Cellular oncology (Dordrecht), 2018, Volume: 41, Issue:3

    Topics: Actin Cytoskeleton; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Insulin-Like Growth Factor I; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Sorafenib; Vitamin K 1

2018
Skull Base Metastasis From Occult Renal Cell Carcinoma.
    The Journal of craniofacial surgery, 2018, Volume: 29, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Neoplasms, Unknown Primary; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Skull Base Neoplasms; Sorafenib; Sunitinib

2018
Trials that say "maybe": the disconnect between exploratory and confirmatory testing after drug approval.
    BMJ (Clinical research ed.), 2018, 03-20, Volume: 360

    Topics: Antineoplastic Agents; Calcium Channel Blockers; Clinical Trials as Topic; Drug Approval; Drug Industry; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pregabalin; Pyrroles; Sorafenib; Sunitinib

2018
Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
    Urologic oncology, 2018, Volume: 36, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Monocarboxylic Acid Transporters; Muscle Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Symporters; Vascular Endothelial Growth Factor A

2018
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2018, May-23, Volume: 40, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Multivariate Analysis; Neutropenia; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Thrombocytopenia; Treatment Outcome

2018
Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.
    Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:Supplement

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Renal Cell; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Female; Humans; Immunotherapy, Adoptive; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Postoperative Care; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome

2018
Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
    Vascular pharmacology, 2018, Volume: 110

    Topics: Animals; Antihypertensive Agents; Arterial Pressure; Autophagy; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Indoles; Male; Monocrotaline; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pulmonary Artery; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling

2018
Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin.
    Anticancer research, 2018, Volume: 38, Issue:9

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antioxidants; Capecitabine; Carotenoids; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Skin; Sorafenib; Sunitinib

2018
Sensitivity of Botrytis cinerea From Nectarine/Cherry in China to Six Fungicides and Characterization of Resistant Isolates.
    Plant disease, 2018, Volume: 102, Issue:12

    Topics: Aminoimidazole Carboxamide; Benzimidazoles; Biphenyl Compounds; Botrytis; Carbamates; China; Dioxoles; Drug Resistance, Fungal; Fruit; Fungicides, Industrial; Hydantoins; Niacinamide; Plant Diseases; Prunus; Pyrimidines; Pyrroles; Spores, Fungal

2018
Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib.
    Frontiers in immunology, 2019, Volume: 10

    Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Cell Proliferation; Chemokine CCL2; Fibroblasts; Humans; Interleukin-6; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Synovial Membrane

2019